Functional characterization of the TP53 mutome using CRISPR/Cas9 saturating mutagenesis by Klimovich, Mariia
 Aus dem Institut für Molekulare Onkologie, 
Direktor: Prof. Dr. Thorsten Stiewe 






Functional characterization of the TP53 mutome using 










zur Erlangung des Doktorgrades der Naturwissenschaften 












Angenommen vom Fachbereich Medizin der Philipps-Universität 
Marburg am:  
 
 







Dekanin: Prof. Dr. Denise Hilfiker-Kleiner 
Referent: Prof. Dr. Thorsten Stiewe 



















“Change is the essential 
process of all existence.” 
 (Mister Spock) 
For my best friend and 
husband Boris & my sister 
4 
Lists of abbreviations .............................................................................................. 7 
Abstract ..................................................................................................................... 9 
Zusammenfassung ................................................................................................. 11 
1. INTRODUCTION ............................................................................................... 13 
1.1 TP53 is a key tumor suppressor ................................................................ 13 
1.2 TP53 structure ............................................................................................. 15 
1.3 p53 mutations and their consequences .................................................... 15 
 Loss of function (LOF) mutations ........................................................... 15 
 Partial loss of function mutations ............................................................ 17 
 Gain of function mutations ...................................................................... 18 
 Dominant-negative effect ........................................................................ 19 
 Importance of functional characterization of non-hotspot mutations ....... 20 
1.4 TP53 isoforms and non-coding mutations ................................................ 21 
 Splice mutations ..................................................................................... 22 
1.5 Clinical significance of TP53 mutations .................................................... 22 
1.6 IARC TP53 and UMD databases ................................................................. 23 
1.7 Targeting p53 for cancer therapy ............................................................... 24 
 Reactivation of wild-type p53 with MDM2 and MDMX inhibitors ............. 24 
 Mutant p53 reactivators .......................................................................... 26 
 Mutant p53 degrading drugs ................................................................... 28 
 Targeting mutant p53 aggregation ......................................................... 30 
 Targeting interactions between mutant p53 and p73 .............................. 30 
1.8 Experimental systems for functional studies of p53 mutations .............. 31 
 Systematic analysis of the p53 mutome ................................................. 31 
1.9 Genome editing using CRISPR-Cas ........................................................... 35 
1.10 Saturation mutagenesis .............................................................................. 38 
1.11 Aim ................................................................................................................ 39 
2. MATERIAL AND METHODS ............................................................................ 41 
2.1 Materials: ...................................................................................................... 41 
 Bacterial strains ...................................................................................... 41 
 Plasmids ................................................................................................. 41 
 Cell lines ................................................................................................. 42 
 Oligonucleotides ..................................................................................... 42 
 sgRNAs .................................................................................................. 43 
 MiSeq kit ................................................................................................. 44 
 Enzymes ................................................................................................. 44 
 Antibodies ............................................................................................... 45 
 Chemicals (drugs, antibiotics) ................................................................ 45 
2.2 Methods ........................................................................................................ 46 
 Molecular cloning procedures ................................................................. 46 
5 
 Cell culture ............................................................................................. 50 
 Establishing of the HCT-116 Δ/TP53E cell line ........................................... 51 
 Flow cytometry and cell sorting .............................................................. 52 
 Cell imaging ............................................................................................ 52 
 X-ray irradiation ...................................................................................... 52 
 Western blotting ..................................................................................... 52 
 Extraction of genomic DNA .................................................................... 54 
 Extraction of RNA ................................................................................... 54 
 PCR ........................................................................................................ 55 
 Compound treatment .............................................................................. 59 
 Preparation of the amplicon library for next generation sequencing ....... 59 
 Data analysis and software .................................................................... 60 
3. RESULTS ......................................................................................................... 62 
3.1 CRISPR-mediated Saturation Mutagenesis Screen (CSMS) .................... 62 
3.2 TP53 targeting strategy ............................................................................... 64 
3.3 Generation of the targeting vector for homologous recombination-driven 
TP53 editing ............................................................................................................ 66 
3.4 Establishment of the TP53-hemizygous HCT-116Δ/TP53E cell line using HR-
1 targeting vector ................................................................................................... 68 
3.5 Generation of cell pools expressing p53 variants .................................... 74 
3.6 The HCT-116Δ/TP53E cell line enables highly efficient HDR-mediated 
mutagenesis of the endogenous TP53 locus ...................................................... 77 
3.7 The HCT-116Δ/TP53E cell line enables the introduction of multiple 
mutations into the TP53 locus: construction of the R175 mutagenic library, 
assessment of the library quality, and targeting efficiency ............................... 81 
3.8 System validation: CSMS quantifies anti-proliferative capacity of p53 
variants ................................................................................................................... 86 
 CSMS dissects the impact of mutations on p53-regulated effector 
pathways .............................................................................................................. 94 
 CSMS measures the impact of p53 mutations on response to 
conventional chemo- and radiotherapy ............................................................... 101 
 CSMS reveals no reactivation of p53 mutants by APR-246 ................. 109 
3.9 CSMS probes the functional status of hundreds of H1 helix mutants .. 110 
3.10 CSMS reveals mutations leading to nonsense-mediated mRNA decay of 
TP53 transcript ..................................................................................................... 123 
3.11 CSMS identifies pathogenic non-coding TP53 mutations ..................... 126 
3.12 CSMS-based functional classification of >1200 p53 protein variants ... 129 
3.13 Comparison of functional classification of exon 5 mutations derived 
from CRISPR- and cDNA-based screening experiments .................................. 139 
 CSMS outperforms the cDNA-based method in the classification of rare 
patient-derived mutations of H1 helix ................................................................. 139 
6 
 CSMS outperforms in silico prediction tools in categorizing of pathogenic 
p53 variants ........................................................................................................ 144 
4. DISCUSSION .................................................................................................. 149 
4.1 CSMS: a novel system for high-content functional classification of TP53 
mutations .............................................................................................................. 150 
4.2 CSMS grasps the complexity of the TP53 mutome: classification of rare 
pLOF and wt-like variants .................................................................................... 152 
4.3 High-content CSMS protocol: advantages and limitations .................... 155 
4.4 CSMS dissects distinct p53-dependent tumor-suppressive programs 157 
4.5 CSMS quantifies the impact of p53 mutations on cellular response to 
therapeutic agents ............................................................................................... 159 
4.6 GOF of mutant p53 in CSMS ..................................................................... 161 
4.7 CSMS identifies pathogenic mutations in non-coding regions ............. 163 
4.8 CSMS outperforms cDNA-based methods in the classification of 
pathogenic variants ............................................................................................. 164 
4.9 Method limitations ..................................................................................... 165 
4.10 Conclusion ................................................................................................. 169 
PUBLICATION BIBLIOGRAPHY .......................................................................... 171 
APPENDIX ............................................................................................................. 224 
Curriculum Vitae................................................................................................... 224 
Supplementary materials ..................................................................................... 225 
List of publications .............................................................................................. 226 
List of academic teachers ................................................................................... 227 
Acknowledgments................................................................................................ 228 




Lists of abbreviations 
ARF Alternative reading frame 
ATM Ataxia Telangiectasia Mutated 
ATP Adenosine triphosphate 
ATR Ataxia Telangiectasia and Rad3-related protein 
BAX BCL2-Associated X Protein 
BBC3/PUMA BCL2 Binding Component 3 
Bcl-2 B-cell lymphoma 2 
Bcl-xL B-cell lymphoma-extra large 
BRCA1 BReast CAncer 1, early-onset 
CDKN1A/CDKN2A 
Cyclin-Dependent Kinase Inhibitor 1A (p21) / 2A 
(p14ARF/p16) 
CHK2 Checkpoint kinase 2 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
DBD DNA binding domain 
DN-effect Dominant-negative effect 
DTT Dithiothreitol 
GADD45 Growth Arrest and DNA Damage 
GOF Gain of function 
Hsp70 Heat Shock Protein 70 kDa 
Hsp90 Heat Shock Protein 90 kDa 
LOF/pLOF Loss of function/partial-loss of function 
MDM2 Mouse double minute 2 homolog 
MDM4/MDMX Mouse double minute 4 
mRNA messenger RNA 
NGS Next generation sequencing 
NOXA Phorbol-12-Myristate-13-Acetate-Induced Protein 1 
PAI1 Plasminogen activator inhibitor-1  
PAM Protospacer adjacent motif 
PML Promyelocytic leukemia protein 
Rb Retinoblastoma 
8 
SESN1/SESN2 Sestrin 1 / Sestrin 2 
Suv39h Histone-lysine N-methyltransferase 
Amino acids table 
A  Alanine 
C Cysteine 
D Aspartic acid 





















TP53 is an essential tumor suppressor gene which is inactivated in every second 
tumor. Most frequently TP53 is disabled by missense mutations which result in the 
expression of a mutant p53 protein. Mutant p53 protein is unable to prevent 
uncontrolled proliferation and can additionally increase cancer growth by dominant 
negative and gain of function effects. Mutations in TP53 are frequently associated 
with aggressive tumor growth, chemotherapy resistance and shortened survival. 
Therefore, the TP53 gene status has important clinical implication. Moreover, 
information about TP53 mutations will be essential for application of emerging p53-
targeted therapeutics: Mdm2 inhibitors and p53 reactivators. 
Eight most frequent hotspot mutations account for nearly 30% of all missense TP53 
variants found in tumors and are extensively studied. Hotspot TP53 mutations lead 
to production of a transcriptionally inactive loss of function protein. The rest 70% of 
TP53-mutated tumors contain one of >2000 distinct mutant p53 variants, most of 
which are uncharacterized. Such a broad spectrum of mutants makes prediction of 
their impact on disease outcome a very challenging task. Therefore, for advancing 
personalized cancer treatment it would be of utmost importance to study how the 
hundreds of individual p53 mutations influence a therapy response. Functional 
characterization of hundreds of mutations in a gene of interest is a tall order task 
which requires time-consuming in vitro and in vivo experiments. Thus, an 
experimental approach for a massive parallel phenotypic screening of mutations in 
TP53 gene would be of a great value. 
In the present work we took advantage of the CRISPR-Cas9 gene editing technology 
to develop the CSMS – CRISPR-based saturated mutagenesis screening of TP53 
gene, an improved system for massive parallel functional screening of p53 mutants. 
We have established rapid and flexible protocol of targeting p53 mutations into 
endogenous TP53 locus using CRISPR-Cas9-induced homology-directed repair. We 
have validated CSMS by performing saturation mutagenesis of the short protein 
motif and demonstrated outstanding performance. We have scaled our protocol up to 
establish a high-throughput method that allows precise functional characterization of 
thousands of p53 variants. We have tested effects of p53 mutations on response to 
Mdm2 inhibitors and irradiation and revealed excellent correlation of screening 
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results with known structural, functional and clinical data. Furthermore, we have 
demonstrated that CMSM is able to highlight even subtle functional difference 
between mutants and identify partially loss of function mutants. Manipulating the 
endogenous TP53 locus allowed us to study effects of mutation in non-coding 
regions, which was previously unachievable. A detailed comparison of our data with 
the previously published studies provided compelling evidence, that the procedure 
established in our study is significantly more accurate in categorization of pathogenic 
TP53 mutations. 
In summary, we have attested CSMS as a powerful tool to catalogue TP53 
mutations. This tool can be used in the future to increase the utility of mutations in 
























TP53 ist ein essentieller Tumorsuppressor, der in jedem zweiten Tumor inaktiviert 
vorliegt. In den meisten Fällen ist die Ursache hierfür eine missense Mutation, 
welche zur Expression eines veränderten p53-Proteins führt. 
Das mutierte p53 Protein ist nicht in der Lage eine unkontrollierte Proliferation zu 
verhindern und kann das Tumorwachstum im Falle von dominant-negativen oder 
gain of function Mutationen sogar aktiv unterstützen.  
Mutationen im TP53 Gen sind häufig assoziiert mit einem aggressiven 
Tumorwachstum, Chemoresistenz und einer kürzeren Überlebensspanne der 
Patienten. Aus diesem Grund ist der p53 Genstatus von hoher klinischer Relevanz. 
Darüber hinaus sind Informationen zu verschiedenen TP53 Mutationen essentiell für 
die Applikation vergleichsweise neuer Therapiestrategien, welche gezielt an p53 
ansetzen: Mdm2-Inhibitoren und p53-Reaktivatoren.   
Die acht häufigsten so genannten Hotspot Mutationen versachen nahezu 30% aller 
in Tumoren gefundenen p53 missense-Mutationen und werden daher umfassend 
untersucht. Diese Hotspot Mutationen führen zur Produktion von transkriptionell 
inaktiven loss-of-function Proteinen. Die restlichen 70% der TP53 Mutationen 
bestehen aus mehr als 2000 unterschiedlichen p53 Varianten, von denen die 
meisten bisher nicht charakterisiert sind. Neben Tumor-assoziierten non-Hotspot 
Mutationen macht diese Vielzahl an Mutanten eine Vorhersage über ihren Einfluss 
auf die Erkrankung zu einer großen Herausforderung.  
Aus diesem Grund wäre es für eine verbesserte personalisierte Krebstherapie von 
großer Wichtigkeit, heraus zu finden, wie hunderte verschiedener individueller p53 
Mutationen die Therapieantwort beeinflussen.  
Die funktionelle Charakterisierung hunderter Mutationen eines Gens ist eine 
umfassende Aufgabe, die zeitaufwendige in vitro und in vivo Studien beinhaltet. 
Daher wäre ein experimenteller Ansatz von großem Vorteil, welcher es erlaubt, 
umfangreiche phänotypische Screenings von p53 Mutanten parallel durchzuführen.  
In der vorliegenden Arbeit wurde das CRISPR-Cas9 System genutzt um das 
CRISPR-basierte gesättigte Mutagenese Screening (CRISPR-based saturated 
mutagenesis screening – CSMS) des TP53 Gens zu entwickeln, ein verbessertes 
System zum parallelen umfangreichen phänotypischen Untersuchung von p53 
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Mutanten. Wir haben damit ein schnelles und flexibles Protokoll entwickelt, um unter 
Einsatz des CRISPR-Cas9-induzierten homology-directed repair (Homologie-
gerichtete Reparatur) p53 Mutationen in den endogenen TP53 Genlocus 
einzubringen. Das CSMS wurde mittels getättigter Mutagenese des kurzen Protein 
Motivs validiert und erwies sich als überaus erfolgreiche Methode. Wir haben unser 
Protokoll soweit verbessert, um eine Hochdurchsatz-Methode zu entwickeln, welche 
eine exakte funktionelle Charakterisierung von tausenden p53 Varianten ermöglicht.   
Wir haben die Effekte von p53 Mutationen auf das Ansprechen auf Mdm2-Inhibitoren 
und Bestrahlung untersucht und dabei eine herausragenden Korrelation zwischen 
den Ergebnissen des Screenings und bekannten strukturellen, funktionalen und 
klinischen Daten feststellen können.  
Darüber hinaus konnten wir zeigen, dass CSMS in der Lage ist selbst kleinste 
funktionelle Unterschiede zwischen Mutationen aufzuzeigen und partielle loss-of-
function Mutanten identifizieren kann.  
Die Manipulation des endogenen TP53 Genlocus erlaubt es uns, die Effekte von 
Mutationen in nicht-kodierenden Regionen zu untersuchen, was bisher unmöglich 
war. Ein genauer Vergleich unserer Daten mit bisher publizierten Studien bewies, 
dass die in unserer Studie etablierte Methode eine deutlich genauere 
Kategoriosierung pathogener p53 Mutationen ermöglicht.  
Zusammegefasst können wir bestätigen, dass CSMS ein leistungsfähiges Instrument 
zur Katalogisierung von TP53 Mutationen darstellt. Diese Methode kann zukünftig 
genutzt werden, um den Nutzen von Mutationen im TP53 Gen als klinischen 










1.1 TP53 is a key tumor suppressor 
TP53 is the most frequently mutated gene in human cancer. On average, the TP53 
gene is altered in every second tumor. In some cancer entities (e.g., ovarian and 
uterine cancers), TP53 is mutated in more than 80% of cases (Leroy et al. 2014b; 
Donehower et al. 2019). The importance of TP53 as a tumor suppressor is 
exemplified by the hereditary cancer predisposition disorder, Li-Fraumeni syndrome. 
Germline TP53 mutations were identified in most individuals with Li-Fraumeni 
syndrome (Guha and Malkin 2017). 
TP53 encodes a transcription factor that controls a network of hundreds of genes: 
p53 reacts to various extrinsic and intrinsic stimuli (DNA damage, oxidative stress, 
activation of oncogenes, nutrient deprivation, telomere shortening) and regulates cell 
fate by inducing various responses: cell cycle arrest, apoptosis, senescence, DNA 
repair and others (Williams and Schumacher 2016). Deregulation of the p53 network 
is a universal hallmark of cancer. The p53-mediated response can be dampened in 
cancer cells either by mutations in the TP53 gene itself or by alterations in the genes 
encoding negative or positive p53 regulators like MDM2 and CDNK2A (p14ARF). 
Mutations in TP53 are frequently associated with poor clinical prognosis, aggressive 
tumor growth, metastasis, and therapy resistance (Olivier et al. 2010). 
p53 protein prevents the spreading of genetically altered cells via two core programs: 
apoptosis and cell cycle arrest (Donehower et al. 2019). P53-driven apoptosis 
involves the transcriptional induction of target genes, including BAX, PMAIP1 (Noxa), 
and BBC3 (Puma), which ultimately leads to permeabilization of the mitochondrial 
outer membrane, release of cytochrome c from mitochondria, activation of caspases, 
and cell death (Riley et al. 2008; Zilfou and Lowe 2009; Aubrey et al. 2018b). 
Furthermore, p53-dependent transcription-independent initiation of apoptosis was 
described in numerous studies (Moll et al. 2005; Haupt et al. 2003; Kim et al. 1999; 
Ho et al. 2019). Besides apoptosis, p53 can engage other cell death pathways: 
necrosis (Baumann 2012), ferroptosis (Le Jiang et al. 2015), pyroptosis (Ranjan and 
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Iwakuma 2016), anoikis (Ghosh et al. 2010), and necroptosis (Muller and Vousden 
2014; Xie et al. 2013). 
Under moderate stress p53 engages a reversible cell cycle arrest and DNA repair, 
thereby limiting the propagation of oncogenic mutations. The key mechanism of p53-
mediated cell cycle arrest relies on the activation of the CDKN1A gene, whose 
product p21 inhibits cyclin-dependent kinases (CDKs) to halt cell cycle progression. 
Inhibition of CDKs prevents the hyperphosphorylation of Rb and thereby induces cell 
cycle arrest. Upon certain conditions (oncogene activation, persistent DNA damage), 
p53 response leads to an irreversible block of cell division (senescence) through 
transcriptional activation of target genes such as CDKN1A, PAI1, SUV39H, and PML 
(Riley et al. 2008; Kortlever et al. 2006). p53 regulates cellular metabolism by 
controlling the expression of anti-oxidative genes SESN1, SESN2, GPX, and 
regulators of glycolysis (TIGAR) (Liu et al. 2008; Sablina et al. 2005). 
Activation of p53-driven response can be lethal for the cell. Therefore, in normal cells 
it is tightly controlled. In unstressed cells, p53 is continuously produced but is 
immediately complexed with MDM2 and MDMX proteins via the N-terminal domain 
(Marine and Jochemsen 2004). The E3-ubiquitin-ligase MDM2 labels p53 with 
polyubiquitin, promoting its nuclear export and proteasomal degradation (Haupt et al. 
1997; Tollini et al. 2014; Sane and Rezvani 2017; Boehme and Blattner 2009).  
MDM2-dependent degradation of p53 is interrupted by stress stimuli. DNA damage-
induced phosphorylation of MDM2 and p53 by CHK1, CHK2, ATM, and ATR protein 
kinases prevents ubiquitination of p53 (Kruse and Gu 2009). Additionally, MDM2-p53 
interaction can be disrupted by the p14ARF protein in response to hyperproliferative 
signaling from oncogenes (Pomerantz et al. 1998; Zhang et al. 1998; Kamijo et al. 
1998). Since elevated levels of p53 are toxic to the cell, the duration of p53 
accumulation is controlled by a negative feedback loop: the MDM2 gene itself is a 
transcriptional target of p53. Therefore, stabilization of p53 induces MDM2 
expression and dampens p53 activity (Wu et al. 1993). 
Taken together, p53 is a key regulator of cellular fate with multifaceted functions and 
complex dynamics. It effectively prevents propagation of stressed and genetically 
altered cells. Deregulation of the p53 response is an imperative for any cancer cell. 
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1.2 TP53 structure 
The p53 protein contains 393 amino acids and is divided into several domains: the 
N-terminal domain (1-62 aa) and the adjacent proline-rich domain (63-97 aa) are 
essential for transactivation (Fig. 1A) (Baptiste et al. 2002; Zhu et al. 2000). The 
central DNA-binding core domain (DBD) (102-292 aa) mediates sequence-specific 
binding to response elements located in promotors of target genes. The binding of 
four p53 subunits to DNA is facilitated by a tetramerization domain (323-356 aa). The 
C-terminal domain (364-393 aa) supports DNA binding (Laptenko et al. 2015). 
Moreover, it can be subjected to multiple post-translational modifications and 
essential for regulating cellular levels of p53 (Gu and Zhu 2012; Joerger and Fersht 
2007).  
1.3 p53 mutations and their consequences 
 Loss of function (LOF) mutations 
Unlike most other tumor suppressor genes, which are frequently inactivated by 
deletions, frameshift, or nonsense mutations, approximately 70% of TP53 alterations 
found in human cancers are missense mutations (Fig. 1B) (Levine and Vosburgh 
2008; Muller and Vousden 2013; Donehower et al. 2019).  
The primary consequence of TP53 mutations is the loss of normal tumor-
suppressive functions due to impaired DNA binding or protein misfolding, which 
confers critical selective advantage during tumor progression. However, disruption of 
protein functionality could also be achieved by nonsense or frameshift mutations. 
The unusual mutational spectrum of the TP53 gene (prevalence of missense over 
nonsense or frameshift mutations) has two explanations. First, the selection of 
missense variants exerts neomorphic pro-oncogenic functions that foster more 
aggressive cancer growth (gain of function, GOF) (Brosh and Rotter 2009; Baugh et 
al. 2018). Second, missense mutants exhibit a dominant-negative effect (DNE), 
nonmutational inactivation of the second wild-type allele (Srivastava et al. 1993; Lee 
et al. 2012). Missense mutations in TP53 generate a vast diversity of more than2000 
mutant proteins. Mutations in TP53 have been traditionally considered equally 
damaging. However, increasing experimental evidence suggests that missense 
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mutations generate a “rainbow” of mutant proteins with distinct characteristics 
(Sabapathy and Lane 2018; Walerych et al. 2015).   
 Consistent with the indispensable role of transactivation for normal p53 functions, 
most cancer patients carry mutations of the DNA-binding domain (Leroy et al. 
2014b). Among them, eight mutations are found in nearly 10% of all human tumors 
with p53 missense mutations and are referred to as hotspot mutations (R175H, 
G245S, R248W, R273C, R273H, R282W, R248Q, and R249S) (Baugh et al. 2018). 
All hotspot mutants represent classical LOF mutations because they are completely 
unable to transactivate target genes and suppress cellular growth (Campomenosi et 
al. 2001; Kotler et al. 2018). Deleterious effects of hotspot mutations on tumor 
suppression are well exemplified by animal models: mice with heterozygous 
Figure 1. Mutational spectrum of TP53 
A. Distribution of missense TP53 mutations (N=27847). B. 
Frequencies of distinct classes of TP53 mutations (N=28866). Data 




germline hotspot mutations (Trp53+/mut) show the same (for example, R172H and 
R270H) or even stronger (R248Q) predisposition to the development of sporadic 
tumors as Trp53+/- animals (Olive et al. 2004; Hanel et al. 2013) 
Hotspot mutations are divided into two classes: contact and structural. Contact 
mutations (R273H and R248W) affect residues that directly interact with DNA, 
whereas structural mutations (R175H, G245S, R249S, and R282H) hit residues 
essential for the maintenance of p53 structure (Joerger and Fersht 2007; Ang et al. 
2006; Joerger et al. 2006). Mutation R248Q fits both categories (Wong et al. 1999). 
In contrast to contact p53 mutants that retain normal folding, structural mutants 
unfold at body temperature and tend to aggregate. Many non-hotspot variants were 
predicted to impair p53 function via structural alterations (Baugh et al. 2018).  
Several studies from our group have described non-hotspot p53 variants that do not 
fit into the aforementioned classes because they neither decrease protein stability 
nor affect residues contacting DNA. These mutations impair another essential 
property of p53: DNA binding cooperativity. The binding of p53 monomers to DNA 
promotes the formation of tetramers via protein-protein interactions between the H1- 
helices of the DNA-binding domains (Weinberg et al. 2004). Mutations at residues 
E180 and R181 disrupt salt bridges between adjacent monomers, weaken 
cooperative binding with DNA and reduce p53-mediated tumor suppression (Kitayner 
et al. 2006; Dehner et al. 2005; Timofeev et al. 2013; Schlereth et al. 2010a; 
Schlereth et al. 2013). Such cooperativity mutations promote tumorigenesis in mice 
and are found in sporadic cancers as well as in Li-Fraumeni syndrome individuals 
with hereditary cancer susceptibility (Schlereth et al. 2010a; Timofeev et al. 2013; 
Timofeev et al. 2019).   
 Partial loss of function mutations 
Comprehensive studies of the hotspot TP53 mutations have undoubtedly 
demonstrated their complete loss of functional properties. Accordingly, all p53 
mutants were regarded as equally non-functional. Nowadays, it is increasingly 
recognized that p53 mutations generate a spectrum of proteins with various degrees 
of residual functionality (Sabapathy and Lane 2018; Manfredi 2019). Some of the 
non-hotspot p53 mutants, which were overlooked by earlier studies, retain the ability 
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to transactivate particular target genes, representing, therefore, “separation-of-
function” or “partial loss of function” (partial-LOF) mutants (Kato et al. 2003; 
Menendez et al. 2006; Jordan et al. 2010). A good example is the tumor-derived 
mutant R175P. Its murine equivalent R172P is devoid of pro-apoptotic activity but 
retains the ability to induce cell cycle arrest, maintains chromosome stability, and 
partially suppresses tumorigenesis (Liu et al. 2004). 
The other example of partial-LOF mutants is cooperativity mutations located in the 
H1 helix, two of which were extensively studied by our group. The mutant E177R 
(the equivalent of human E180R) is unable to induce apoptosis but efficiently 
activates cell cycle arrest, controls oxidative stress, and partially protects mice from 
tumorigenesis (Timofeev et al. 2013). The other mutant R178E (the equivalent of 
human R181E) is transcriptionally inactive but can still drive mighty chemotherapy 
response in vivo via a non-transcriptional mechanism (Timofeev et al. 2019). These 
studies pinpoint the chance that many of the non-hotspot mutants retain residual 
activities. Whether partial-LOF mutants can be exploited for cancer therapy is 
unknown. Since non-hotspot mutations account for 70% of all missense variants 
found in cancers, this question deserves deeper investigation. 
 Gain of function mutations 
Besides losing transactivating ability, some mutant p53 variants (for example, 
R175H, R273H, R248Q, R248W, and others) can actively fuel malignant growth by 
acquiring novel oncogenic functions (gain of function, GOF) (Muller and Vousden 
2014; Kim and Lozano 2018; Mello and Attardi 2013). Experimentally, GOF 
properties of some mutants were initially demonstrated upon their overexpression in 
p53-null cells, where they conferred enhanced cell growth and tumorigenicity 
(Dittmer et al. 1993). Studies of such GOF-mutants in in vivo models have 
demonstrated that they provide a strong survival advantage to cancer cells, creating 
oncogene-like addiction, confer enhanced metastatic and invasive potential, drug 
resistance, drive angiogenesis, and epigenetic reprogramming (Basu et al. 2018; 
Morton et al. 2010; Muller and Vousden 2013; Vogiatzi et al. 2016; Lang et al. 2004; 
Olive et al. 2004; Hanel et al. 2013; Do et al. 2012; Hientz et al. 2017; Blandino et al. 
1999; Buganim et al. 2006; Aschauer and Muller 2016; Schulz-Heddergott and Moll 
2018; Alexandrova et al. 2015).  
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Mechanistically, GOF properties are still incompletely understood and seem to 
involve, among others, aberrant interactions of mutant p53 with transcriptional 
cofactors (e.g., NF-Y, YAP, NF-κB, E2F1, Sp-1, Ets-1), which result in 
transactivation of non-canonical target genes (Vogiatzi et al. 2016; Chin et al. 1992; 
Frazier et al. 1998; Lee et al. 2000; Ludes-Meyers et al. 1996; Quante et al. 2012; 
Freed-Pastor et al. 2012; Weisz et al. 2007). Interestingly, GOF activity was 
demonstrated for several non-missense p53 mutants. For example, truncating 
mutations in exon 6 generate proteins that are devoid of transactivating function and 
induce epithelial-mesenchymal transition and grant prometastatic features via 
binding to cyclophilin D in mitochondria (Shirole et al. 2016). 
GOF effects can also be driven by interactions of mutant p53 with its two homologs, 
p63 and p73 (Li and Prives 2007; Hall and Muller 2019). The two transcription 
factors normally exhibit tumor-suppressive properties. The binding of mutant p53 to 
p63 and p73 can lead to improper binding to target gene promoters and 
downregulation of proapoptotic functions (Muller and Vousden 2014; Li and Prives 
2007).  
 Dominant-negative effect 
Monoallelic missense TP53 mutations can compromise functions of the wild-type 
TP53 allele. This phenomenon is known as a dominant-negative effect (DN-effect) 
and was demonstrated upon coexpression of mutant and wild-type p53 proteins 
(Vries et al. 2002; Srivastava S. et al. 1993; Kern et al. 1992; Shaulian et al. 1992; 
Sun et al. 1993). DN-effect has also been demonstrated in mouse models: co-
expression of one mutant Trp53 allele with wild-type protein accelerates 
cancerogenesis compared to Trp53+/- animals (Michele Harvey et al. 1995; Geng Liu 
et al. 2000; Vries et al. 2002; Giacomelli et al. 2018). Similarly, Li-Fraumeni 
syndrome patients carrying missense TP53 mutations are diagnosed with cancer 
earlier in life than patients with truncating mutations (Jillian M Birch et al. 1998). Of 
note, the DN-effect was shown to be mutant-specific: the degree of residual 
transactivation of target genes by wild-type p53 depends on the particular co-
expressed mutant (Paola Monti et al. 2002). The DN-effect is mechanistically 
explained by the formation of non-functional tetramers composed of both normal and 
mutant subunits, which results in decreased concentration of functional tetramers 
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and unfolding of the wild-type protein (Milner and Medcalf 1991; DiGiammarino et al. 
2002).  
Even though the DN-effect and GOF properties were conclusively demonstrated in 
multiple in vitro and animal studies, their relevance for the progression of human 
tumors is still under debate. Two recent studies have conclusively shown that the 
majority of the hundreds of tested missense mutations exert a dominant-negative 
effect in multiple cancer cell lines (Boettcher et al. 2019; Giacomelli et al. 2018). 
However, one of these reports found no evidence of GOF properties (e.g., growth 
stimulation or drug resistance) for hotspot mutants in leukemia cell lines (Boettcher 
et al. 2019). A recent analysis of the TCGA dataset revealed that 90% of tumors 
have biallelic TP53 loss, suggesting that the DN-effect alone is unable to completely 
impair p53-mediated tumor suppression (Donehower et al. 2019). In line with this, a 
recent study in the mouse lymphoma model demonstrated that DNE does not 
globally impair functions of the wild-type protein but rather selectively suppresses 
only a subset of target genes, which is sufficient for deregulation of tumor-
suppressive circuits and transformation of premalignant cells in cooperation with c-
Myc (Aubrey et al. 2018a). 
Presumably, both GOF-effect and DNE are relevant for oncogenesis. However, they 
can operate at distinct cancer progression stages and be strongly dependent on the 
particular mutant, genetic, and cellular contexts. Therefore, the importance of both 
phenomena for cancer patients still needs to be firmly established. 
 Importance of functional characterization of non-hotspot mutations  
The prevalence of eight hotspot mutations over the others prompted a 
comprehensive characterization of these variants in multiple in vivo and in vitro 
models (Lang et al. 2004; Olive et al. 2004; Hanel et al. 2013; Muller and Vousden 
2013; Muller et al. 2011; Liu et al. 2016; Xu et al. 2014; Achatz and Zambetti 2016). 
At the same time, functional consequences of non-hotspot missense p53 mutations 
remain poorly characterized. While some of these mutants exhibit full loss of function 
(identical to null allele), many others can retain particular wild-type properties, exhibit 
DN or neomorphic GOF effects (Freed-Pastor and Prives 2012; Muller and Vousden 
2014; Shirole et al. 2016). GOF activities of mutant p53 vary between particular 
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mutants, depend on oncogenic context and tissue type (Olive et al. 2004; Lang et al. 
2004; Stein et al. 2020). Together with a vast array of LOF and partial LOF 
mutations, they create tremendous diversity of protein variants, many of which can 
represent potential targets for distinct therapeutic modalities (Liu et al. 2015; 
Parrales and Iwakuma 2015; Sur et al. 2009; Martins et al. 2006; Muller and 
Vousden 2014). The fact that only eight mutations among more than 2000 are well-
characterized emphasizes the high demand for a comprehensive functional 
characterization of non-hotspot p53 mutants.  
1.4 TP53 isoforms and non-coding mutations 
The human TP53 locus encodes 12 protein isoforms. Isoforms are generated by 
alternative splicing, alternative initiation of transcription or translation (Surget et al. 
2013; Joruiz and Bourdon 2016). The existence of p53 isoforms adds another level 
of complexity to the p53 network. For example, canonical full-length p53 isoform 
(p53α) is produced from mRNA with complete exclusion of intron 9. Partial retention 
of this intron generates two isoforms (p53β and γ) with a truncated C-terminal 
domain. p53 isoforms are expressed in a tissue-specific manner, and their functional 
importance is still far from being fully understood. In normal cells, p53 isoforms are 
believed to finetune the p53 network, while in malignant cells, they may inhibit 
functions of the full-length protein, e.g., via a dominant-negative effect or by 
promoting aggregation (Vieler and Sanyal 2018). Deregulated expression of p53 
isoforms was found to participate in many pathological conditions: premature aging, 
inflammation, developmental disorders, and many human cancer entities (Muhlinen 
et al. 2018; Cooks et al. 2014; Marcel et al. 2011). For example, overexpression of 
the p53 isoform Δ133p53α, produced from an internal promoter in intron 4, was 
described in colorectal cancer, serous ovarian cancer, breast cancer, and 
cholangiocarcinoma (Vieler and Sanyal 2018; Joruiz and Bourdon 2016; Khoury and 
Bourdon 2011; Surget et al. 2013).  
Non-coding variants can change the balance between p53 isoforms. Mutations 
localized in the intron 4 affect the alternative promoter and impair the synthesis of 
several p53 isoforms (Leroy et al. 2014b; Leroy et al. 2017). Mutations at the 
boundary between intron 6 and exon 7 lead to the production of the shortened p53Ψ 
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isoform, which drives the reprogramming of cells into a premetastatic state (Senturk 
et al. 2014). Moreover, multiple synonymous and non-synonymous germline variants 
were discovered in intron 9, which encodes alternative exons for p53β and p53γ 
isoforms. Although the clinical significance of these variants is unclear, it is possible 
that they may determine expression levels of distinct p53 isoforms (Silden et al. 
2013; Solomon et al. 2014; Graupner et al. 2009). In summary, mutations in the non-
coding sequence of TP53 deserve more comprehensive characterization. 
 Splice mutations 
Although missense mutations in TP53 exons are most frequent, much more rare 
alterations in non-coding regions can also alter p53 protein synthesis and have, 
therefore, clinical significance. For example, recurrent rearrangements in the first 
intron are frequently found in osteosarcomas, and mutations at splice sites in introns 
1 and 9 are associated with Li-Fraumeni syndrome (Chen et al. 2014; Ribi et al. 
2015; Verselis et al. 2000). Splice-site mutations result in the expression of aberrant 
transcript variants and shortened polypeptides. The production of truncated p53 
isoforms was reported in colorectal cancer (Smeby et al. 2019), chronic lymphocytic 
leukemia (Bromidge et al. 2000), lung cancer (Takahashi et al. 1990), and other 
cancer entities (Holmila et al. 2003). Besides, recent study reported a novel type of 
TP53 alterations: splice-site-creating mutations (Jayasinghe et al. 2018). Finally, 
mutations in exonic splicing enhancers and silencers can impair mRNA splicing 
(Gorlov et al. 2004; Wang et al. 2004; Laverdière et al. 2000).  
Hence, TP53 variants affecting splicing can have important clinical implications and 
require more comprehensive characterization.  
1.5 Clinical significance of TP53 mutations 
Some germline mutations in TP53 undoubtedly predispose individuals to cancer 
development (Malkin et al. 1990; Gonzalez et al. 2009). Tumors developing in 
animals harboring p53 genomic mutations demonstrate early onset, aggressive 
metastatic growth, and therapy resistance (Zuber et al. 2009; Lozano 2010). In 
cancer patients, TP53 mutations are also associated with poor prognosis and 
therapy resistance in multiple studies. One of the best examples of the clinical value 
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of TP53 status is chronic lymphocytic leukemia (CLL). Although the frequency of 
TP53 variants is very low in asymptomatic patients, the presence of TP53 variants is 
often associated with poor prognosis characterized by advanced clinical stage, rapid 
disease progression, chemoresistance, and shorter overall survival (Leroy et al. 
2017). Besides, TP53 mutational status in acute myeloid leukemia (AML) is an 
important predictor for the therapy outcome (Hunter and Sallman 2019). 
Nevertheless, the clinical significance of p53 mutation status remains controversial 
(Robles and Harris 2010). The majority of studies demonstrate an association 
between TP53 mutations and poor survival for patients with breast, hematopoietic, 
head and neck, and liver cancers (Zhang et al. 2017). Conversely, roughly half of the 
studies in bladder, brain, lung, colon, esophagus, and ovarian cancer patients failed 
to identify such association (Robles and Harris 2010). Likewise, a report based on 
the TCGA dataset analysis has also demonstrated that the presence of the TP53 
mutation alone has poor prognostic value for many cancer types (Olivier et al. 2007). 
By contrast, a mutant TP53-associated gene expression signature was a much more 
informative outcome predictor (Donehower et al. 2019). The controversial diagnostic 
utility of TP53 mutational status for clinical prognosis can be partially explained by 
the immense complexity of the p53 network and the multitude of mutations. This 
underscores the need for comprehensive functional analysis of the full mutational 
spectra to increase the predictive value of TP53 mutational status (Sinn et al. 2020).  
1.6 IARC TP53 and UMD databases 
The immense diversity of TP53 mutations and clinical value of TP53 mutational 
status substantiated the need of tools to classify and sort information on p53 variants 
retrieved from thousands of publications and medical reports. Nowadays, two 
regularly updated databases of TP53 variants are available: the IARC TP53 
database (www.iarc.fr/P53) and the UMD-p53 database (Universal Mutation 
Database) (http://p53.curie.fr/ and www.umd.necker.fr:2001/). The IARC TP53 
database has been launched in 1989 (Olivier et al. 2002; Bouaoun et al. 2016; 
Hollstein et al. 1994; Hernandez-Boussard et al. 1999). The currently available 
version R20 July 2019 comprises data on 29900 somatic mutations and 9200 
variants. The UMD-p53 database was released in 1994, and the last 2017_R2 
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version includes data on the TP53 status of more than 80400 tumors and 6870 TP53 
variants (Cariello et al. 1994; Leroy et al. 2014a). Both databases contain information 
about germline and somatic mutations, common TP53 polymorphisms in human 
populations, TP53 status in human cell lines. Besides information on mutation 
frequencies, databases contain functional annotations retrieved from the literature, 
including three high-content studies (Kato et al. 2003; Kotler et al. 2018; Giacomelli 
et al. 2018). IARC TP53 and UMD databases are essential sources of information on 
p53 mutations for scientists and clinicians. 
1.7 Targeting p53 for cancer therapy  
 Reactivation of wild-type p53 with MDM2 and MDMX inhibitors 
In approximately 50% of all tumors, the wild-type TP53 gene is retained (Donehower 
et al. 2019). In such tumors, cellular levels of p53 protein are kept low due to 
constant proteasomal degradation of p53 promoted by E3 ubiquitin ligases (most 
notably, MDM2) (Kruse and Gu 2009). Tumors with retained wild-type p53 need to 
enforce this negative feedback loop to avoid lethal activation of p53 by oncogenic 
signaling. Therefore, the amplification of MDM2 and the inactivation of the CDNK2A 
gene, encoding the MDM2-inhibiting protein p14ARF, are common genetic 
alterations of wild-type p53 tumors (Mina et al. 2017; Donehower et al. 2019). The 
central role of MDM2 in the degradation of wild-type p53 encouraged the 
development of inhibitors of MDM2 and its homolog MDMX as a means for 
reactivation of the p53 pathway in cancers without TP53 alterations. In 2021, 25 
clinical trials of 10 MDM2 and MDMX inhibitors were registered at clinicaltrials.gov. 
The prototypic compound for MDM2-inhibitors is nutlin-3a, a cis-imidazoline that 
occupies the p53-binding pocket of MDM2 and disrupts the p53-MDM2 interaction 
(Vassilev et al. 2004). Inhibition of p53-MDM2 interaction with nutlin leads to p53 
stabilization, cell cycle arrest, and apoptosis (Khoo et al. 2014). More potent nutlin 
derivatives (e.g., RG7112 and RG7388 by Roche) are extensively tested in 
preclinical and clinical studies, alone or in combination with other drugs (e.g., 
chemotherapy, BH3 mimetics, or monoclonal antibodies) (Ding et al. 2013; Tovar et 
al. 2013; Andreeff et al. 2016; Tisato et al. 2017). Another drug, SAR405838 (MI-
773, Sanofi), forms the MI-773-MDM2 complex by mimicking three key amino acid 
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residues of p53 involved in MDM2 binding. Additionally, the compound induces 
refolding of the unstructured N-terminus of MDM2, which further enhances 
interactions between the molecule and the protein and enhances the binding affinity 
(Jiaxiong Lu et al. 2016; Wang et al. 2014). At present, two clinical trials were 
completed with MI-773 (NCT01636479 and NCT01985191). AMG 232 (Amgen) is a 
piperidinone inhibitor of the MDM2-p53 interaction. AMG 232 is tested in clinical 
trials on melanoma, glioblastoma, and acute myeloid leukemia (NCT02110355, 
NCT01723020, NCT02016729) (Sun et al. 2007). Besides the drugs listed above, 
several other compounds are currently under clinical development: MK-8242 
(Merck), CGM097, and HDM201 (Novartis). 
Recently, the MDM2 homolog MDMX (or MDM4) also gained attention as a 
therapeutic target. MDMX has non-overlapping functions with MDM2. It lacks the E3 
ubiquitin-ligase activity and negatively regulates p53 via direct interaction and 
sequestration, and forms regulatory complexes with MDM2 (Tollini et al. 2014). 
Reports on amplification of MDMX in some tumors raise concerns that MDM2 
inhibition alone may be ineffective in such patients (Donehower et al. 2019; 
Riemenschneider et al. 1999; Yu et al. 2014a; Danovi et al. 2004; Bao et al. 2016). 
This prompted the development of a novel class of dual MDM2/MDMX inhibitors (Wu 
et al. 2015; Bernal et al. 2010; Chang et al. 2013; Chen et al. 2017). One member of 
this class of molecules is RO-5963 (Graves et al. 2012). RO-5963 is a cell-
permeable indolyl-hydantoin compound that simultaneously hinders binding of both 
MDM2 and MDMX with p53 and activates p53 signaling and apoptosis in cells with 
high levels of MDMX. Besides inhibiting MDMX-p53 interaction, additional strategies 
of targeting MDMX are explored, for example, inducing protein degradation and 
inhibiting its expression (Yu et al. 2020).  
Although MDM2 inhibitors were developed to treat cancers with wild-type TP53, 
there is evidence that they may have some activity against mutant TP53-expressing 
tumors. For example, apoptosis-deficient mutants E177R and R178E reveal lethal 
activities during embryonic development in an Mdm2-null background, highlighting 
the fact that even variants with strongly compromised pro-apoptotic function can 
exert cytotoxic action upon excessive stabilization (Klimovich et al. 2019). Moreover, 
treatment of cells expressing transcriptionally-inactive mutant R178E with a 
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combination of nutlin and doxorubicin unleashes residual cytoplasmic activities of the 
mutant and kills cells by apoptosis (Timofeev et al. 2019). In clinical trials, some 
activity of RG7112 was reported for a few leukemia patients with p53 mutations 
(Andreeff et al. 2016). Thus, MDM2 inhibitors may potentially have clinical utility for 
the treatment of tumors with certain p53 mutants. 
Another unexplored possibility is that treatment of patients carrying p53 mutation 
with MDM2 inhibitors may have a detrimental effect due to excessive stabilization of 
mutant p53 and amplification of their GOF or DN-effect (Alexandrova et al. 2017a; 
Yue et al. 2017). Therefore, MDM2 inhibitors need to be tested in the context of the 
whole mutational spectra to fully understand the hidden benefits and potential side 
effects of these compounds.  
 Mutant p53 reactivators 
Since p53 is most frequently inactivated by missense mutations, the mutant protein 
is retained in cancer cells. This opens an opportunity to harness mutant p53 for 
therapy. Two major strategies are pursued: the first approach involves the 
restoration of wild-type-like conformation and functions of the improperly folded 
mutant protein. This concept was supported by numerous studies demonstrating that 
re-expression of p53 kills p53-negative cells (Feldser et al. 2010; Junttila et al. 2010; 
Martins et al. 2006; Xue et al. 2007). Many mutant p53 variants are unfolded at body 
temperature. Experiments with temperature-sensitive p53 mutants demonstrated that 
stabilization of protein conformation turns unfolded p53 back into a wild-type state 
(Friedlander et al. 1996; Michalovitz et al. 1990). Therefore the development of small 
molecular compounds leading to stabilization and functional rescue of mutant p53 
was actively pursued, and more than a dozen compounds were developed in the 
past decades, some of which are listed in Table 1 (Bykov et al. 2017). 
Mechanistically, many mutant p53-reactivators rely on the same principle: they bind 
covalently to the mutant protein, elevating its thermostability and shifting the 
equilibrium toward a native conformation by mass action (Bullock and Fersht 2001). 
The most advanced compound of this class is APR-246 (PRIMA-Met). APR-246 is a 
prodrug that is converted to the Michael acceptor methylene quinuclidinone (MQ) 
(Bykov et al. 2005; Bykov et al. 2016). MQ covalently binds to cysteines (Cys124 
and 277) in p53, followed by protein refolding and restoration of wild-type function 
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(Wassman et al. 2013; Lambert et al. 2009; Zhang et al. 2018). The drug has 
demonstrated cytotoxic activity against tumors with the p53 mutations R175H and 
R273H (Bykov et al. 2016). APR-246 demonstrated a favorable safety in phase I 
clinical trials in patients with hematological tumors (NCT03931291, 
NCT03588078, NCT03072043) and in phase II trials in prostate cancer patients 
(NCT00900614). APR-246 in combination with azacitidine showed robust clinical 
efficacy in TP53 mutant MDS/AML patients (NCT03745716) (Sallman 2020; Cluzeau 
et al. 2019). Further clinical trials are currently ongoing. Notably, MQ has been 
reported to inhibit thioredoxin reductase 1 (Trxr1) and deplete the cellular pool of 
glutathione, thereby killing mutant p53-expressing cells, which are more vulnerable 
to oxidative damage (Liu et al. 2017; Peng et al. 2013). These reports highlight that 
some mutant p53 reactivators have low selectivity and may exert a plethora of side 
effects, questioning whether observed clinical effects are indeed dependent on 
mutant TP53 refolding. Other examples of p53 reactivators sharing the same mode 
of action are shown in Table 1 (Bykov et al. 2017). While some p53 reactivators 
target a broader spectrum of mutants by stabilizing their conformation (e.g., CP-
Table 1. Overview of mutant p53-reactivating compounds (Bykov et al. 2017) 
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31398 was shown to refold V173A, S241F, R249S, and R273H), other compounds 
were explicitly designed to target single mutants, e.g., PK7088 refolds only p53 
Y220C by filling a surface cleft left by the mutation of tyrosine and stabilizing the 
native conformation (Parrales and Iwakuma 2015; Boeckler et al. 2008). Another 
class of p53 reactivators is zinc chelators. Zinc (Zn2+) ions are required for correct 
folding of p53, DNA binding, and transactivation (Loh 2010; Butler and Loh 2003, 
2007). Zn2+ stabilizes two loops in the DBD by tetrahedral coordination by Cys176-
His179 and Cys238-Cys242. Zinc-free DBD is unfolded at body temperature (Butler 
and Loh 2003). Incubation of cells with Zn2+ chelators results in the transition of p53 
into unfolded inactive conformation, which can be reversed back to normal by 
supplementing cells with Zn2+ (Hainaut and Milner 1993). The binding of Zn2+ can be 
perturbed by several mutations, including the most frequent hotspot variant R175H 
(Cho et al. 1994). Supplementation of mutant p53-expressing cells with an excess of 
Zn2+ can partially rescue DNA binding, supporting the idea of using zinc 
administration for mutant p53 reactivation (Puca et al. 2011). However, 
supplementation with free zinc is not a feasible strategy because a relatively small 
excess of zinc also induces p53 denaturation (Butler and Loh 2007). A 
thiosemicarbazone compound ZMC-1 (zinc metallochaperone) functions as a zinc 
ion buffer, providing an optimal concentration of intracellular Zn2+ ions and 
supporting correct p53 folding without direct binding to the protein (Blanden et al. 
2015). Accordingly, ZMC-1 was shown to selectively inhibit the growth of cells 
harboring p53 mutants with impaired zinc-binding (e.g., R175H, C238S, C242F, and 
C176F) (Yu et al. 2014b). 
 Mutant p53 degrading drugs 
The universal characteristic of the majority of mutant p53-expressing tumors is the 
massive accumulation of the mutant protein. Therefore intensive p53 
immunostaining is a reliable surrogate marker of p53 mutations, widely used by 
pathologists (Bartek et al. 1990; Yemelyanova et al. 2011; Köbel et al. 2016).  
Importantly, mutant p53 is not accumulated when expressed in non-transformed 
cells or in normal tissues of transgenic (mutant knock-in) mice (Lang et al. 2004; 
Olive et al. 2004). Therefore, stabilization of mutant p53 is a specific hallmark of 
cancer cells and considered required for its oncogenic GOF activities (Mantovani et 
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al. 2019). Several mechanisms drive the accumulation of mutant p53. First, lack of 
transactivation and impaired ubiquitination by MDM2 and CHIP lead to disfunction of 
the p53-MDM2 feedback loop. Furthermore, short MDM2 isoforms frequently 
produced in cancer cells can inhibit the ubiquitination of mutant p53 (Zheng et al. 
2013; Sigalas et al. 1996; Jacob et al. 2013). Second, Hsp90 and Hsp70 chaperons 
bind to mutant p53 and protect it from aggregation and MDM2-dependent 
ubiquitination (Frum R.A. 2014; Li et al. 2011; Blagosklonny et al. 1996; Whitesell et 
al. 1998). Finally, co-chaperone proteins from the BAG family were shown to interact 
with mutant p53, protect it from degradation and promote GOF (Yue et al. 2016; Yue 
et al. 2015).   
Excessive stabilization of mutant p53 creates an oncogene-like addiction to GOF 
mutants (Parrales and Iwakuma 2015; Schulz-Heddergott and Moll 2018; Sabapathy 
2015). Targeting this addiction by inhibition or genetic ablation of mutant p53 
counteracts cancer growth in vitro and in vivo (Schulz-Heddergott and Moll 2018; 
Freed-Pastor et al. 2012; Weissmueller et al. 2014; Walerych et al. 2016; 
Alexandrova et al. 2015; Schulz-Heddergott et al. 2018; Zhu et al. 2015). Hence, 
elimination of mutant p53 from cancer cells by promoting its degradation is a 
reasonable therapeutic approach. Inhibition of HSP90 with ganetespib or 
combination of 17AAG (HSP90 inhibitor) with SAHA (HDAC 6 inhibitor) was shown 
to deplete mutant p53 levels and significantly extended the survival of mice carrying 
T cell lymphomas expressing p53 R172H and R248Q (Alexandrova et al. 2015). 
Moreover, ganetespib synergized with chemotherapy to eliminate mutant p53-
expressing tumors (Alexandrova et al. 2017b). A combination of ganetespib with 
paclitaxel was tested in cancer patients (Ray-Coquard et al. 2019). 
Another mechanism of mutant p53 stabilization implicates the Hsp40 family member 
DNAJA1, which shelters mutant p53 from CHIP-mediated degradation in conjunction 
with the mevalonate pathway intermediate mevalonate-5-phosphate (Parrales et al. 
2016). Interestingly, inhibition of the mevalonate pathway with HMG-CoA reductase 
inhibitors (statins), the most common cholesterol-lowering drugs, was shown to 
decrease levels of several mutant p53 variants (Parrales et al. 2016; Xu et al. 2019). 
Statins were also shown to prevent HSP90-mediated mutant p53 stabilization and 
induce MDM2-dependent degradation (Ingallina et al. 2017). Mutant p53 directly 
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activates the mevalonate pathway by interacting with SREBP2, which supports the 
malignant behavior of cancer cells via activation of Ras, Rho, and YAP/TAZ 
(Sorrentino et al. 2014). Therefore, statins directly counteract mutant p53 by 
reducing oncogenic signaling (Parrales et al. 2018). Statins have shown cytotoxicity 
in lung cancer cells (Chou et al. 2019). Moreover, moderate efficacy was evident in 
autochthonous T-lymphomas expressing two different GOF mutant p53 alleles. 
(Tutuska et al. 2020). Whether statin therapy can be translated into clinical benefit 
for patients with p53-mutant cancer, remains to be established (Chae et al. 2015; 
Blandino and Di Agostino 2018).  
 Targeting mutant p53 aggregation 
Mutant p53 is improperly folded and forms amyloid aggregates in cancer cell lines 
and human tumor samples (Silva et al. 2014; Xu et al. 2011; Levy et al. 2011; 
Oliveira et al. 2020). Disaggregation is a prospective approach for the rescue of 
normal functions of mutant p53. This concept was tested in high-grade serous 
ovarian carcinomas by designing the peptide Reacp53 that disrupts p53 aggregates 
and shifts the dynamic equilibrium towards a correctly folded form, recovering a wild-
type-like protein. Reacp53 restores the p53 functions in hotspot mutants R175 and 
R248 and improves survival of animals xenografted with ovarian carcinoma (Soragni 
et al. 2016).  
 Targeting interactions between mutant p53 and p73 
Several p53 GOF mutants strongly bind and inactivate the p53 family member p73 
that has many overlapping functions with p53. The mutant p53-p73 heterotetramers 
block p73 function supporting proliferation and chemoresistance (Schulz-Heddergott 
and Moll 2018). The disruption of the mutant p53-p73 complex would restore p73 
functions. RETRA (“reactivation of transcriptional reporter activity”) disrupts such 
complexes and restores p73-mediated transcription and cell death (Kravchenko et al. 
2008; Hong et al. 2014; Hepburn 2007). 
Pharmacological targeting of mutant p53 was proven to be very challenging, and 
despite substantial efforts, no drugs have been approved for clinical application so 
far. All currently available compounds were shown to act on a specific small set of 
hotspot mutants (Parrales and Iwakuma 2015). How suitable these emerging 
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therapeutics are to the broader spectrum of p53 mutants is unknown. Therefore, the 
development of a mutant p53 screening system allowing for parallel testing of 
multiple p53-targeting compounds in the context of the full mutational spectrum is of 
high translational value. 
1.8 Experimental systems for functional studies of p53 mutations 
Mouse models were extensively used to study p53. Animal experiments gave 
supporting evidence for the development of p53-targeting therapies. Despite their 
utility, only a small amount of mouse models with germline p53 mutations 
corresponding to human ones were generated (e.g., Trp53R172P, Trp53R172H, and 
Trp53R270H) (Liu et al. 2004; Geng Liu et al. 2000; Olive et al. 2004). Mouse 
models carrying the human variants R248W, R248Q, or G245S, are also available 
(Hanel et al. 2013). These models gave invaluable insight into p53 biology. However, 
mouse models have lots of limitations, first of all, the limited number of available 
genotypes. Therefore, they are unsuitable for studying the vast diversity of mutant 
p53 protein variants. 
Cell lines are widely used to investigate mutant p53. Not surprisingly, mutation 
occurrence in cell lines reflects their frequency in human cancers: among more than 
2000 mutant p53 cell lines listed in the IARC-p53 database, more than 500 contain 
mutations in one of 8 hotspot codons. Mutations occurrence among cell lines is 
strongly biased towards hotspot mutations probably due to survival benefit during in 
vitro culture, whereas non-hotspot mutants are strongly underrepresented. Cell lines 
lack for majority of non-hotspot mutations, therefore they can be characterized only 
using engineered cell lines. Since every cell line has a unique genetic background 
and carries mutations in many genes, comparisons of large groups of cell lines 
would be needed to reveal phenotypic effects of multiple p53 mutants. Therefore, for 
the detailed studies of large sets of mutations, a common isogenic background is 
needed. 
 Systematic analysis of the p53 mutome 
The tremendous diversity of p53 variants, a wide range of biological effects of mutant 
proteins (DN, LOF, and GOF), as well as lack of suitable models for most of the 
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mutants, prompted the development of high-throughput screening approaches aimed 
to characterize the full mutational continuum. The first attempt to gain a deep insight 
into the complexity of p53 mutations was made in 2001 (Campomenosi et al, 2001), 
followed by Kato and co-authors in 2003 (Kato S. et al. 2003). 2314 mutant p53 
variants were tested in a yeast-based reporter assay for their ability to activate 
transcription from p53 response elements of different target genes (MDM2, PMAIP1, 
BAX, CDKN1a, GADD45, AIP1, 14-3-3δ). This work confirmed that the majority of 
mutations localized in the DNA binding domain completely impair transactivation. 
The other domains turned out to be much more resistant to mutagenesis. 
Importantly, this assay also demonstrated that many non-spot variants exhibit only 
partial loss of transactivation, suggesting that the p53 mutome is functionally much 
more diverse than previously appreciated. This publication demonstrated the value 
of deep mutational scanning for functional and structural studies of p53 and served 
since then as the most important source of functional annotation for most of the p53 
variants identified in patients and listed in databases (IARC p53, UMD, and ClinVar).  
A later study from the Kato group highlighted an important disadvantage of the 
transactivation reporter-based screening system (Kakudo Y. et al. 2005). Testing a 
panel of 179 mutants in p53-negative Saos-2 cells surprisingly revealed that the 
transactivating properties of many mutants did not correlate with their ability to 
induce apoptosis. This implied that the functional impact of p53 mutations is not a 
direct result of target genes transactivation, supporting the importance of 
transactivation-independent apoptosis. In support of this, wild-type p53 was shown to 
directly interact with pro- and anti-apoptotic proteins (Bak, Bax, Bcl-xL, and Bcl-2) 
and induce mitochondrial outer membrane permeabilization and consecutive 
apoptosis independently of target genes transactivation (Chipuk et al. 2004; Mihara 
et al. 2003). These findings were recently corroborated by the description of a 
transactivation-deficient mutant, which is nevertheless able to induce apoptosis in 
response to chemotherapy in vivo (Timofeev et al. 2019). This study highlighted the 
problem: comprehensive profiling of p53 variants requires not just a measurement of 
the transactivating potential but rather quantification of their impact on cell fitness. 
Advances in next-generation sequencing have allowed the implementation of high-
throughput functional screening of p53 variants in mammalian cells. Three recent 
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publications reported the application of lentiviral cDNA libraries containing thousands 
of p53 variants introduced into human cells (Kotler et al. 2018; Giacomelli et al. 
2018; Boettcher et al. 2019). Next-generation sequencing was used as a readout to 
quantify changes in mutation abundance. The first study assessed enrichment or 
dropout of mutations after the prolonged cultivation of p53-deficient H1299 lung 
cancer cells infected with the lentiviral library and demonstrated a profound 
correlation between functional effects of p53 mutations, structural features, and 
evolutionary conservation. This experimental system was able to delineate wild-type-
like and LOF mutations accurately. Moreover, passaging of the library infected cells 
in vivo revealed preferential enrichment of some cancer-associated variants, 
highlighting the GOF activities of selected mutants. 
The second study (Giacomelli et al. 2018) assayed human A549 lung cancer cells 
infected with a lentiviral library of p53 variants and treated them with nutlin in two 
configurations. For the assessment of the dominant-negative effect, cells carrying 
wild-type p53 locus were infected. LOF mutants were identified after delivery of the 
library into p53-knockout A549 cells. This work has demonstrated that 80% of the 
mutants tested exert DN-effect on the wild-type allele.  
The third study (Boettcher et al. 2019) utilized a p53 wild-type AML cell line MOLM-
13 engineered to express a p21-GFP reporter. After introducing a saturated library of 
p53 missense mutants sorting of cells showing weak GFP fluorescence allowed to 
isolate p53 variants that exert a dominant-negative effect on the normal p53. Similar 
to the previous report, this work also revealed that the vast majority of DBD-mutants 
exert a strong DN-effect on the wild-type protein.  
Interestingly, the aforementioned studies reported conflicting results regarding the 
GOF effects of p53 mutants. Kotler et al. have assessed the enrichment of mutants 
from their library in three settings: standard cell culture conditions, 3D-culture in 
spheroids, and in vivo growth upon subcutaneous injection in NSG mice. Strikingly, 
enrichment of variants from in vivo experiments did not correlate with both in vitro 
systems. Among mutations recovered from the tumors formed in mice, 10 mutants 
belong to the most frequent cancer-associated variants, suggesting that they elicit 
GOF effects in the in vivo model. Notably, enrichment of variants was highly 
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correlated between standard and 3D culture conditions in vitro. These results clearly 
demonstrate that GOF effects are strongly dependent on selective forces that 
operate only in a particular context.  
Conversely, the other two studies did not find any evidence of GOF for any of the 
mutants tested. Such discrepancies in reporting GOF activities of p53 mutants point 
out that the functional consequences of p53 mutations are strongly dependent on the 
experimental system used to uncover them. This emphasizes the need for the 
development of more advanced screening systems.  
The elegant studies by S. Kato, E. Kotler, A. Giacomelli, and S. Boettcher have 
made important advances in exploring the diversity of mutant p53 variants. However, 
these studies have several disadvantages: 
- the study of Kato and coauthors (Kato et al., 2012) was performed in yeast cells 
that naturally lack p53 and, in turn, the complete network of p53 regulators and 
posttranslational modifications, making the system overtly non-physiological; 
moreover, the screening was focused on only 8 short response elements from p53 
target genes: MDM2, p53R2, BAX, Noxa, GADD-45, AIP1, 14-3-3δ, WAF1, whereas 
the transcriptional network of p53 includes hundreds of genes controlled by complex 
enhancer-promoter interactions (Sullivan et al. 2018; Bieging and Attardi 2012) 
- the more recent studies utilized lentiviral cDNA libraries to express p53 in human 
cells. In the conditions of p53 overexpression from a strong lentiviral promoter, 
cellular effects may have been exaggerated;  
- using cDNA makes it impossible to test non-coding intronic variants and mutations 
of splice-sites;  
- expression of p53 from cDNA simplifies the complexity of p53 isoforms; 
- another drawback of using cDNA is the non-physiological regulation of expression 
by a lentiviral promoter and lack of post-transcriptional regulation via miRNA binding 
to sites in the 3’UTR  (Kafri et al. 2000; Brendel et al. 2012; Matoulkova et al. 2012; 
Bottini et al. 2017; Kotagama et al. 2015; Vislovukh et al. 2014). 
To overcome these inherent drawbacks of the cDNA-based screening system, 
mutations need to be introduced into the endogenous genomic locus. The discovery 
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of CRISPR and tremendous progress in the development of gene-editing technology 
makes this task feasible. 
1.9 Genome editing using CRISPR-Cas 
The discovery of the CRISPR (clustered regularly interspaced short palindromic 
repeats) system has led to a giant leap in the field of genome editing and 
dramatically simplified genome engineering and mutagenesis. In 2013, two groups 
(of Feng Zhang and George Church) simultaneously published the description of 
genome editing using the CRISPR/Cas9 system in human cells (Le Cong et al. 2013; 
Mali et al. 2013). By the end of 2014, nearly 1000 papers mentioning CRISPR had 
been published. Nowadays, the CRISPR/Cas system is involved in clinical trials 
worldwide and demonstrated successful treatment of sickle cell disease in the 
patient (Ledford 2020). 
The CRISPR-Cas system originates from genomes of prokaryotic organisms such as 
archaea and bacteria (Wiedenheft et al. 2012). The system serves as a defense 
mechanism against infections by bacteriophages. Riboprotein complexes encoded 
by CRISPR recognize and cleave DNA from bacteriophages, preventing the entry of 
foreign genetic material. CRISPR-Cas systems from various bacterial species were 
used to develop highly efficient programmable endonucleases suitable for site-
specific DNA cleavage in any living organism. 
The most widely used CRISPR-Cas9 system that was also implemented in the 
present work was derived from Streptococcus pyogenes. The S. pyogenes CRISPR-
Cas9 complex comprises two RNA molecules: (crRNA and tracrRNA) and the Cas9 
nuclease (Fig. 2A) (Barrangou 2015; Deltcheva et al. 2011). Two RNAs are fused in 
a chimeric single-guide RNA (sgRNA) in most currently employed systems (Jinek et 
al. 2012). sgRNA targets the nuclease to the specific DNA sequence in the genome. 
Most of the 100 bp-long sequences of the sgRNA are invariant; the binding 
specificity of the complex is determined by the 20 bp-long fragments on the 5’-end of 
the sgRNA. Therefore, the specificity of the Cas9 protein can be easily changed by 
replacing the 20 bp fragment in the sgRNA (Fig.2B).  
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Cleavage of DNA by the Cas9 enzyme requires a specific motif in the proximity of 
the recognition sequence, the protospacer adjacent motif (PAM). The PAM 
sequence recognized by the Cas9 nuclease is NGG and is located 3 nucleotides 
downstream of the cleavage site. Cas9 binds to the target sequence determined by 
sgRNA homology and makes a blunt double-strand break in DNA between the 17th 
and 18th bases of the target sequence (Jinek et al. 2012) (Fig. 2C). The DNA repair 
machinery immediately recognizes a double-strand break. Genome editing exploits 
two distinct DNA repair mechanisms: non-homologous end-joining (NHEJ) and 
homology-directed repair (HDR) (Fig. 2A,C). NHEJ occurs in the absence of the 
homologous DNA molecule and forms random short insertions or deletions (indels), 
leading to frameshifts and ultimately to knockout of the gene (Fig. 2C). When the 
DNA template homologous to the double strand break site is provided in the form of 
a homologous chromosome, plasmid DNA or oligonucleotide, the HDR mechanism 
can proceed (Fig. 2C). HDR replaces a damaged DNA segment with a template 
sequence, seamlessly introducing the template into the genome. If the HDR template 
contains desired modifications, they are integrated into the genome. Therefore, 
unlike the inaccurate NHEJ mechanism, which generates random indels, HDR 
enables precise editing of genomic DNA by introducing single mutations or 
substantially large inserts into the genome in the proximity of the cleavage site. 
Importantly, NHEJ and HDR mechanisms are competing with each other (Sargent et 
al. 1997). NHEJ is a preferential repair pathway, making the selection of cells which 
have undergone HDR a substantial challenge during gene editing. Additional 
obstacle for the efficient gene editing is p53-mediated DNA damage response 
induced by double strand breaks. Besides limiting the frequency of HDR-mediated 
transgene integration, DNA damage response promotes selection of cells with 
inactivating mutations in TP53 (Enache et al. 2020; Haapaniemi et al. 2018; Ihry et 
al. 2018). Inactivation of p53 during editing enhances editing efficiency and protects 







Figure 2. CRISPR-Cas9-mediated genome editing 
A. Structure of the S. pyogenes Cas9-sgRNA RNA-guided nuclease 
complex Figure adapted from Yu Wang et al., Applied and Environmental 
Microbiology 2018. B. A plasmid for the expression of the human codon-
optimized SpCas9 and chimeric single guide RNA (sgRNA). BbsI 
recognition sites indicate the cloning site for the sgRNA. Modified from 
https://www.addgene.org/42230. C. Cas9 protein forms a complex with a 
sgRNA, binds the target site, and cleaves genomic DNA creating a 
double-strand break (DSB) 3-4 nucleotides upstream of the PAM 
sequence. DSB is repaired by the non-homologous end-joining (NHEJ) or 
homology-directed repair (HDR). As a result of NHEJ, random insertions 
and deletions are generated. HDR results in the precise integration of the 
provided donor template which has sequence homology with the target 







1.10 Saturation mutagenesis 
Saturation mutagenesis is a technique applied in functional studies and protein 
engineering, in which a codon at a certain position is exchanged with all possible 
amino acids. Generation of scanning site saturation libraries enables the 
interrogation of every possible alteration in the given protein (Fig. 3A,B).  
This approach was implemented in studies of numerous genes, including tumor 
suppressors (PTEN) (Mighell et al. 2018). However, before the advent of the 
CRISPR-Cas9 era, saturation mutagenesis in mammalian cells was possible only in 
trans (by episomal expression of mutagenic libraries from plasmid or lentiviral 
vectors) (Siloto and Weselake 2012). Nowadays, the CRISPR-Cas9 system has 
been widely implemented for targeted genome editing allowing to perform site-
Figure. 3 Schematic of the saturation mutagenesis principle 
employed in the work shown for the R175 and H1 helix libraries 
A. A single site-saturation library for the codon R175 included mutations 
to all 19 amino acids, 3 synonymous mutations, stop codon, codon 
deletion, and 3 frameshifts. B. Amino acid sequence of the p53 H1 helix. 
Each position (shown as X) was mutated to the 19 amino acids, one 




saturation mutagenesis at almost any genomic locus using HDR (Findlay et al. 2014; 
Ma et al. 2017; Canver et al. 2020).  
A good example of the CRISPR-Cas-guided HDR-based saturated mutagenesis is a 
comprehensive mutational screening of nearly 4000 variants in the BRCA1 gene 
(Gregory M. Findlay et al. 2018). The study revealed many new pathogenic variants 
in the gene and showcased the utility of CRISPR-based mutagenesis for functional 
studies. CRISPR-Cas9 system was recently implemented to introduce the most 
frequent hotspot mutations into TP53 locus of leukemia cell lines (Boettcher et al. 
2019). However, no reports on systematical mutagenesis of the endogenous TP53 
locus were published so far to our knowledge. 
We aimed to take advantage of CRISPR-Cas9-induced genome editing to design an 
improved system for high-content phenotypic characterization of TP53 mutations, 
considering the limitation of the prior studies.  
1.11 Aim 
The aim of the present study was to develop a system for massive parallel 
phenotypic analysis of p53 mutations in the context of the endogenous TP53 locus. 
To achieve this goal, we set several objectives: 
1. Establish a protocol for the generation of site-saturation libraries of the TP53 
gene. Develop an efficient strategy using CRISPR-Cas9-induced HDR to target 
variant libraries into the endogenous genomic locus of human cancer cells to 
produce isogenic cellular libraries.  
2. Develop a workflow for the high-content quantification of anti-proliferative capacity 
and specific tumor-suppressive functions (apoptosis, cell cycle arrest) of p53 
variants. 
3. Validate the system using libraries of increasing complexity. Compare the 
phenotypical impact of variants with previously published experimental evidence and 
clinical data from the public databases (IARC TP53 and UMD). 
4. Assess the impact of p53 mutations on the sensitivity of cancer cells to therapeutic 
agents activating wild-type or mutant p53. 
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5. Explore phenotypic consequences of intronic mutations to showcase the 
advantages of the employed strategy. 
6. Perform a comprehensive analysis of thousands of p53 DNA binding domain 





2. Material and methods 
2.1 Materials: 
 Bacterial strains 
Name Source 
DH10B ElectroMAX LifeTechnologies 
OneShot Mach1-T1® LifeTechnologies 
 Plasmids 
Backbone Name Insert Source 
pENTR™/D-TOPO® pENTR™/D-TOPO®  LifeTechnologies 
pENTR™/D-TOPO® pENTR_HA1 TP53 ex4-int4 Present work 
pENTR™/D-TOPO® pENTR_HA2_GGate TP53 ex4-int6 Present work 
HR700PA-1 HR700PA-1  System Biosciences 








































HR700PA-1 HR_H1 helix 
















 Cell lines 
Cell line p53 status 
HCT-116 (human colon carcinoma) +/+ 
HCT-116 Δ/TP53E Δ/LSL-editable 
HCT-116 Δ/LSL-R175-Lib Δ/LSL-R175-mutation library 
HCT-116 Δ/R175-Lib Δ/R175-mutation library 
HCT-116 Δ/LSL-H1 helix-Lib Δ/LSL-H1 helix-mutation library 
HCT-116 Δ/H1 helix-Lib Δ/H1 helix-mutation library 
HCT-116 Δ/LSL-Exon5-Library Δ/LSL-Exon 5-mutation library 
HCT-116 Δp53-L Δ/Δ (deletion from exon 2 to exon 9) 
HCT-116 +/LSL +/LSL 
HCT-116 Δ/LSL-Splicing-Lib Δ/LSL-Splicing-library 
HCT-116 Δ/ Splicing-Lib Δ/Splicing-library 
 
 Oligonucleotides 
Name Sense  (5’-3’) Antisense (5’-3’) 
1 HA1_f_CACC_BsrGI CACCTATATGTACAAGAGGCTGCTCCCCCCGTG 
2 HA1_r_BsaI_S TATAGAGACCGATGGATAAAAGCCCAAATTC 
3 HA2_f_CACC_MluI_L CACCACGCGTCCATCACACCCTCAGCATCTC 
4 HA2_r_SalI TATAGTCGACGAGATGGAATCTCGCTCTGTC 
5 P53Int4-for1 CCCTTTGGCTTCCTGTCAGTG 
6 CRISPR_seq_for AGCAACAGATGGAAGGCCTC 
7 MCS2_HR700PA_1_f GGGGGCTGTCCCTAGATCTATAA 
8 TP53Exon5 fwd GTTGATTCCACACCCCCGCC 
9 TP53Exon6 rev GGGCACCACCACACTATGTC 
10 Ex7 hp53_2 rev GATGGTGGTACAGTCAGAGCC 

















17 TP53_ex5_NGS_BC11_r-1bp GAACCAGAAGACTTGCCAACTGGCCAAGACCT 










22 EE_Ggate_f GCGCTGCCCCCACCATGAGGAATGCTCAGATAGC 
23 EE_Ggate_r CATCGCTATCTGAGCATTCCTCATGGTGGGGGCA 
24 Intron_4_mut_oligo_13nt_fwd CAATATGAAGACCTCTGTCTCCTTC 







28 p53_cDNA_rev GCCAACCTCAGGCGGCTCAT 
 
 sgRNAs 
Name Sense  (5’-3’) Antisense (5’-3’) 
gRNA in5wt CACCGTCAGTGAGGAATCAGAGGCC AAACGGCCTCTGATTCCTCACTGAC 
gRNA in5del CACCGAGAGCAATCAGTGGGGACCC AAACGGGTCCCCACTGATTGCTCTC 
gRNA in5+T CACCGTGAGGAATCAGAGGACCTG AAACCAGGTCCTCTGATTCCTCAC 




 MiSeq kit 
Name Source 


















T7 Endonuclease I 
Q5® Hot Start High-
Fidelity DNA Polymerase 
GoTaq® G2 DNA 
Polymerase 
Promega 











β-actin AC-15 mouse monoclonal 1:10000 Abcam 
p53 DO1 mouse monoclonal 1:10000 
Dr. B. 
Vojtesek 











Alexa Fluor 488-linked anti-mouse-
IgG 
goat monoclonal 1:60 
Life 
Technologies 
HRP-linked anti-mouse IgG sheep monoclonal 1:10000 
GE 
Healthcare 








RG7388 MedChem Express 
MEL23 Merck 
AMG 232 MedChem Express 
RO-5963 Merck-Millipore 
puromycin dichloride Thermo Fisher 
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2.2 Methods 
 Molecular cloning procedures 
Site directed mutagenesis 
Site directed mutagenesis was performed using QuikChange Lightning Multi Site-
Directed Mutagenesis Kit – Academic according to manufacturer’s protocol 
(#210513, Agilent).  
Splicing, R175 and H1 helix libraries design 
P53 variant libraries were prepared by cloning of double-stranded oligonucleotides 
containing individual mutations into vector HR-2-Golden-Gate. Individual single-
stranded 26, 37 and 34 bp oligonucleotides for the Splicing, R175 and H1 helix 
libraries correspondingly were synthesized by Eurofins*. Pairs of single-stranded 
oligonucleotides (sense and antisense) were reannealed to generate double-
stranded fragments with sticky ends. 
Exon5 library design 
To prepare the HDR template library a pool of 3843 230 nucleotide-long single-
stranded oligonucleotides was manufactured by Agilent using array-based synthesis 
(SurePrint technology)*. Each oligonucleotide was spanning the region Chr. 17: 
7,675,045 - 7,675,261 (assembly hg28) and contained a single codon substitution. 
The pool of single-stranded oligonucleotides was converted into double-stranded 
using PCR with primers #26 and #27 containing BbsI recognition sequences at 5’-
ends (see primer table in Materials and methods). The resulting PCR fragments 
were cloned into the modified HR-Golden Gate cloning vector.  
Golden Gate cloning 
Oligonucleotides reannealing was performed in 96-well PCR plates (Engler et al. 
2008). Each pair of oligonucleotides was mixed in individual well and after 
reannealing all double-stranded oligonucleotides were pooled together in 2 ml 
eppendorf tube. 
Reannealing buffer: 
• 10 µl 1M Tris-HCl pH=7.5 
• 10 µl 5M NaCl 
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• 980 µl H2O 
Reannealing reaction (in PCR tubes): 
• 16 µl reannealing buffer 
• 2 µl 10 µM sense oligonucleotide (dilute stock of oligo 10 times) 
• 2 µl 10 µM antisense oligonucleotide (dilute stock of oligo 10 times) 
Cycling parameters were: 95ºC 5 min, afterwards cooling down 1 degree per 30 






















* The list of all mutant libraries, sequences and raw data see on the USB stick. 
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For library assembly, Golden Gate cloning reaction included the following 
components:  
2.5 µl reannealed oligo 
1 µl HR-2-Golden-Gate vector (1µg) 
1 µl BbsI NEB (10U) 
0.5 µl DNA ligase NEB (30 U) 
2 µl 10x buffer 2.1 NEB 
1 µl 10 mM ATP (NEB or Fermentas) 
1 µl 100 mM DTT 
H2O up to 20 µl 
 
 Cycling parameters: 
37°C 2 min 
20°C 5 min 
65°C 25 min 
4°C ∞  
Golden Gate cloning reaction (in PCR tubes) was setup in three tubes. 
Samples were then pooled together before transformed into bacteria. 
TOPO cloning 
Cloning of PCR products was performed using pENTR/D-TOPO or Zero Blunt TOPO 
PCR cloning kits according to manufacturer’s protocol (#K240020, #450245 Thermo 
Fisher correspondingly).  
Bacterial culture and plasmid DNA isolation 
Transformation of cloning product was performed into electrocompetent bacteria. 
Frozen bacteria were thawed on ice and mixed with 1-2 μl of the cloning product. 
Bacteria were then transferred into a cooled electroporation cuvette and pulsed with 
1.8 kV pulse in a Micropulser (BioRad). Bacteria were incubated in 500 µl of LB 
medium for 30-40 minutes at 37°C under shaking at 250 rpm. 100-200 μl of 
transformed bacteria were plated on LB agar plates supplemented with antibiotics for 
selection of positive clones. Agar plates were incubated overnight at 37°C and 
 50x 
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clones were picked for small scale plasmid preparations. Following reagents were 
used: 
• LB medium: 5 g/l NaCl, 5 g/l yeast extract, 10 g/l Bactotryptone 
• Agar Plates: 1.5% agar-agar in LB medium with Kanamycin (50μg/ml) or 
Ampicillin (100μg/ml) 
Preparation of plasmid DNA for the libraries 
Plasmid DNA was prepared at 3 distinct scales for R175, H1 helix or Exon 5 
libraries. 
Transformation of cloning product was performed into the electrocompetent bacteria. 
2, 3 or 10 frozen bacteria aliquots were thawed on ice and mixed with 1-2 μl of the 
cloning product for R175, H1 helix or Exon 5 libraries respectively. Bacteria were 
then transferred into a cooled electroporation cuvette and pulsed with 1.8 kV pulse in 
a Micropulser (BioRad). Bacteria were incubated in 1 ml, 2ml or 5 ml LB media 
respectively for 30-40 minutes at 37°C upon shaking at 250 rpm. 100-200 μl of 
transformed bacteria were plated respectively on 5, 15 or 40 15 cm LB agar plates 
supplemented with antibiotics for selection of positive clones. Agar plates were 
incubated overnight at 37°C. Bacterial colonies were scraped from all plates using a 
rubber cell scrapper, resuspended in LB medium and used for medium scale plasmid 
preparations. 
Small scale plasmid isolation (Mini-prep) 
To screen for appropriate clones by control restriction digest and Sanger 
sequencing, small-scale plasmid preparation was performed by alkaline lysis method 
using following solutions: 
• P1 buffer: 50 mM Tris HCl pH 7.5, 10 mM EDTA pH 8.0, 100 μg/ml RNaseA 
• P2 buffer: 200 mM NaOH, 1% SDS 
• P3 buffer: 3 M potassium acetate pH 5.5 
Overnight cultures were inoculated into LB medium supplemented with Kanamycin 
(50μg/ml) or Ampicillin (100μg/ml). 2 ml of the overnight culture were centrifuged and 
resuspended in 300 μl P1 buffer. After addition of 300 μl P2 buffer bacteria were 
lysed for 5 min on ice. 300 μl of buffer P3 were added to neutralize the reaction. The 
suspension was centrifuged (10 min at 13 000 g) and supernatant was transferred 
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into a fresh tube. DNA was precipitated with 700 μl isopropanol and pelleted by 
centrifugation at 13 000 g for 30 min at 4°C. Pellets were washed once with 70% 
ethanol, dried at 37 °C for 10-20 min and resuspended in 50 μl ddH2O. DNA yield 
and quality were assessed using Nanodrop ND-1000. 
Medium scale plasmid isolation (Midi-prep) 
Medium scale plasmid preparation was performed to obtain highly purified plasmid 
DNA for transfection of eukaryotic cells or further cloning steps. Mini-prep cultures of 
scrapped bacterial colonies were used to inoculate 100 ml of LB medium containing 
proper antibiotics. Plasmid DNA purification from overnight cultures was performed 
by anion-exchange chromatography using Nucleobond Xtra Midi Kit (Macherey-
Nagel #740410.100) according to manufacturer´s protocol. 
 Cell culture 
HCT-116 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 1% penicillin (10.000 
U/ml)/streptomycin (10 mg/ml) and 0,4% amphotericin B (250 g/ml). Cells were kept 
at 37°C with 5% CO2 in humidified incubator. Passaging of cells was performed 
when cells reached confluency. Cells were washed once with 1xPBS and then 
incubated with 2% trypsin-EDTA solution for 5 min, resuspended in medium, washed 
once´and plated. Cell were counted using Beckman Culter Z-series counter. 
Following reagents were used: 
• DMEM high glucose, sodium pyruvate, with L-glutamine (#41966, Life 
Technologies)  
• FBS (#F0804, Sigma-Aldrich) 
• Amphotericin B (#A2942, Sigma-Aldrich)  
• Pen-Strep 100 units/ml penicillin, 100 μg/ml streptomycin (#15140-122, Life 
Technologies)  
• 1x PBS Dulbecco's phosphate-buffered saline without Ca2+, Mg2+ (#14190 
Life Technologies) 
• Trypsin 10x Trypsin-EDTA solution (#T4174, Sigma-Aldrich)  
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 Establishing of the HCT-116 Δ/TP53E cell line 
Transient transfection 
Cells were plated 24 hours before transfection into appropriate tissue culture dish at 
60% confluency. Number of plated cells was adjusted according to the library size to 
achieve a ratio of 1000-10000 cells per each mutation. Before transfection cells were 
washed once with serum-free DMEM. Transfection was performed in serum-free 
DMEM without additives. Lipofectamine 2000 Reagent (#11668027, 
LifeTechnologies) and DNA were diluted in Opti-MEM reduced serum medium and 
transfection was performed according to the manufacturer´s protocol. The amount of 
reagents for the transfection is shown in the table below. Medium was changed to 











6 well 2 0.2 2.5 4.6 
10 cm 10 1 12.5 23 
15 cm 20 2 25 46 
 
Three days after transfection cells were treated with 1 µg/ml puromycin for 5 days. 
After 5 days medium was changed to complete DMEM. 
Infection with Cre-recombinase adenovirus 
For reactivation of the silenced TP53 allele after editing cells were transduced with 
adenovirus expressing Cre-recombinase (Ad5CMVCre VVC-U of Iowa-5, University 
of Iowa Healthcare). Cells were plated 24 hours before infection at 60% confluency 
into an appropriate cell culture dish. Infection was performed with concentration 
sufficient to infect 50% of cells determined by titration. Cells were incubated with 
virus 30 minutes; cells were carefully swirled every 10 minutes.  After that medium 
was changed to complete DMEM. Cells were cultured 10-14 days until complete loss 
of GFP signal indicating complete Cre-mediated recombination in most of the cells. 
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 Flow cytometry and cell sorting  
To assess the efficiency of Cre-mediated recombination GFP expression in infected 
cells was tested by flow cytometry. GFP signal was quantified in the FL1-A channel 
on a BD Accuri C6 flow cytometer. Data were analyzed using BD Accuri C6 
software. 
Annexin V positive and negative cells were sorted with MoFlo Astrios sorter 
(Beckman Coulter, AY16010) using the Summit 6.3.1 software.   
 Cell imaging 
96-well plates were imaged hourly in the IncuCyte S3 time-lapse microscopy system 
(Sartorius) equipped with an IncuCyte Zoom 10× Plan Fluor objective (Sartorius). 
Imaging was performed up to 72 h at 37°C. The graphs were generated using the 
time plot feature in the graph/export menu of the IncuCyte Zoom software. Raw data 
were exported in the MS Excel and GraphPad Prism to calculate the confluency. 
 X-ray irradiation 
Cells were irradiated in 60% confluency using an X-RAD 320iX tube with settings of 
320 kV voltage and current of 8 mA with the dose rate ~1Gy/min. 
 Western blotting 
Protein extraction 
Proteins of interest were detected by western blot technique. Protein extracts were 
prepared by lysing the cells in an appropriate amount of NP40 lysis buffer 
supplemented with protease inhibitor. After three rounds of freezing in liquid nitrogen 
and thawing in warm water bath lysates were centrifuged for 20 min at 13 000 g and 
supernatant was transferred into a new tube.  
Protein concentration was measured using Bradford-based Bio-Rad Protein Assay 
(#5000006) following manufacturer’s instructions.  
Protein lysates were denatured by adding LDS sample buffer and reducing agent 
(#NP0007, #NP0009, Thermo Fisher) followed by heating at 95°C for 5 minutes. 
Protein electrophoresis and blotting 
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Denatured protein lysates were loaded on precast gels (NuPAGE Novex 4-12% Bis-
Tris). Gels were run under constant voltage (100-150 V) in NuPAGE SDS MOPS 
running buffer for 1-2 hrs.  
Proteins were transferred from gels to nitrocellulose membranes in XCell II Blotting 
modules. Blotting was performed in NuPAGE Transfer Buffer supplemented with 
15% methanol at constant voltage (100V) and current limit of 500 mA for 60-90 
minutes, depending on protein size. All antibodies were diluted in TBST containing 
5% nonfat dry milk. To avoid unspecific binding of primary antibodies, membranes 
were blocked in TBST containing 10% nonfat dry milk prior to overnight incubation 
with primary antibodies at 4°C. After three washings with TBST, HRP- or Alexa 
Fluor-488-coupled secondary antibodies were incubated for 1 hour at room 
temperature, followed by 3 washing steps with TBST. Chemiluminescent and 
fluorescent signals were detected by the Gel Doc XR System (Biorad). Following 
reagents were used: 
• NP-40 lysis buffer: 
50 mM Tris-HCl pH 7,4  
150 mM NaCl 
5 mM EDTA pH 8,0 
2% NP-40 
• Protease inhibitor cocktail complete (#04693116001, Roche) 
• Loading buffer 1x LDS sample buffer (#NP0008, Life Technologies) 
• 1x Reducing agent (#NP0009, Life Technologies) 
• SDS-Page gels NuPAGE Novex Bis-Tris Mini and Midi Gels (#WG1402BOX, 
Life Technologies) 
• Running buffer NuPAGE MOPS SDS Running Buffer (#NP0001, Life 
Technologies) 
• Protein ladder PageRuler Prestained Protein Ladder (#26616, Thermo 
Scientific) 
• Transfer buffer NuPAGE® Transfer Buffer (#NP00061, (Life Technologies) 
• Nitrocellulose membrane (#RPN303D, GE Healthcare) 
• TBS 15 mM NaCl, 5 mM Tris HCl pH 7.5 
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• TBST 1x TBS with 0.1% Tween 20 
• Nonfat dry milk Skim Milk Powder (Sigma #70166) 
• HRP substrate Western Bright Chemiluminescence Substrate Sirius (Biozym 
#541021) 
 Extraction of genomic DNA 
Purification of genomic (g)DNA from cells was performed according to 
manufacturer’s protocol using either the QIAamp DNA blood Mini Kit or Blood & Cell 
Culture DNA Max Kit (#51104 or #13362, Qiagen). DNA quality and yield were 
evaluated using microvolume spectrophotometer (Nanodrop ND-1000). 
 Extraction of RNA 
Before isolation of total RNA cells were washed once with PBS, lysed directly on the 
cell culture dish by adding 600 μl RLT buffer (#79216, Qiagen) and scraped from the 
dish. RNA was isolated from cell lysates with the RNeasy Mini Kit (#74106, Qiagen) 
according to manufacturer´s protocol using the QIAcube (Qiagen). RNA quality and 
yield were evaluated by microvolume spectrophotometer (Nanodrop ND-1000). 
cDNA synthesis 
Total RNA was reverse transcribed using the SuperScript VILO cDNA synthesis kit 
(#11754, Life Technologies) according to the manufacturer’s protocol. cDNA was 
diluted up to concentration 5 ng RNA/μl and used for qPCR. 
Reagents Amount  
RNA 500 ng 
5x VILO Script mix 2 µl 
10x SuperScript enzyme 1 µl 
ddH2O up to 10 µl 
 
Cycling parameters:  
25°C 10 min 
42°C 60 min 




Genotyping of cell lines with PCR 
Screening for correct genetic modifications during engineering of cell lines was 
performed by PCR using GoTaq polymerase (M3005, Promega) according to the 
following protocol: 
Reagents Amount  
Template ng/reaction 150 ng 
10 µM sense oligonucleotide 1 µl 
10 µM antisense 
oligonucleotide 
1 µl 
PCR buffer 4 µl 
dNTPs 0.4 µl 
DMSO 1 µl 
GoTaq polymerase 10U 0.2 µl 
H2O, ul up to 20 µl  
 
Cycling parameters:  
95 °C - 2 min 
95 °C - 0:30 min                     
56 °C – 1min/kb min           
72 °C - 0:30 min 
72 °C - 5 min 
4 °C - ∞ 
The presence of fragment was analyzed by agarose gel electrophoresis using 1,5-
2% agarose gel and RedSafe DNA stain (#21141, Chembio). 
Amplification of oligonucleotides for the exon 5 library 
Amplification was performed using primers #24 and 25 with 13 bp homology regions 
and additional BbsI recognition sequences. Fragments were purified using QIAquick 





 35 cycles        
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Reagents Amount  
Template 5 pg 
10 µM sense oligonucleotide 1 µl 
10 µM antisense 
oligonucleotide 
1 µl 
PCR buffer 4 µl 
dNTPs 0.4 µl 
DMSO 1 µl 
GoTaq polymerase 10U 0,2 µl 
H2O up to 20 µl 
 
Cycling parameters:  
95 °C - 2 min 
95 °C - 0:30 min                     
56 °C – 0:30 min 
72 °C - 0:30 min 
72 °C - 5 min 
4 °C - ∞ 
 
PCR for amplicon library preparation 
Preparation of amplicon libraries for next generation sequencing was performed 
using nested PCR. Nested PCR using two sets of primers enabled exclusive 
amplification of the mutation-carrying TP53 allele. 
The first PCR reaction was used to amplify a region from intron 4 to exon 7 from both 
p53 alleles and exclude amplification of non-recombined alleles. Amount of gDNA 
used for amplification was adjusted in order to ensure proper coverage of each 
mutant corresponded to 1,5; 0,45; 1,5 and 10 µg per replicate for splicing-, R175-, 
H1 helix and Exon 5-libraries respectively. Therefore, PCR was performed in 10, 3, 
10 and 70 parallel reactions for respective libraries. Afterwards PCR products of 
PCR reaction were pooled together and 40, 20, 40 and 280 µl of splicing-, R175-, H1 
helix- and Exon 5-library respectively were purified with QIAquick PCR Purification 
Kit (#28106, Qiagen) according to manufacturer’s instructions and eluted in 30 µl 
H2O.  
 35 cycles        
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Reagents Amount  
Template 150 ng 
10 µM sense oligonucleotide 1 µl 
10 µM antisense 
oligonucleotide 
1 µl 
PCR buffer 4 µl 
10 mM dNTPs 0.4 µl 
DMSO 1 µl 
GoTaq polymerase 10 U 0.2 µl 
H2O up to 20 µl 
 
Cycling parameters:  
95 °C - 2 min 
95 °C - 0:30 min                     
59 °C – 1:30 min                 
72 °C - 0:30 min 
72 °C - 5 min 
4 °C - ∞ 
 
The presence and concentration of 1,48 kb PCR product was detected by capillary 
electrophoresis using DNA Screening Kit QIAxcel and QIAxcel Advanced instrument 
(#929004 and #9001941, Qiagen).  
Second reaction was performed for specific amplification of the targeted mutation-
carrying allele splicing-, R175- and H1 helix libraries (primers #12-16 and #11, 17, 
18) or 270 bp long primers #12-16 and #24) for the Exon5 library. Primers #12-16 
specifically bind to mutated PAM sequence and carries internal barcodes used to 
identify reads from corresponding replicates in sequencing data. Primers #11, 17, 18 
bind in exon 5 for splicing-, R175 and H1 helix libraries. Primer #24 binds in intron 4 
for the Exon 5 library. The specificity of the PCR reaction was improved by reducing 
amount of MgCl2 and dNTPs. To reduce amounts of PCR errors amplification was 
performed in 5; 3; 5 or 10 parallel reactions for splicing-; R175-; H1 helix- and Exon 5 
library respectively. Afterwards PCR reaction products were pooled together and 
purified with QIAquick PCR Purification Kit (#28106, Qiagen) according to 
 20-25 cycles        
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manufacturer’s instructions and eluted in 30 µl H2O. The second round of purification 
was performed with Agencourt AMPure XP (63881, Beckman Coulter).   
 
Reagents Amount  
Template pg/reaction 5 pg 
10 µM sense oligonucleotide 1 µl 
10 µM antisense oligonucleotide 1 µl 
MgCl2, 25 mM 1 µl 
10x Mg2+-free PCR buffer 2 µl 
10 mM dNTPs 0.1 µl 
DMSO 1 µl 
GoTaq polymerase 10U 0.2 µl 





95 °C - 2 min 
95 °C - 0:30 min 
66 °C – 0:30 min 
72 °C - 0:30 min 
72 °C - 5 min 
4 °C - ∞ 
 
Concentration of 1,48 kb PCR product was detected by capillary electrophoresis 
DNA Screening Kit QIAxcel using QIAxcel Advanced Instrument (#929004 and 
#9001941, Qiagen).  
Triplicate samples were pooled together at equal concentrations (3.3 ng) and used 
for NGS sequencing library preparation. 
 Compound treatment 
All substances were dissolved in DMSO and stored according to manufacturer’s 
recommendations.  Compounds were titrated to determine the half maximal 
inhibitory concentration (IC50). Briefly, cells were treated with a range of 
concentrations of compounds and viability was determined after 3 days using Cell 
Titer Glo assay (#G7573, Promega). IC50 values were calculated using GraphPad 
Prism 8.0 software. Library-carrying cells were treated with compounds at their 
corresponding IC50 concentrations for 2-16 days and harvested for DNA isolation.  
 Preparation of the amplicon library for next generation sequencing  
Quantification of the mutation abundance in genomic DNA from library-expressing 
cells was performed using massive parallel sequencing (next generation sequencing, 
NGS) of amplicon libraries. Sequencing libraries were prepared from amplicons 
using NEBNext ChIP-Seq Library Prep Master Mix Set for Illumina and NEBNext 
Multiplex Oligos for Illumina (Index Primer Set 1) (E6240L and E7335S, New 
England Biolabs) according to manufacturer’s protocol. Samples were sequenced 
using MiSeq Reagent Kit v2 Nano or MiSeq Reagent Kit v3 (Illumina) on the MiSeq 
system.  
22 cycles        
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 Data analysis and software  
GraphPad Prism 8.0 
Statistical analysis, IC50 calculations, and preparation of figures were performed in 
GraphPad Prism 8.0 software. Pearson and Spearman correlation coefficients were 
calculated regarding the Normality test in GraphPad Prism 8.0. Methods used to 
infer statistical significance are shown in figure legends and in the text.  
TP53 databases 
Information about p53 mutant frequencies was taken from the UMD database. 
Scores from in silico predictors (SIFT, Polyphen2, REVEL, BayesDel, Mutassessor, 
Provean) were retrieved from the UMD database as well. Align-GVGD scores were 
retrieved from http://agvgd.hci.utah.edu/agvgd_input.php.  
Bioinformatics 
Edited regions of p53 were analyzed using paired-end AmpliconSeq 
workflow. Sequenced paired-end reads were further demultiplexed according to the 
combination of forward/reverse barcoded primer sequences found in the reads. 
Primer sequences were identified using CutAdapt (version 2.7) with a 
parametrization that allowed for a maximal hamming distance of 2 and discarded 
truncated adapter sequences ensuring that at most two mismatches were accepted. 
Subsequently, primers were trimmed from the reads and corresponding mate pairs 
were merged using NGMerge (version 0.3) using "stiched" mode with enabled 
checking for dovetailing with 3' overhangs. 
Merged reads were then compared to a set of in silico precompiled edited coding 
sequences. Since the genome editing should potentially create sequences that differ 
from the wild-type sequence only by a single base pair, merged reads were simply 
checked for identity to the expected reads and tallied. If no correspondence was 
found reads were discarded. 
Relative read counts were obtained by dividing the raw counts by the sum of all 
expected sequences omitting wild-type and non-matched read counts. 
Principal component analysis (PCA) was performed ClustVis software 
(https://biit.cs.ut.ee/clustvis/). Values of reporter genes activity extracted from the 
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study of Kato and colleagues (Kato et al., 2002) were uploaded on the website and 
processed using default parameters.  
Evolutionary conservation scores were extracted from the ConSurf database 






3.1 CRISPR-mediated Saturation Mutagenesis Screen (CSMS) 
We aimed to improve the existing methodologies for high-content analysis of TP53 
mutants and developed the CRISPR-mediated Saturation Mutagenesis Screen 
(CSMS). We have employed recent advances in the CRISPR-Cas9-mediated 
genome editing to target the library of mutants into endogenous TP53 locus via 
homologous recombination. 
A brief description of the method is shown in Fig. 4. First, the wild-type TP53 locus in 
the cell line is exchanged for the mutant allele using CRISPR-Cas9-mediated 
homology-directed repair. For this purpose, cells expressing wild-type p53 are co-
transfected with two plasmids. The first plasmid encodes the TP53-specific CRISPR-
nuclease. The second plasmid or plasmid pool contains the TP53 gene fragments 
with multiple mutations (one mutation per construct) and represents a library of 
donor templates for homology-directed repair. After co-transfection, CRISPR-
nuclease cleaves DNA in the TP53 locus. The double-strand break is repaired by 
HDR using the provided library as donor templates. As a result, the wild-type TP53 
allele is exchanged for one of the mutated alleles from the library, and the pool of 
isogenic cells containing multiple TP53 alterations is generated. Afterward, library-
expressing cells are treated with p53-activating stimuli (e.g., MDM2-inhibitor or DNA 
damaging agent). 
Activation of p53 mutants with preserved wild-type function promotes cell cycle 
arrest or apoptosis, which results in depletion of cells harboring such mutations from 
the pool. Conversely, cells carrying LOF mutants stay unresponsive to the p53-
activating stimuli and proliferate, becoming enriched in the population. Thus, 
counting the number of cells expressing a mutant before and after treatment enables 
measuring antiproliferative properties of each protein variant. The stronger the 
mutation is enriched after p53 activation, the less functional the mutant protein is. 
The abundance of cells carrying particular mutants in the population is quantified 
using massive parallel sequencing (next generation sequencing, NGS) of the TP53 
locus. Sequencing data from untreated (control) and treated samples are compared 
to identify enriched and depleted variants (Fig. 4). Finally, the enrichment score is 
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calculated for each mutant as a measure of p53 protein functionality: low enrichment 
score of depleted variants reflects preserved wt-like function, whereas high 
Figure 4. Experimental design of the CSMS 
A.  Cells are co-transfected with a CRISPR/Cas9 nuclease targeting TP53 
locus and vectors carrying a mutant library. CRISPR nuclease cleaves 
DNA in the TP53 locus. Double-strand breaks are repaired by HDR. Cells 
utilize provided library as homology recombination templates and integrate 
mutations into the locus. B. CSMS employs massive parallel 
measurement of the impact of p53 mutations on cellular fitness. Cells 
expressing the library of p53 variants are subjected to p53-activating 
stimuli and harvested later for DNA isolation, allele-specific PCR, and 
sequencing library preparation. The relative abundance of each variant is 
quantified using next-generation sequencing and compared between 
treated and untreated samples. Wild type-like mutations are depleted after 
the treatment, LOF mutations are strongly enriched after the treatment, 




enrichment score of enriched variants indicates loss of function. 
We aimed to conduct initial proof-of-concept experiments by performing saturation 
mutagenesis of the most frequently mutated hotspot codon R175 because functional 
outcomes of most mutations at this position are well studied (Freed-Pastor and 
Prives 2012; Walerych et al. 2015; Timofeev et al. 2019; Freed-Pastor et al. 2012; 
Yu et al. 2012; Xu et al. 2014). We have further expanded our analysis to the R175-
adjacent region (H1 helix) and, finally, to the complete 5th exon of TP53 
(approximately 22% of all TP53 mutations affect the 5th exon).  
3.2 TP53 targeting strategy 
For the development of the CSMS-system, we have chosen the colorectal cancer 
cell line HCT-116. HCT-116 cells respond to DNA damage and treatment with MDM2 
inhibitors with p53 stabilization, induction of p53 target genes, and undergo cell cycle 
arrest and apoptosis. These cells have been widely used during the last decade for 
studying the biology of p53 (Polyak et al. 1996; Sur et al. 2009). The cell line is 
diploid and contains two intact TP53 copies (Liu and Bodmer 2006). This allows 
inactivating one allele and manipulating the other in a hemizygous configuration to 
avoid interference from the second allele and establish clear genotype-phenotype 
correlations. Moreover, the functionality of both TP53 alleles ensures that mutations 
will be engineered in the normal genomic context with functional regulatory 
elements. In this section the general concept is described, the experimental details 
are explained in detail in following sections. 
Insertional mutagenesis mediated by homologous recombination has inherently low 
efficiency (Maruyama et al. 2015). An additional factor limiting the efficiency of 
CRISPR-mediated gene editing is p53 activation: Cas9-induced double-strand 
breaks activate the p53-dependent DNA damage response and proliferation arrest in 
the edited cells (Haapaniemi et al. 2018). To overcome these limitations and 
enhance HDR-mediated targeting, we have devised a cell line with an editable TP53-
locus (HCT-116Δ/TP53E), which enabled us to perform mutagenesis with 
unprecedented efficiency. The schematic view of the TP53 targeting strategy is 
shown on Fig. 5. One TP53 allele in this cell line (TP53Δ) is permanently inactivated 
to ensure that each cell will express a single mutant after editing. The second allele 
undergoes CRISPR-mediated editing and is therefore called “editable” (TP53E). It is 
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temporarily inactivated to disable p53-mediated DNA damage response provoked by 
CRISPR-Cas9. After completion of the gene editing, this allele is reactivated to 
express the mutant protein (Fig.5). 
We have created the cell line with described characteristics using two rounds of 
CRISPR-mediated genome editing. Initially, we were attempting to inactivate one 
TP53 allele by deleting it with a pair of two CRISPR-nucleases that target upstream 
and downstream sequences in the gene locus, respectively. However, resulting cell 
lines revealed instability and rapidly inactivated the remaining wild-type allele via loss 
of heterozygosity (LOH). Interestingly, we found that relatively small deletions in the 
5th intron completely impaired p53 mRNA splicing and protein translation. This fact 
allowed us to knock out one TP53 copy with a small intronic deletion and generate a 
Figure 5. Simplified scheme of TP53 targeting strategy 
Cells are co-transfected with a CRISPR/Cas9 nuclease targeting TP53 
locus and a vector carrying the LSL-cassette. After CRISPR/Cas9 
overexpression the first p53 allele is permanently inactivated by deletion. 
The second allele is temporary inactivated by the integration of LSL-
cassette. Next, this cell line undergoes transient transfection with 
CRISPR/Cas9 nuclease targeting TP53 locus in the LSL-allele and vector 
carrying a single p53 mutation or a plasmid mutant library. After infection 
with adeno-Cre LSL-cassette is excised and mutant p53 expression is 
restored. 
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genetically stable cell line with a single active TP53 copy.  
Therefore, in the first editing round, we have used a single CRISPR-nuclease to 
induce a deletion in the intron 5 of one TP53 allele. In the same gene editing step, 
we have integrated the transcription termination cassette (lox-stop-lox, LSL carrying 
green fluorescent protein (GFP) and the puromycin selection marker) into the 4th 
intron of the second TP53 allele using homologous recombination. 
HDR-mediated integration of the LSL cassette into the TP53 locus created the 
conditionally silenced allele and enabled the selection of targeted cells using 
puromycin resistance or GFP expression. Additionally, erroneous repair of the 5th 
intron by Cas9-nuclease in the edited conditional allele (TP53E) has generated a 
single nucleotide variant (SNV). The SNV was used as an allele-specific recognition 
site for CRISPR-nuclease in the second gene editing round. 
In the second step of editing, we have employed the allele-specific CRISPR-
nuclease to induce double-strand breaks exclusively in the TP53E allele and to target 
the library of TP53 variants into the locus. Lack of p53 expression (the second allele 
is permanently inactivated) enabled to increase the editing rate due to dampened 
DNA-damage response.  
After the second editing round, the silenced conditional TP53E allele was turned back 
into an active state by Cre-recombinase expression, which excised the LSL cassette.  
As a result, a population of cells expressing a single mutant or a pool (library) of 
mutants from a single TP53 allele was generated. 
To validate the system, we decided to perform mutagenesis of the small region of 
the gene. Therefore, initially we have focused on the most frequently mutated codon 
R175. Next, we have explored the adjacent region (H1 hellix) which contains several 
functionally important conserved residues (e.g. C176, H179, E180, R181). Later we 
have performed mutagenesis of the complete 5th exon of the TP53 gene. Targeting 
of the exon 5 is described in section 3.10. 
3.3 Generation of the targeting vector for homologous recombination-driven 
TP53 editing 
To engineer the endogenous TP53 locus we have designed a series of plasmid 
templates for homologous recombination (targeting vectors). One vector was used to 
generate the editable TP53 allele; the others were utilized for the mutagenesis. 
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For conversion of the wild-type TP53 allele into the editable one we have designed 
the targeting vector (HR-1) consisting of the following components: 
- the HA700PA-1 backbone (Fig. 6A), 
- two homology arms spanning the region between 4th exon and 6th intron of TP53 
(chr. 17:7.676.244-7.674.422, GRCh38 assembly),  
- lox-STOP-lox (LSL) cassette in the 4th intron, composed of two LoxP sites flanking 
the puromycin N-acetyl transferase gene (pac, confers puromycin resistance), green 
fluorescent protein gene (GFP), the transcription termination sequence (STOP) and 
insulator sequences (to prevent activation of endogenous genes by the EF1 
promoter in the proximity of the integration site). 
Homology arm one spanning 3’-end of the exon 4 and 5’-end of the intron 4 (chr.17:  
Figure 6. Schematics of the targeting vector for HDR-mediated TP53 
editing 
A. Vector HR700PA-1 contains two polylinkers (MCS) for cloning of the 
homology arms and the LSL cassette (used for selection of targeted cells, 
harbors GFP and puromycin resistance genes and the transcription 
terminator sequence (STOP) flanked by insulators and LoxP sites). 
Integration of the LSL cassette into the TP53 locus leads to silencing of 
p53 expression. B. Assembly of the HR-1 targeting vector. TP53 
homology arms were amplified from genomic DNA and cloned into MCS 1 
and 2. The location of primers for amplification of homology arms is 
shown with arrowheads. Coordinates are according to the GRCh38 
human genome assembly. 
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7.676.224-7.675.841) was amplified by PCR from genomic DNA of HCT-116 cells. 
The amplicon was digested with BsaI and BsrGI and ligated into the multiple cloning 
site (MCS1) of the HR700-1A vector (Fig. 6B) (primers #1, 2). Homology arm two 
spanning the region between exon 4 and intron 6 (chr.17: 7.675.842-7.674.422) was 
amplified using primers to the 3’-end of intron 4 and 5’-end of the intron 6 and cloned 
via SalI and MluI digestion and ligation into MCS2 of the HR700-1A vector with 
previously cloned homology arm one (primers #3, 4) (Fig. 6B). 
3.4 Establishment of the TP53-hemizygous HCT-116Δ/TP53E cell line using HR-1 
targeting vector  
The efficacy of homologous recombination strongly depends on the distance 
between the homology arm and the double-strand break (Elliott et al. 1998). To 
ensure the complete replacement of the endogenous H1 helix region at the end of 
exon 5 with the mutants’ library, we have located the targeting site for the Cas9 
nuclease in direct proximity of this region in intron 5 (Fig. 7A). 
In the first step, we have co-transfected parental HCT-116 cells with a plasmid 
encoding Cas9 nuclease with intron 5-specific single guide RNA (sgRNA) (pX330-
sgRNAp53i5) and an HR-1 targeting vector. Cells with an integrated targeting vector 
were selected with puromycin (Fig. 7A). Then resistant transfectants were treated 
with MDM2-inhibitor nutlin for 14 days to enrich the population for p53-null cells, 
which either harbor TP53 allele temporarily inactivated by the LSL-cassette, or 
inactivating deletion or both. This nutlin-enriched population was subcloned to select 
a cell line with the desired configuration of TP53 alleles. For this purpose, cells were 
plated at clonal density, single-cell clones were isolated, and gDNA from the clones 
was analyzed for the correctly integrated targeting vector using PCR. Forward primer 
#7 (Fig. 7B) was located in the LoxP site in the targeting vector, whereas reverse 
primer #10 (Fig. 7B) was placed in the 7th exon, located downstream of the right 
homology arm. Therefore, amplification proceeded only with template DNA from 
clones with on-target integration of the targeting vector (Fig. 7B,C). Clones 1, 3, and 
5 with confirmed on-target integration of the HR-1 vector were amplified and infected 
with the Cre-recombinase-expressing adenovirus (adeno-Cre) to excise the LSL 
cassette and restore p53 expression. Two weeks after infection, cells were treated 
for 24 hours with 10 µM nutlin to activate p53 and analyzed with western blotting 
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together with lysates from non-infected cells. As shown in Fig. 7D, clones have 
responded to adeno-Cre infection differently. Clone 3 showed no reactivation of p53 
upon adeno-Cre infection and nutlin treatment, suggesting complete inactivation of 
both alleles. Clone 5 revealed high levels of p53 in the absence of Cre, indicating 
that at least one allele was spared by editing. Finally, clone 1 was identical to p53-
knockout cells under basal conditions (lanes 5 and 6) but demonstrated Cre-
dependent restoration of p53 expression (lanes 7 and 8), implying that at least one 
TP53 allele contained an integrated targeted vector with the LSL cassette. Moreover, 
similarly to p53 wild-type cells, clone 1 revealed nutlin-dependent p53 stabilization 
and expression of the p21 protein, as expected for the cell line carrying the  
conditional p53 allele.  
To confirm that the TP53 locus in the engineered cell line had the desired 
configuration, we have designed a series of PCR primers to generate amplicons 
covering the region between 4th and 6th exons. The location of amplicons and 
sequencing results are shown in Fig. 7E. 
First, we have amplified DNA with primers #5 and #10 (upper part of Fig. 7E). This 
primer pair amplified the 1,6 kb long fragment from the intact intron 4. Integration of 
the LSL cassette would generate the 4.6 kb long fragment; therefore, the targeted 
allele was not amplified. Sanger sequencing of the 5’-end of the amplicon showed 
the intact sequence of the TP53 intron 4 without the integration of the LSL cassette 
(upper left chromatogram, the dashed line shows the boundary between intron 4 and 
LSL cassette in the targeting vector). The sequence of the 3’-end of the same 
amplicon contained 15-bp deletion at the CRISPR-nuclease recognition site (upper 
right chromatogram). Since cells did not express detectable levels of p53 in the 
absence of adeno-Cre (Fig. 7D, lanes 5 and 6) we have concluded that the first allele 
in the engineered cell line contained inactivating deletion and designated this allele 
as TP53Δ. 
Next, we have selectively amplified the second, targeted allele with primers #6 and 
#10 (primer #6 is specific to the pac gene) (Fig. 7E). The sequencing of the resulting 
amplicon confirmed integration of the targeting vector in the TP53 locus (5’ end of 
the amplicon was identical to the pac sequence from the vector, lower left 
chromatogram). Since the treatment of cells with Cre-recombinase led to re-
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expression of p53 (Fig. 7D, lanes 7 and 8), we concluded that the second allele was 
converted into a conditional allele by the integration of the targeting vector. Notably, 
the sequencing of the 3’-end of the same amplicon revealed a single nucleotide 
insertion in the 5th intron (lower right chromatogram). This single nucleotide variant 
(SNV) was exploited as a target site for allele-specific CRISPR-nuclease in the 
second editing step. We have designated the second allele in the cell line as editable 
(TP53E). 
The stability of the cell line properties was confirmed by analyzing three independent 
subclones of clone 1 from Fig. 7F for their ability to restore p53 expression upon 
adeno-Cre infection and upregulate p21 after nutlin treatment (Fig. 7F). The 
established cell line Δ/TP53E.1 was designated as HCT-116Δ/TP53E and was utilized 
in all consecutive experiments.  
Western blotting (Fig. 7F) revealed that HCT-116Δ/TP53E cells show markedly lower 
p53 and p21 expression after adeno-Cre infection and nutlin treatment than the 
parental cell line (compare lanes 1 and 3 with lanes 7 and 8). P53 is a known 
haploinsufficient tumor suppressor. In line, the lack of one gene copy was shown to 
significantly decrease mRNA and protein levels in HCT-116 cells (Lynch and Milner 
2006). Insufficient expression of p53 could potentially lead to reduced activity and, 
consequently, to improper classification of wild-type-like variants. We have 
addressed this issue in Discussion.  
The selection of cells after homologous recombination is essential to ensure a high 
yield of edited cells. HCT-116Δ/TP53E cells already contained a puromycin resistance 
gene in the TP53E allele. To enable the puromycin selection of the targeted cells 
carrying the library in the second round of editing, we have inactivated the pac gene 
using CRISPR/Cas9. We have designed a single guide RNA specific to the pac 
gene, cloned it into pX330 vector, and transfected into HCT-116Δ/TP53E cells. (Fig. 
7G). We expected that double-strand breaks induced by the pac-specific Cas9 
nuclease would be repaired via NHEJ generating inactivating indels. For the 
selection of cells with inactivating pac mutations, single-cell clones were isolated and 
tested for puromycin sensitivity. One clone with restored puromycin sensitivity was 











Figure 7. Establishment of the TP53-hemizygous cell line HCT-
116
Δ/TP53E 
for highly efficient editing of the TP53 locus 
A. HCT-116 cells were co-transfected with the plasmid encoding 
CRISPR nuclease targeting intron 5 of TP53 and donor template for 
homologous recombination (HR-1). Blue rectangles represent active 
alleles, grey – inactive. Transfected cells were selected with puromycin. 
Afterward cells with the functional p53 were eliminated by nutlin 
treatment. Single-cell clones were established and genotyped. B. The 
desired configuration of the TP53 locus after targeting. Primers used for 
genotyping of single-cell clones are shown as arrowheads. Primers #7 
and #10 were used for the identification of clones with correct integration 
of LSL cassette, primers #8 and #9 - for Sanger sequencing of the intron 
5, primer #5 was used for Sanger sequencing of the intron 4, primers #6 
and #10 were used for amplification of the LSL cassette, primer #6 was 
used for Sanger sequencing of the LSL cassette. Black dot – single 
nucleotide variant (SNV), +T insertion in the targeted conditional allele. 
Red triangles: Lox-P sites. C. Identification of single-cell clones with the 
correct integration of the targeting vector using PCR with primer #7 to 
LSL cassette and #10 to the exon 7. Single cell clones are labeled from 1 
to 22. 1.4 kb PCR fragments corresponding to targeted TP53 alleles are 
labeled. Parental HCT-116 cells serve as a negative control. D. Western 
blot analysis of p53 and p21 expression in 3 clones with targeted TP53 
alleles from (C) (designated as Δ/TP53
LSL
). Cells were infected with 
adenovirus encoding Cre-recombinase and after 2 weeks were treated 
with 10 µM nutlin for 24h. Clone 1 demonstrates the Cre-controlled 





To summarize, the engineered HCT-116Δ/TP53E cell line has the following properties. 
1. One copy of the TP53 gene is permanently inactivated by a 15-bp deletion in 
intron 5 to ensure a single active TP53 allele presents in each cell. 
2. The second conditional “editable” TP53 allele (TP53E) is temporarily 
inactivated by the LSL cassette to allow editing in p53-negative background. 
After editing is completed, the allele is reactivated by Cre-recombinase, and 
p53 is re-expressed. 
3. TP53E-allele can be targeted by the allele-specific CRISPR-nuclease directed 
against a single-nucleotide variant in intron 5 (Fig. 7H). Thereby monoallelic 
integration of the library of p53 variants in the following round of genome 
editing is ensured. 
Figure 7. Continued 
E. Sanger sequencing results and schematic representation of two TP53 
alleles of the clone 1 (from D). Two upper chromatograms demonstrate 
the intact intron 4 without vector integration (vertical dashed line shows 
the end of homology arm 1 and the beginning of the homology arm 2) and 
the 15 bp inactivating deletion in the 5
th
 intron (dotted line) of one allele 
(TP53
Δ
). Amplicon was produced using primers #5 and #10 and 
sequenced using primers #5, 8, and 9. Two lower chromatograms 
demonstrate the integration of the LSL cassette into the second allele and 
+T insertion (SNV) in the targeted conditional allele (TP53E). Sequenced 
amplicons are shown with dashed lines, primers shown with arrows. 
Amplicon was sequenced using primers #6, 8, and 9.  Red triangles: Lox-
P sites. F. Western blot analysis of p53 and p21 expression in three 
independent single-cell subclones of the clone 1 from (D) after 
transduction with adeno-Cre. Cells were treated with 10 μM nutlin for 24h 
to stabilize p53. Parental cells (WT) and TP53-knockout cells (KO) were 
used as positive and negative controls respectively. β-actin serves as a 
loading control. G. Restoration of the puromycin sensitivity in HCT-
116
Δ/TP53E 
cells via inactivation of the pac gene. Cells were transfected 
with the plasmid encoding sgRNA targeting pac, single-cell clones were 
established and tested for puromycin sensitivity. H. Schematics of the 
TP53 locus of the HCT-116
Δ/TP53E 
cell line. The puromycin-sensitive cell 
line contains one allele inactivated by 15 bp CRISPR-induced deletion in 
the intron 5. The second allele contains the cassette with the non-
functional pac gene and GFP in the intron 4 (red cross). 
74 
4. The puromycin resistance gene in the HCT-116Δ/TP53E cell line is disrupted, 
making cells puromycin-sensitive. Therefore, cells that successfully 
underwent recombination with the pac-containing HDR template can be 
selected. 
3.5  Generation of cell pools expressing p53 variants 
To introduce mutations into the TP53E allele, we have employed the second round of 
genome editing. We first aimed to perform mutagenesis of the codon R175 and the 
adjacent region (H1 helix). To generate the library of targeting vectors carrying 
mutations, we have utilized the Golden Gate cloning procedure. The protocol 
enables the rapid single-step cloning of inserts into the vector with almost 100% 
efficiency (Engler et al. 2008). Golden Gate cloning procedure utilizes the digest of 
the vector with the Type IIs restriction enzyme, which cleaves DNA outside the 
recognition site, ensuring seamless cloning. To make the HR-1 targeting vector 
compatible with this procedure, we have performed site-directed mutagenesis and 
introduced two recognition sites for the type IIs enzyme BbsI into the vector. Since 
we first aimed to modify the hotspot codon R175 and the H1 helix domain, we have 
flanked this region with the recognition sites. Cleavage of this vector with BbsI 
generates two pairs of incompatible sticky ends that can be ligated only with double-
stranded oligonucleotides with corresponding compatible sticky ends (Fig. 8). This 
precludes circularization of the empty vector and ensures superior cloning efficiency. 
Additionally, a dinucleotide mutation was introduced into the vector to destroy the 
protospacer-adjacent motif (PAM) in the 5th intron in the donor template (TCC to 
TGG, chr.17:7.674.839-7.674.841). The PAM sequence is essential for the binding 
of CRISPR nuclease to DNA. Therefore, its mutation in the HDR template prevents 
cleavage of transfected plasmid and the recombined allele. In addition, the GG 
dinucleotide was used as the unique primer binding site for the amplification of the 
TP53 DNA exclusively from library-carrying cells. Thereby cells that were not 
targeted and retained the non-edited TP53E allele were excluded from further 
analysis. The resulting vector was named HR-2-Golden Gate.  
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As a first step we have introduced single mutations one by one into the modified 
targeting vector by cloning double-stranded oligonucleotides using the Golden Gate 
protocol (Fig. 8). To do so, a pair of single-stranded complementary oligonucleotides 
Figure 8. Generation of the HDR template vector for the introduction 
of the library of H1 helix mutants into TP53 locus (HR-2-Golden Gate) 
To enable Golden Gate cloning of the oligonucleotide library into the 
targeting vector, two BbsI recognition sites in opposite orientation were 
introduced into the sequence encoding H1 helix in the right homology arm 
of the HR-1 targeting vector using site-directed mutagenesis (BbsI 
recognition sequences are marked in red, cleavage sites are marked with 
arrowheads). 34 bp double-stranded oligonucleotides with 4-bp 
overhangs encoding variants of the H1 helix (5
th
 exon) (shown in blue) 
were cloned into the vector either separately or as a pool using Golden 
Gate cloning protocol. R181E mutation is shown as an example. HR-2-
Golden Gate vector contains a mutated PAM sequence in the intron 5 
(GG). GG dinucleotide is used as a primer annealing site for specific 
amplification of the edited allele (arrow). For mutagenesis of the full exon 
5, the vector was redesigned to allow cloning of 230 bp oligonucleotides 
spanning exon 5 (HR_Exon5) (section 3.10). 
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with a mutation was designed to form two sticky ends compatible with the BbsI-
digested HR-2-Golden Gate vector. Oligonucleotides were annealed and cloned into 
the HR-2-Golden Gate vector. Cloning product was transformed in E. coli; bacteria 
were plated on LB-agar plates. Plasmid DNA purified from harvested colony and was 
designated as vector carrying a single p53 mutation. To examine the presence of a 
TP53 mutation a fragment was amplified with primers #3 and #4 and sequenced 
using Sanger sequencing. Co-transfection of cells with the pX330 plasmid encoding 
the allele-specific sgRNA and targeting vector resulted in HDR-mediated integration 
of the mutation into the TP53E allele (Fig. 9A). Subsequent puromycin selection 
generated a mutation-carrying cell line (Fig. 9B). After infection with adeno-Cre the 
LSL-cassette was excised, restoring the p53 expression (Fig. 9C). 
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3.6 The HCT-116Δ/TP53E cell line enables highly efficient HDR-mediated 
mutagenesis of the endogenous TP53 locus 
To test the efficiency of mutagenesis in our system, we have introduced a single 
inactivating mutation (R181E, CGC > GAA) in the H1 helix-encoding region of the 
TP53E allele, as shown in Fig. 10A. This mutation destroys the AfeI restriction site. 
Therefore, cells can be easily genotyped using restriction fragment length 
polymorphism analysis. Following the co-transfection of the pX330-sgRNAp53i5 
plasmid encoding the TP53E-specific CRISPR nuclease with the HR-vector carrying 
the R181E donor, template cells were selected with puromycin. Afterward, 13 single-
Figure 9. Schematic representation of the introduction of variants 
into the TP53
E
 allele of the HCT-116 
Δ/TP53E 
cell line using HDR 
A. Cells were co-transfected with the plasmid encoding the CRISPR 
nuclease targeting the 1-bp insertion in the intron 5 of the TP53
E
 allele 
(black dot, SNV) and HR-2-Golden Gate vector carrying a single mutation 
or a mutagenic library (red rectangle in the exon 5). GG denotes the 
mutated PAM-sequence which prevents repeated cleavage of the 
targeted allele and is used as a site for primer binding. B,C. Schematic of 
the conditional allele carrying a single p53 mutation or the variant library 
before (B) and after (C) Cre-mediated restoration of the p53 expression. 





cell clones were established, and genomic DNA was assayed for HDR template 
integration. Strikingly, amplicons from 11 clones were resistant to AfeI digestion, 




Figure 10. Highly efficient introduction of the R181E mutation into 
the TP53 locus of the HCT-116 
Δ/TP53E
 cell line 
A. Schematic of the TP53 locus in the cell line targeted with the donor 
template carrying the R181E mutation. AfeI recognition site is disrupted 
by the mutation (red rectangle). Arrows indicate primers used for the 
allele-specific PCR. Bottom: PCR-RFLP-genotyping of single-cell clones 
of HCT-116
Δ/TP53E
 cells co-transfected with the CRISPR plasmid and the 
HR-2 Golden Gate-R181E donor template. PCR fragments from 11 of 13 
clones were resistant to digest with AfeI, demonstrating targeting efficacy 
of 75%. KO - cell line with the deletion spanning exons 2 to 9 of TP53, 
used as a negative control, WT – parental HCT-116 cells serve as a 
positive control for AfeI digestion. B. Western blot analysis of p53 and 
p21 expression after infection with adeno-Cre in parental (WT), p53-null 
(KO), and HCT-116 
Δ/TP53E 
cells as well as in one of the R181E-carrying 
clones from (A) (untreated and nutlin-treated). C. Sanger sequencing 
confirms the presence of the R181E mutation in the genomic DNA of the 
engineered cell line. 
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allele (Fig. 10A). After adeno-Cre infection, expression of p53 was restored, but no 
p21 activation was evident after nutlin treatment in agreement with transactivation 
deficiency of the R181E mutant (Fig. 10B) (Timofeev et al. 2019; Schlereth et al. 
2010a; Schlereth et al. 2013; Kitayner et al. 2006; Dehner et al. 2005). Finally, 
successful targeting in 11 clones was confirmed with Sanger sequencing (Fig. 10C). 
 Later, a panel of 8 mutant cell lines was generated in our group using a similar 
approach (data courtesy of Julianne Funk, Michelle Neuman, and Pascal Hunold). 
The presence of desired mutations in all cell lines (R175Stop, R175H, R175P, 
C176F, H179R, R181L, R181P, and E180R) (Fig. 11A) was validated with Sanger 
sequencing (Fig. 11B) and western blot after nutlin treatment (Fig. 11C). 
Additionally, two other cell lines carrying H1 helix mutants (S183A, S185A, and 
S183D, S185D) were established using the approach developed in this work. These 
cell lines were used to explore the importance of H1 helix phosphorylation for tuning 
the p53 activity (Fig. 11D) (Timofeev et al. 2020). 
Summarizing, the HCT-116Δ/TP53E cell line together with a set of targeting vectors and 
corresponding protocols established in this work comprise a highly effective system 
for targeted mutagenesis of the endogenous TP53 locus.  
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3.7 The HCT-116Δ/TP53E cell line enables the introduction of 
multiple mutations into the TP53 locus: construction of the R175 
mutagenic library, assessment of the library quality, and targeting 
efficiency 
CSMS approach requires the efficient generation of mutational diversity. To test if 
the HCT-116Δ/TP53E cell line is suitable for massive parallel mutagenesis, we have 
constructed a library representing all possible variants of the hotspot codon R175. 
The library was composed of 27 oligonucleotides encoding 19 amino acid 
substitutions, three synonymous mutations (R175R), one stop codon (TGA), R175 
deletion, and three frameshift mutations (+1, -1, and -2). The HDR template was 
prepared by cloning a pool of all double-stranded oligonucleotides into the HR-2-
Golden Gate vector. Before establishing a cellular library, we have verified the 
presence of all variants in the donor vector by NGS. Vector fragments were amplified 
with primers flanking the R175 region sequence (primers #11 and 12). After 
sequencing, the number of reads corresponding to each variant was calculated. 
Normalized read counts were calculated by dividing the number of reads assigned to 
each variant by the total amount of reads in the sample. The analysis revealed that 
all variants were presented in the library. Mutation frequencies were normally 
Figure 11. HCT-116 
Δ/TP53E
 enables the of the panel of isogenic cell 
lines with H1 helix mutations 
A. Schematic of the TP53 locus in the HCT-116
Δ/TP53E
 cell line and the list 
of mutations introduced. Primers used for Sanger sequencing are shown 
with arrows. B. Sanger sequencing confirming the successful generation 
of mutant isogenic cell lines. Data courtesy of Julianne Funk and Pascal 
Hunold. C. Western blot analysis of p53 and p21 expression in HCT-
116
Δ/TP53E 
cell (before and after adeno-Cre infection, Δ/E and Δ/WT) and in 
8 isogenic cell lines expressing corresponding p53 mutants. No 
expression of p21 by mutant cell lines under nutlin treatment is evident 
except cells expressing a known pLOF mutant R181L. Data courtesy of 





cells (in response to 
doxorubicin, after adeno-Cre infection, Δ/WT and Δ/E cells serve as 
positive and negative controls). Data courtesy of Oleg Timofeev and 
Constantin Niederau.  
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distributed (Kolmogorov-Smirnov test p>0.1, skewness 0.74) and none of the 
variants were lost from the pool, which demonstrates that cloning protocol generates 
libraries with fairly uniform coverage (Fig. 12). 
After transfection of cells with a plasmid encoding the allele-specific CRISPR-
nuclease and a pool of HDR templates and consecutive puromycin selection, a 
population of library-carrying cells was established. 
Next, we have assessed the targeting efficiency. From our experience, adenoviral 
infection is stressful for cells. Therefore, to exclude stress-induced changes in 
variant abundance, we have first analyzed cellular libraries before adeno-Cre 
infection. We have isolated genomic DNA from cells and amplified it using two 
rounds of PCR.  
CRISPR-nucleases always demonstrate some degree of unpredictable off-target 
cleavage (Wang et al. 2020; Chakrabarti et al. 2019; Tuladhar et al. 2019; Zhang et 
al. 2015). To exclude the possibility that changes in variant abundance are caused 
by off-target damage of the irrelevant gene, we have always maintained the amount 
of input DNA used for sequencing library preparation above a certain threshold. This 
ensured the amplification of variants from a sufficient number of different cells and 
minimized random off-target effects. We calculated a minimal amount of genomic 
DNA for PCR as follows: 
Figure 12. Distribution of variant frequencies across the R175 library 
The relative abundance of sequence variants in the plasmid pools 
carrying saturation R175 mutagenic library in the three independently 
prepared replicates of the HR-2-Golden-Gate plasmid. Fraction of reads 
±SD for each variant is shown. 
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gDNA amount = x∙1000∙6 pg 
 
where x – the number of mutations in the library, 1000 – desirable representation of 
each mutant in the sequencing library, 6 pg – the amount of DNA in one diploid cell. 
The calculated amount was increased by 30% to account for a fraction of non-
recombined cells after adeno-Cre infection (amount of non-recombined GFP-
expressing cells did not exceed 30% as determined by flow cytometry, data not 
shown).  
In the first PCR round, the TP53E allele was amplified using one primer annealing to 
the LSL cassette and the other annealing to the sequence downstream of the donor 
template (exon 7, primers #7 and #10) (Fig. 13A). Using this primer combination 
precluded the amplification of HDR templates falsely integrated outside of the TP53 
locus. The second allele (TP53Δ) failed to amplify due to the absence of the LSL 
cassette. The second PCR round with a primer specific to the dinucleotide mutation 
in the 5th intron (CC > GG) ensured exclusive amplification of DNA from the properly 
edited allele (primers #11 and 12-14) (Fig. 13B). During all PCR steps, the number of 
cycles was kept below 20-25 to minimize amplification bias.  
PCR products were used to construct the fragment library for massive parallel 
amplicon sequencing. Before library preparation, PCR fragments were purified, and 
their concentrations were adjusted. To exclude PCR errors, each sample was 
amplified in three independent PCR reactions, and then products were pooled. 
Molecular barcoding was used to enable parallel sequencing of multiple samples. 
First, three allele-specific primers (#12-14) with unique barcodes were employed 
(Fig. 13B). Groups of three barcoded samples were combined and additionally 
barcoded during the library preparation step using the NEBNext kit. Such a strategy 
enabled parallel sequencing of up to 90 samples. Libraries were sequenced using 
Illumina Miseq sequencer and analyzed as described in section 2.2.10. To assess 
the reproducibility of the procedure, all experiments were performed three times, and 
triplicate samples from every test condition were sequenced. After sequencing, read 
counts for each variant were calculated and normalized to total read counts in each 
sample as described above.  
84 
 
The distribution of mutations in the cell population before Cre-mediated p53 
activation was strongly correlated with the distribution in the targeting vector 
(r2=0.94) (Fig. 14A). The abundance of individual mutants was very similar between 
triplicate preparation of cellular libraries (r2=0.98) (Fig. 14B). Therefore, our approach 
reproducibly generates cell libraries with significant mutational diversity in the TP53 
locus. 
Figure 13. Preparation of the amplicon library before Cre-mediated 
recombination using nested PCR 
A. In the first round of PCR only the TP53
E
 allele was amplified due to the 
specificity of a primer #7 to the LSL cassette. Mutations are shown with a 
red rectangle. B. In the second round of PCR, a primer specific to the 
GG-dinucleotide in the conditional allele ensured the selective 
amplification of the targeted allele with the full-length integration of the 
targeting vector. Cells that have undergone partial targeting (LSL 
cassette is integrated, the mutation is not integrated) were excluded from 
amplification. Primers and amplicons are indicated with arrows and 





Next, cells were infected with adeno-Cre to restore p53 expression from the 
conditional TP53E allele. Fourteen days after infection, genomic DNA was isolated 
and amplified using two rounds of PCR. In the first PCR round, the Cre-recombined 
TP53E allele was amplified together with the inactive second allele (primers #5 and 
10, Fig. 15A). Under the chosen conditions, residual non-recombined TP53E alleles 
containing the LSL cassette failed to amplify due to their large size (Fig. 15A). The 
second round of PCR with a primer specific to the dinucleotide mutation in the 5th 
intron (CC > GG) ensured exclusive amplification of DNA from the properly edited 
and recombined allele (Fig. 15B, primers #11 and 12-14). Sequencing data from 
triplicate samples were analyzed as described above. Analysis of mutation 
frequencies in cultures after Cre-mediated p53 activation revealed a strong 
correlation between triplicates, Rs=0.96 and 0.97, respectively (Fig. 16A). 
Reassuringly, comparing the relative abundance of variants in cellular libraries 
before and after Cre-mediated p53 activation also revealed a remarkable correlation 
(Fig. 16B, Rs=0.85, 0.9 and 0.87 respectively, p<0.0001). These data further 
demonstrated the reproducibility of the developed mutagenesis procedure and 
highlighted the stability of library-expressing pools after adeno-Cre infection.  
A B 
Figure 14. CRISPR-mediated homologous recombination in HCT-
116
Δ/TP53E 
cells results in the reproducible introduction of the R175 
site-saturation library into the TP53 locus 
A,B. Correlation of normalized read counts for each of the 27 variants 
between (A) triplicates of the plasmid library and library-expressing cells 
before adeno-Cre infection, (B) triplicate cultures of library-expressing 
cells before adeno-Cre infection. r
2 
- squared Pearson correlation 
coefficient. 
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3.8 System validation: CSMS quantifies anti-proliferative capacity of p53 
variants 
We have used two metrics to measure the impact of mutations on tumor cell fitness: 
enrichment score and relative fitness score. The enrichment score (ES) is a measure 
of the relative enrichment or depletion of the variant in a given sample, where p53 
was activated by treatment, compared to the untreated sample. It was calculated as 
a ratio between normalized read counts (n) in the treated and untreated sample: 
A 
B 
Figure 15. Preparation of the amplicon library after Cre-mediated 
recombination using nested PCR 
A. In the first round of PCR the non-recombined TP53
E
 allele (above) 
was not amplified due to its the large size (3.5 kb) and was excluded from 
the amplicon library. Recombined TP53 allele without LSL-cassette and 
inactive second allele were both amplified (below). The mutation is 
shown with a red rectangle. B. In the second round of PCR a primer 
specific to the GG-dinucleotide in the conditional allele ensured selective 
amplification of the targeted allele and exclusion of the second inactive 
allele. Primers and amplicons are indicated with arrows and dashed lines. 
Amplicons were purified and used for NGS library preparation.  
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ES=ntreated/nuntreated. The relative fitness score (RFS) was calculated as log2-
transformed ES (RFS=log2ES).  
It was expected that cells carrying wild-type p53 and mutants with preserved function 
would respond to p53-activating stimuli with cell cycle arrest or apoptosis. Such 
variants would be depleted from the population, generating low ES values and 
negative RFS values. Conversely, cells expressing LOF mutants would remain 
unaffected and continue to proliferate, leading to the expansion of the variant and 
Figure 16. Restoration of the p53 expression after adeno-Cre 
infection does not change the abundance of the variants. 
A. Correlation of normalized read counts for each of the 27 variants in 
triplicate cultures of library-expressing cells after adeno-Cre infection. r
2
 - 
squared Pearson correlation coefficient. B. Correlation of normalized 
read counts between three independent replicates before and after 
infection with adeno-Cre. r
2





generating high ES or positive RFS values at the endpoint analysis. For most of the 
calculations, non-log-transformed ES values were used. To ease data interpretation, 
we used RFS values in heat maps (positive RFS values show enrichment (red color), 
negative RFS values show depletion (blue color). We have first measured the 
dynamics of each variant in the R175 library during eight weeks of passaging. We 
have collected and sequenced DNA samples 2, 4, 6, and 8 weeks after adeno-Cre 
infection. Analysis of sequencing data revealed modest changes in relative variant 
abundance after eight weeks of culture (Fig. 17A). Synonymous (wild-type-like) 
mutations R175R were slightly depleted during passaging (RFS=-0.5), while several 
missense and nonsense variants were marginally enriched (RFS=0.2-0.3). 
Our recent study has demonstrated that HCT-116 cells are highly tolerant to the 
expression of wild-type p53 and that p53 depletion gives them only a weak 
proliferative advantage (Klimovich et al. 2019). Therefore, minor changes in the 
abundance of mutants imply that their expression from the edited allele does not 
exceed normal physiological levels and that changes observed can be predominantly 
related to the stress induced by adenoviral infection. 
To validate the ability of CSMS to measure the anti-proliferative capacity of p53 
mutants, we have activated p53 in library-expressing cells with a panel of MDM2-
inhibitors. We have utilized five structurally distinct p53-activating compounds.  
Nutlin-3a was chosen as the first-in-class compound and the most extensively tested 
MDM2 antagonist (>900 citations in Pubmed). To improve the clinical relevance of 
our data, we have included three compounds that are currently undergoing clinical 
evaluation: a nutlin derivative with improved potency RG7388 (Hoffmann-La Roche) 
and two structurally unrelated compounds: the piperidinone AMG 232 (Amgen) and 
the spirooxindole MI-773 (15, 8, and 2 clinical trials respectively, clinicaltrials.gov). 
Finally, RO-5963 was added to our drug panel as a member of the class of dual 
MDM2/MDM-X inhibitors (Graves et al. 2012). Using several structurally distinct 
compounds allowed us to address several issues. First, to our knowledge, a 
systematic comparison of the efficacy of structurally distinct MDM2 antagonists 
against cells expressing multiple mutant p53 variants has not been performed so far. 
Second, using five distinct compounds could improve the robustness of the 
screening and address potential off-target effects of the inhibitorsNutlin-3a was 
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chosen as the first-in-class compound and the most extensively tested MDM2 
Figure 17. Impact of mutations at the codon R175 on cellular fitness 
under treatment with MDM2 inhibitors 
A. Dynamics of the R175 codon variants in the untreated cellular pool 
along the 8 weeks time course (3 left columns) and treatment with 
indicated MDM2 inhibitors (5 right columns). Cells expressing the R175 
library after adeno-Cre infection were cultured 2, 4, 6, and 8 weeks or 
treated with MDM2 inhibitors at IC50 concentrations for 8 days. Relative 
fitness scores (RFS) calculated relative to 2 weeks for 8 weeks time 
course experiment or relative to 8 days without treatment for the MDM2 




antagonist (>900 citations in Pubmed). To improve the clinical relevance of our data, 
we have included three compounds that are currently undergoing clinical evaluation: 
a nutlin derivative with improved potency RG7388 (Hoffmann-La Roche) and two 
structurally unrelated compounds: the piperidinone AMG 232 (Amgen) and the 
spirooxindole MI-773 (15, 8, and 2 clinical trials respectively, clinicaltrials.gov). 
Finally, RO-5963 was added to our drug panel as a member of the class of dual 
MDM2/MDM-X inhibitors (Graves et al. 2012). Using several structurally distinct 
compounds allowed us to address two issues. First, to our knowledge, a systematic 
comparison of the efficacy of structurally distinct MDM2 antagonists against cells 
expressing multiple mutant p53 variants has not been performed so far. Second, 
using five distinct compounds could improve the robustness of the screening and 
address potential off-target effects of the inhibitors. 
  
Figure 17. Continued 
RFS values are shown for triplicates according to the color scale: Red 
indicates high fitness (retention of the variant), blue indicates low fitness 
(depletion of the variant). Hereinafter: R175R1,2,3 – synonymous 
mutations, Stop – premature stop codon, Delta R – R175 deletion, F.S. – 
frameshifts. * - mutations annotated in the UMD TP53 database (UMD), ** 
- R175H. B. Correlation matrix demonstrating the similarity between cell 
libraries treated with MDM2 inhibitors. Spearman correlation coefficient of 
pairwise comparisons is shown according to the color bar. C. Enrichment 
scores of 3 groups of protein variants. Each point is ES of the individual 
mutation in the nutlin-treated library. Mutants demonstrating high, 
medium, and low enrichment scores are combined in groups 1, 2, and 3 
respectively. ***p<0.0001, ANOVA with Tukey post-test.  
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Library-expressing cells were treated for eight days with MDM2-inhibitors at 
corresponding IC50 concentrations. Then DNA was isolated, and amplicon 
sequencing was performed. Enrichment scores were calculated relative to untreated 
samples, as described above. A comparison of enrichment scores derived from 
replicate libraries revealed a high correlation (Rs>0.9) (Fig. 17A,B), further 
demonstrating the superior accuracy of the screening protocol. Treatment of the 
library with MDM2 inhibitors resulted in strong changes in variants abundance, 
evident from the reduced correlation between untreated and treated samples 
(Rs<0.8, Fig. 17B). Treatment of cells with five MDM2-inhibitors revealed very similar 
response patterns exemplified by high correlation between the samples (Fig. 17B). 
Enrichment scores calculated for each variant did not differ significantly between 
inhibitors (Friedman test, p=0.058). This indicates that all compounds exert similar 
effects independently of chemical structure. 
Further analysis of the dataset uncovered the differential impact of R175 variants on 
cellular fitness (Fig. 17A). Expectedly, all three synonymous mutations (R175R) were 
strongly depleted under treatment with all five compounds (mean ES=0.14±0.02). 
Conversely, the nonsense mutation (stop codon) and three frame-shift variants were 
significantly enriched after treatment (mean ES=1.49±0.07), as well as the hotspot 
mutation R175H (mean ES=1.63±0.1) (Kruskal-Wallis test p<0.0001). Almost equal 
ES computed for distinct DNA sequences with similar functional impact further 
verified the robustness of the system (note comparable depletion of all synonymous 
mutations and equal enrichment of frameshifts and stop codon).  
Detailed examination of the data presented in Fig. 17A revealed that all missense 
R175 variants could be divided into three groups based on their behavior under 
treatment (Fig. 17C). Nine mutants, including the most frequent cancer-associated 
variant R175H, were retained in the population comparable to nonsense variants 
demonstrating apparent LOF phenotype (R175D, E, F, G, H, L, Q, W, and Y, mean 
ES for nutlin=1.51±0.07 versus 1.49±0.07). Group of six variants (R175I, K, N, P, S, 
M) showed weak changes upon treatment (mean ES for nutlin=0.95±0.15). The 
relative abundance of these mutants was significantly different from both nonsense 
and synonymous mutations, suggesting partial-LOF properties (ANOVA with Tukey 
test, p<0.0001). Finally, four mutants (R175A, C, T, V) were depleted comparable to 
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synonymous mutations being, therefore, wild-type like (mean ES for 
nutlin=0.22±0.11 versus 0.14±0.02) (Fig. 17C). Surprisingly, two tumor-derived 
variants, R175S and R175C, demonstrated moderate (ES=0.81±0.11) to strong 
(ES=0.33±0.15) depletion upon treatment with all MDM2 inhibitors classifying them 
as wild-type-like variants with only little LOF (Fig. 17A). R175C was found in tumor 
samples as frequently as variant R175L, which was classified as LOF by CSMS (71 
and 74 UMD records, respectively). Since recurrent cancer-associated TP53 
mutations are expected to be damaging, both these variants ought to be enriched in 
our screen.  
Supporting this expectation, three in silico predictors have classified both variants to 
be as damaging as other LOF mutants (data were retrieved from UMD database) 
(Fig. 18A). Such discrepancy raised doubts about the accuracy of the classification 
made by CSMS. To verify the validity of our classification, we have analyzed data on 
the transcriptional activity of the six R175 variants as an independent predictor of 
protein functionality. Specifically, we have retrieved the data from the study of Kato 
(Kato S. et al. 2003). In this study, the transcriptional activity of hundreds of p53 
mutants was measured in the yeast system. The reporter gene was coupled with p53 
response elements from the promoters of eight distinct p53 target genes, and 
reporter expression levels were measured for each mutant. To identify patterns in 
this multivariate dataset, we have performed principal component analysis using 
ClustVis software (https://biit.cs.ut.ee/clustvis/) (Fig. 18B). PCA revealed that R175C 
and R175S were most strongly separated from other variants along with the principal 
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component 1 axis, suggesting that they have mostly distinct transactivation patterns 
among all six mutants (Fig. 18B,C). Furthermore, PC1 values exhibited a strong 
correlation with enrichment score (R2=0.81), demonstrating that anti-proliferative 
Figure 18. Cancer-associated variants R175S and R175C are 
functional  
A. Prediction of the functionality of R175 mutants made by in silico 
predictors Polyphen2, REVEL, and BayesDel. All variants are predicted to 
be equally damaging (scores >0.8 (Polyphen2), >0.5 (REVEL), and >0 
(BayesDel) predict the deleterious effect of mutation). B. Principal 
component analysis of the transcriptional activity of R175 mutants. 
Transcriptional signature for each mutant was extracted from the study of 
Kato et al., 2003. It is composed of transactivation values of p53 response 
elements from 8 p53 target genes measured in the yeast reporter assay 
and normalized to transactivation values of the wild-type protein. Values 
we subjected to principal component analysis using ClustVis 
(https://biit.cs.ut.ee/clustvis). Two orthogonal principal components are 
shown. Large distance between mutants R175C, S, and R175 G, H along 
the 1st principal component axis reflects a distinct transactivation pattern. 
Analysis performed by Boris Klimovich. C. Correlation between 
enrichment scores and PC1 values from B. r
2
 - squared Pearson 
correlation coefficient. D. Transcriptional activation of individual p53 
response elements by R175 mutants. Data are shown as expression 




capacity measured by CSMS indeed reflects the transactivating properties of 
selected p53 mutants (Fig. 18C). 
Closer examination of the transactivation of single response elements by individual 
mutants uncovered a clear pattern (Fig. 18D). Mutants with the highest enrichment 
scores (R175H, G, and L) showed weak transactivating activity. The mutant with 
intermediate enrichment (R175P, mean ES=1.21) showed substantial transactivation 
of three response elements (>50% of wild-type) (Fig. 18D). Finally, mutants R175S 
and R175C, classified by CSMS as wild-type like, demonstrated strong (>50% of 
wild-type) induction of reporter gene expression with five and six response elements, 
respectively. Remarkably, both these mutants activated promoter of the pro-
apoptotic gene Noxa stronger than the wild-type protein (132 and 162%, 
respectively) (Fig. 18D). Thus, CSMS has identified anti-proliferative properties in 
mutants with preserved transactivating capacity. 
Further evidence supporting the validity of our classification can be found in the 
literature. Mutant R175S (showed weak depletion in CSMS) was shown to activate 
cell cycle arrest (Ryan and Vousden 1998; Goh et al. 2011; Billant et al. 2017). 
Similarly, mutant R175C was shown to induce both cell cycle arrest and apoptosis in 
different cell lines (MCF7, Saos, and PC-3) (Ryan and Vousden 1998; Flaman et al. 
1998; Blagosklonny 1997; Ory et al. 1994; Blagosklonny 2002). Finally, cDNA-based 
screening by Kotler and colleagues has produced scores for the R175C mutant 
strikingly similar with ours: (RFS for R175C and WT respectively: -2.15 and -2.56 for 
CSMS and -2.69 and -2.43 for the cDNA screen).  
Mutation R175C originates from a C>T transition at a methylated CpG site, which is 
the most frequent mutation signature of p53 (Giacomelli et al. 2018). Therefore, it is 
highly plausible that R175C is a non-pathogenic passenger mutation. 
Taken together, the CSMS classified six cancer-associated R175 variants in better 
agreement with previously published data than the commonly used in silico tools. 
 CSMS dissects the impact of mutations on p53-regulated effector pathways 
Inspired by the good agreement of our results with previous findings, we have 
continued experimenting with the R175 library to further explore the capabilities of 
the CSMS. Apart from LOF and wild-type-like mutants, the R175 library screening 
revealed a group of six mutants with intermediate enrichment (R175I, K, N, P, S, and 
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M) (group 2 Fig. 17D). Outcomes of p53-mediated response strongly depend on the 
intensity and duration of treatment. Shorter treatment preferentially induces cell cycle 
arrest, whereas prolonged treatment leads to apoptosis (Kracikova et al. 2013; 
Murray-Zmijewski et al. 2008; Paek et al. 2016). Therefore, to gain more detailed 
mechanistic insight into mutants’ properties, we have profiled antiproliferative effects 
of R175 variants across the range of nutlin concentrations (2.5 – 20 µM nutlin) or 
treatment durations (2-25 days). 
As expected, LOF mutants from group 1 (from Fig. 17D) (R175D, E, F, G, H, L, Q, 
W, and Y) were strongly enriched even when treated with the lowest concentration of 
nutlin (2.5 µM) (Fig. 19A,B) and demonstrated progressive enrichment upon 
increased treatment duration (Fig. 19C,D). Wild-type-like mutants (R175A, C, T, V) 
revealed rapid depletion from the population even at the lowest concentration of 
nutlin and after shorter treatment (4-8 days) (Fig. 19B,D). 
In striking contrast, five variants from group 2 from Fig. 17D (R175I, K, M, N, S) 
showed a changing response pattern. In detail, the mutants in the sample treated 
with 2.5 µM nutlin, demonstrated significant dose-dependent depletion (Fig. 19B). A 
similar trend was revealed when the mutants-expressing cell library was treated for 
an extended period: the abundance of five mutants was comparable to LOF mutants 
after 2-4 days but was significantly decreased upon more extended treatment and 
reached the level of wt-like variants for two mutants (mean ES at 25 days wt-like: 
0.12±0.01, R175M 0.11±0.02, R175S 0.1±0.02, 2-way ANOVA with Sidak’s test, 
p>0.0001). Interestingly, the mutant R175P with documented partial-LOF features 
did not change its abundance in both experiments (Barboza et al. 2006; Liu et al. 
2004) but was nevertheless depleted significantly stronger than LOF variants 
(p=0.0002 and 0.0027 for Fig. 19B and D respectively, 2-way ANOVA). Collectively, 
such behavior revealed partial-LOF properties of the group of six mutants.  
These observations uncovered substantial qualitative differences in the response of 
p53 mutants to MDM2 inhibition. Wild-type-like variants were rapidly cleared from the 
population even in response to low levels of the stimulus (mean ES at 2.5 µM nutlin= 
0.12±0.01, mean ES after two days of treatment 0.36 ±0.08), suggesting that 
apoptosis is the principal mechanism eliminating variant-carrying cells. Conversely, 
the persistence of partial-LOF mutants in the population under low concentrations of 
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nutlin and their depletion under prolonged treatment or elevated concentrations 
evident from Fig. 19B indicate selective apoptosis defect in these mutants and 
suggest cell cycle arrest as the principal tumor-suppressive mechanism involved 
(Fig. 19D). 




Figure 19. Dose- and time-dependent variations of the impact of 
mutations at the codon R175 on the response to MDM2 inhibitors 
A. Cells were treated with 2.5 – 20 µM nutlin for 8 days. Heatmap shows 
RFS values for individual replicates. B. Mean enrichment score values for 
the selected R175 mutants from A. ns: p=0.29, ****p<0.0001, Two-way 
ANOVA with Sidak’s test. C. Time course dynamics of variants in the 
R175 library (n=3) under nutlin treatment. Cells carrying R175 library 
were treated with 10 µM nutlin for 2 - 25 days as indicated on the 
heatmap. Mean RFS across triplicates are shown. D. Mean enrichment 
scores for the selected R175 mutants from C. ns: p=0.93, ****p<0.0001, 












been extensively studied. For example, mutants R175P, R181L, and E180R 
demonstrate a specific defect in apoptosis but retain the ability to arrest proliferation 
(Rowan et al. 1996; Ludwig et al. 1996; Liu et al. 2004; Timofeev et al. 2013). 
Furthermore, it is plausible that partially preserved functionality can be a widespread 
intrinsic property of non-hotspot tumor-associated mutations. Indeed, our analysis of 
the dataset “functionalAssessment” from the IARC database, which consists of 
manually curated information from almost 350 publications, identified 317 patient-
derived variants that were reported to suppress cellular growth despite being 
apoptosis-deficient. Therefore, it was of considerable interest to examine if CSMS 
could identify mutants with selective defects in effector functions. Hence, we have 
designed experiments to explore the impact of mutants on apoptosis and cell cycle 
arrest. 
In the first experiment, instead of continuously treating cells with MDM2-inhibitor, we 
have exposed them to nutlin for 4, 6, or 8 days. Afterward, nutlin was washed out, 
and surviving cells were further expanded and harvested eight days later. Control 
samples were either treated with nutlin for 16 days or left untreated (Fig. 20A). We 
assumed that cells harboring wild-type-like variants would be rapidly killed by 
apoptosis and strongly depleted from the population even after 4 days of treatment. 
Conversely, cells harboring LOF mutants will be markedly enriched in the population 
irrespective of the treatment duration. Partial-LOF mutants capable of arresting 
proliferation were expected to stay relatively abundant after short nutlin treatment 
due to resuming proliferation after drug withdrawal. Upon extended exposure to 
nutlin these mutants were anticipated to stay in cell cycle arrest and become 
progressively eliminated. In good agreement with our expectations, synonymous 
variants were strongly depleted already 4 days after the beginning of the treatment 
(mean ES=0.27±0.18), whereas nonsense and frameshift mutations, as well as 
hotspot R175H and other missense LOF variants, were enriched (mean 
ES=2.56±1.15) (Fig. 20B) in line with previous experiments (Fig. 19). Partial-LOF 
mutants identified in the experiment shown in Fig. 20B (R175I, K, M, N, S) and the 
extensively studied pLOF mutant R175P demonstrated an intermediate enrichment 
pattern. After four days of nutlin treatment, they were almost as abundant as LOF 
mutants (mean ES 1.00±0.17 versus 1.26±0.14), indicating that cells have resumed 
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proliferation. However, after 16 days of continuous MDM2 inhibition, partial-LOF 
mutants were eliminated (mean ES=0.39±0.28). Therefore, the pattern of enrichment 
and depletion of partial LOF mutants perfectly fits our expectations regarding protein 
variants with the selective defect in apoptosis and preserved ability to induce cell 
cycle arrest.  
Next, we applied CSMS to demonstrate apoptosis deficiency of partial-LOF mutants 
directly. We have treated library-carrying cells with 10 µM nutlin and stained 
apoptotic cells after two and four days with annexin V-APC conjugate. Next, we 
Figure 20. Annotation of the cell cycle arrest-proficient R175 mutants 
A. Schematic of the experiment. Cells expressing the R175 library were 
treated with nutlin for 4, 6, 10, and 12 days. After 4-8 days drug was 
washed away, and cells were harvested on the 16
th
 day from the beginning 
of the experiment for gDNA extraction. B. Heatmap shows RFS values for 
individual replicates calculated relative to untreated control. * -mutations 





separated annexin V positive and negative populations using fluorescence-activated 
Figure 21. CSMS captures the apoptosis proficiency of R175 
mutants 
A. Schematic representation of the experiment. Cells carrying the R175 
library were treated with 10 µM nutlin for 2 or 4 days and apoptotic cells 
were stained with annexin V-APC. Annexin V positive and negative 
fractions were separated using fluorescence-activated sorting and used 
for DNA isolation and library preparation. Representative FACS plot 
demonstrates the gating strategy. B. Heatmap demonstrates triplicate 
RFS values of each variant in the annexin V-positive population (RFS 
for each variant was calculated relative to the annexin V-negative 
population). Right 3 column: RFS of variants after 8 days of nutlin 
treatment (relative to untreated cells). C. Mean enrichment scores of 
apoptosis-proficient R175 mutants 2 and 4 days after p53 activation 
with nutlin. R175R – mean ES of 3 synonymous codons. **p=0.0048, 
***p=0.0009, two-way ANOVA with Sidak's test. D. Enrichment scores 
of partial-LOF mutants (R175I, K, M, N, P, S) after 16 days of nutlin 




cell sorting. We have prepared amplicon libraries from both samples and sequenced 
them (Fig. 21A). 
We have compared the fraction of reads corresponding to each sequence variant in 
annexin-positive and annexin-negative fractions and plotted the relative enrichment 
scores along with RFS for the library treated with nutlin for 16 days (Fig. 21B). 
Concordant with their intact proapoptotic activity synonymous mutants were strongly 
enriched in annexin-positive fraction after two days of treatment (mean 
ES=1.64±0.23). Likewise, missense mutants characterized as wild-type-like in 
previous experiments (R175A, C, T, V) were also prevalent among the annexin-
positive population after two and four days of treatment (Fig. 21B). Tumor-associated 
variant R175C revealed partially preserved apoptotic function in good agreement 
with our data and with previous reports (Ory et al. 1994). As expected, all apoptosis-
proficient variants were depleted from the library after 16 days of continuous nutlin 
treatment (Fig. 21B). Interestingly, the abundance of synonymous variants, R175T 
and R175V, was strongly decreased after four days of treatment (mean ES at 4d 
0.35±0.12), indicating rapid depletion of apoptotic cells. (Fig. 21C). At the same time, 
mutants R175A and C were significantly less abundant than wild-type among 
apoptotic cells at two days of treatment (ES=0.80 and 0.94, p=0.0048 and 0.0009, 
two-way ANOVA with Sidak’s multiple comparison test, p<0.005) and were depleted 
from the annexin-positive fraction to a lesser extent at day 4 (mean ES 0.68±0.13). 
Distinct dynamics of the two groups of variants suggest partially compromised pro-
apoptotic activity of R175A and R175C. 
Loss-of-function mutants identified in the previous experiments (R175D, E, F, G, H, 
L, Q, W, Y) were expectedly unable to activate apoptosis, as evident from the 
depletion of these variants from the annexin-positive population (Fig. 21C). 
Mutants categorized as partial-LOF (R175I, K, M, N, P, S) showed no enrichment in 
the annexin-positive fraction over nonsense variants (mean ES at 2 days 0.95±0.21 
versus 0.82±0.31), highlighting their severe apoptosis deficiency (Fig. 21C). 
Nevertheless, they were depleted significantly more than stop codons after 16 days 
of nutlin treatment (mean ES=0.36±0.21 versus 1.74±0.13, unpaired t-test p<0.0001) 
(Fig. 21D). This observation further demonstrates that these apoptosis-deficient 
mutants retain the ability to induce cell cycle arrest. 
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In summary, our system accurately delineated p53 mutations with differential impact 
on effector mechanisms and identified several partial-LOF mutants in good 
agreement with previously published findings. 
 CSMS measures the impact of p53 mutations on response to conventional 
chemo- and radiotherapy  
We have validated the CSMS as a sensitive tool for measuring the antiproliferative 
effects of p53 mutants in response to MDM2-inhibitors. MDM2-inhibitors act as direct 
non-genotoxic p53 activators. However, the therapy of many cancer entities still 
relies on the induction of DNA damage by genotoxic substances or irradiation. P53 
integrates stress response signals to activate cell cycle arrest or cell death. 
Therefore, mutations in p53 enforce chemo- and radioresistance and are selected 
during therapy (Lee and Bernstein 1993; Sturm et al. 2003; Keshelava et al. 2001; 
Wong et al. 2015). Moreover, drug resistance can be further enhanced via 
neomorphic gain-of-function activities (Stiewe and Haran 2018; Blandino et al. 1999; 
Lavra et al. 2009; Wong et al. 2007). Therefore, the cataloging of p53 mutations 
causing resistance to DNA damaging agents would be of great value to advance 
personalized cancer treatment. 
DNA-damaging agents induce extensive post-translational modifications of p53, 
which modulate p53-mediated responses. Therefore, p53 might show different 
activities upon treatment with DNA-damaging stimuli compared to nutlin. For 
example, treatment of cancer cells with nutlin or doxorubicin results in substantially 
different genome-wide binding patterns and transactivation outcomes (Tonelli et al. 
2017; Menendez et al. 2006).  
To examine how DNA damage response is affected by mutations in p53, we have 
treated cells expressing the R175-library with two genotoxic agents: X-rays and 5-
fluorouracil (5-FU). Both modalities are used for the therapy of colorectal cancer and, 
therefore, are expected to produce clinically valuable estimates in our system based 
on the colorectal cancer cell line. Unlike MDM2-inhibitors, which specifically trigger 
apoptosis by stabilizing p53, DNA damage can result in both p53-dependent and 
p53-independent apoptosis (Clarke et al. 1993; Strasser et al. 1994; Lanni et al. 
1997). Therefore, to minimize p53-independent effects and achieve maximal 
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resolution between wild-type, LOF, and partial LOF mutants, we have first optimized 
treatment conditions.  
Preliminary experiments have demonstrated that X-ray irradiation with 6 Gy 
completely inhibited the growth of parental HCT-116 cells at clonogenic density (Fig. 
22A). To determine the optimal treatment dose for cells growing in a dense culture, 
we have irradiated parental HCT-116 and HCT-116Δ/TP53E (p53-null) cells with 8 Gy 
and evaluated the viability of cells by monitoring the confluence using the live-cell 
imaging system Incucyte S3. Relative viability was calculated by normalizing 
confluence at each timepoint to the confluence readings of untreated cells at the last 
time point (69 hours). As shown in Figure 22B, irradiation with 8 Gy resulted in a 
marked decrease in the viability of both cell lines. Parental p53 wt cells were more 
sensitive to irradiation, as evident from significantly lower relative viability (two-sided 
t-test, p<0.0001). Higher doses of irradiation resulted in the low viability of both cell 
Figure 22. Establishment of the optimal irradiation regime for library-
expressing cells 
A. HCT-116 p53 wild-type and knockout cells were irradiated with 1-6 Gy 
and plated at clonogenic density. After 7 days of culture, colonies were 
counted. Survival fraction was calculated as a ratio of the number of 
colonies formed by treated versus untreated cells. Data courtesy of 
Bernadette Wezorke. B. Parental HCT-116 and HCT-116
Δ/TP53E   
cells 
were plated 3000 per well of 96 well plate. 18h after plating cells were 
irradiated with 8 Gy. Growth was monitored for 3 days by live-cell 
microscopy using the IncuCyte S3. Hour 0 is a time point after irradiation. 
All confluence values were normalized to the confluence of untreated 
cells at the end of the time course (69h) and shown as mean. 
****p<0.0001, two-sided t-test. 
A B 
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lines (data not shown). We have irradiated library-expressing HCT-116Δ/TP53E cells 
with 4 doses ranging from 2 to 8 Gy based on these results.  
Examination of changes in clonal abundance after X-ray irradiation revealed a 
characteristic pattern. Synonymous mutations, as well as wild-type-like mutations 
(R175A, C, M, T, V), were progressively depleted from the population with increasing 
irradiation dose, whereas nonsense and LOF variants (R175 D, E, F, G, H, L, Q, W, 
and Y) were markedly enriched (Fig. 23A). Mostly, functional effects of substitutions 
at the position R175 were correlated in irradiated and nutlin-treated cells (Rs=0.79 
A B 
C 
Figure 23. Annotation of R175 mutations conferring radioresistance 
A. Cells harboring the R175 library were irradiated with X-rays with 2, 4, 
6, and 8 Gy and harvested 8 days later. RFS values for irradiated cells 
relative to untreated cells are shown (n=3, four left columns). Right 
column: RFS values for cells treated for 8 days with nutlin. B. Correlation 
between RFS values of R175 mutants in nutlin- and X-ray-treated 
libraries. Rs: Spearman correlation coefficient. C. Comparison of ES 
between nutlin- and X-rays-treated libraries for 3 groups of mutants: LOF 
(red) wild type-like (blue) and partial-LOF (green). ****p<0.0001 mixed-
effects analysis with Sidak’s multiple comparison test. 
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and 0.77 for 6 Gy and 8 Gy versus nutlin) (Fig. 23B). More specifically, LOF and 
partially-LOF variants were similarly enriched after both treatments. Interestingly, 
synonymous and wild-type-like mutants demonstrated distinct behavior: all these 
variants were depleted by nutlin significantly stronger than by irradiation (mean ES 
for nutlin 0.16 ± 0.034, mean ES for 8Gy X-ray 0.52±0.06, p<0.001) (Fig 23C). This 
result points to the essential mechanistic difference in the cellular response to these 
stimuli. Moderate depletion of cells carrying wild-type-like p53 variants after 
irradiation suggests that this type of treatment induces both p53-dependent and p53-
independent response, and thereby diminishes proliferation of all cells. By contrast, 
non-genotoxic activation of p53 with nutlin affects particularly wild-type cells and 
leaves cells with LOF mutants unaffected. Therefore, the difference between wild-
type-like and LOF variants is stronger for nutlin than for the X-ray irradiation. 
Additionally, distinct depletion of wild-type variants can be explained by various 
stimuli duration. Transient p53 stabilization after irradiation results preferentially in 
cell cycle arrest and DNA repair leading to retention of funcitonal variants, whereas 
sustained p53 signaling under MDM2 inhibition triggers apoptosis and eliminates 
these mutants (Paek et al. 2016; Purvis et al. 2012). Examination of changes in 
clonal abundance after X-ray irradiation revealed a characteristic pattern. 
Synonymous mutations, as well as wild-type-like mutations (R175A, C, M, T, V), 
were progressively depleted from the population with increasing irradiation dose, 
whereas nonsense and LOF variants (R175 D, E, F, G, H, L, Q, W, and Y) were 
markedly enriched (Fig. 23A). Mostly, functional effects of substitutions at the 
position R175 were correlated in irradiated and nutlin-treated cells (Rs=0.79 and 
0.77 for 6 Gy and 8 Gy versus nutlin) (Fig. 23B). More specifically, LOF and partially-
LOF variants were similarly enriched after both treatments. Interestingly, 
synonymous and wild-type-like mutants demonstrated distinct behavior: all these 
variants were depleted by nutlin significantly stronger than by irradiation (mean ES 
for nutlin 0.16 ± 0.034, mean ES for 8Gy X-ray 0.52±0.06, p<0.001) (Fig 23C). This 
result points to the essential mechanistic difference in the cellular response to these 
stimuli. Moderate depletion of cells carrying wild-type-like p53 variants after 
irradiation suggests that X-ray irradiation induces both: p53-dependent and p53-
independent response, and thereby diminishes proliferation of all cells. Since nutlin 
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affects particularly wild-type cells remaining LOF cells unaffected, the difference 
between wild-type-like and LOF is stronger for nutlin than for the X-ray irradiation. 
Besides, we measure enrichment relative to the population mean, ES values are 
more pronounced. they rather underwent cell cycle arrest than apoptosis. This 
difference can be explained by distinct stimuli duration: transient p53 stabilization 
after irradiation results preferentially in cell cycle arrest and DNA repair, whereas 
sustained p53 signaling under MDM2 inhibition triggers apoptosis (Paek et al. 2016; 
Purvis et al. 2012).  
Next, we have treated library-expressing cells with 5-FU. To optimize 5-FU 
concentration, we have treated parental HCT-116 and HCT-116Δ/TP53E cells with four 
concentrations of the compound (2.5-20 µM) and monitored culture confluence over 
one week using the Incucyte S3 (Fig. 24A, B). Nutlin treatment was used as a 
positive control. Treatment with 10 µM nutlin expectedly affected the growth of p53 
wild-type cells and did not affect p53 knockout HCT-116Δ/TP53E. Treatment with the 
lowest dose of 5-FU (2.5 µM) did not influence the viability of both cell lines, whereas 
higher doses (10-20 µM) decreased proliferation below the level of nutlin-treated 
wild-type cells pointing at p53-independent toxicity. Cells treated with 5 µM 5-FU 
demonstrated an intermediate proliferation rate between nutlin-treated wild-type and 
HCT-116Δ/TP53E cells. Moreover, p53-wt cells showed pronounced growth retardation 
80h after treatment, whereas HCT-116Δ/TP53E cells continued to proliferate 
(corresponding curves are labeled with arrowheads). We have reasoned that such 
treatment conditions would be the most suitable to measure the anti-proliferative 
effects accurately. Therefore, the library was treated with 5 µM 5-FU. To minimize 
the p53-independent effects of continuous treatment, we have exposed cells to 5-FU 
for 24 or 48h, washed the drug away, and harvested cells eight days after plating 
(Fig. 25A). Analysis of relative variant frequency revealed a high correlation with the 
nutlin dataset (Fig. 25B) (Rs=0.93 and 0.88 for 24 h and 48h, respectively). 
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Similar to the irradiation experiment, enrichment of most of the LOF variants was 
comparable to enrichment under nutlin treatment (Fig. 25C). However, by contrast to 
the nutlin-treated library, exposure to 5-FU produced more similar enrichment scores 
for distinct mutant groups. For example, synonymous and wild-type-like mutants 
Figure 24 Estimation of the optimal concentration of 5-fluorouracil 
for the treatment of library-expressing cells 
HCT-116
Δ/TP53E 
(A) and parental p53 wild-type (B) cells were treated with 
2.5-20 µM of 5-FU. Growth was monitored for 7 days by live-cell 
microscopy using the IncuCyte S3. Hour 0 is the beginning of treatment. 
All confluence values were normalized to the confluence of untreated 
cells at the end of the time course (172 h) and shown as mean. Curves 





were depleted by 5-FU markedly less than by nultin (mean ES=0.53 ± 0.09 versus 
0.13±0.07) (Fig. 25C). Likewise, depletion of pLOF mutants was less prominent 
(mean ES for 5-FU 48h 0.92±0.15 versus 0.76±0.18 for nutlin). On the contrary, 
enrichment of LOF mutants was significantly lower under 5-FU treatment than under 
Figure 25. Impact of mutations at the codon R175 on the DNA 
damage response induced by 5-fluorouracil 
A. Cells harboring the R175 library were treated with 5 µM 5-FU for 24 or 
48h, washed with medium, and harvested 8 days after the beginning of 
treatment. RFS values for treated library triplicates are shown (two left 
columns). Right column: RFS values for cells treated for 8 days with 
nutlin. B. Correlation between enrichment scores of R175 mutants in 
nutlin- and 5-FU-treated libraries. Rs, Spearman correlation coefficient. 
C. Comparison of ES between nutlin- and 5-FU-treated libraries for 3 
groups of mutants: LOF (red), wild-type-like (blue), and partial-LOF 
(green). Each dot represents one variant averaged across replicates. **** 





nutlin (mean ES 5-FU 48h 1.24±0.27 versus 1.43±0.27 for nutlin Fig. 25C). Most 
likely, this was a result of distinct treatment duration. Under the short-term 5-FU 
treatment, some cells carrying wild-type-like mutants undergo cell cycle arrest and 
recover upon treatment withdrawal. Meanwhile, eight days long nutlin treatment 
Figure 26. CSMS reveals no restoration mutants p53 functions by 
APR-246  
A. Estimation of the optimal concentration of APR-246 for treatment of 
the library in H1299 cells expressing p53 mutants. Parental p53-negative 
H1299 cells and cells overexpressing R175H and R273H hot-spot 
mutants were treated with 25 µM APR-246. The growth of cells was 
monitored for 5 days by live-cell microscopy using the Incucyte S3. Hour 
0 is the beginning of treatment. All confluence values were normalized to 
the confluence of untreated cells at the end of the time course (120 h) 
and shown as mean. B. Cells harboring the R175 library were treated 
with 12.5 and 25 µM of APR-246 for 8 days and harvested for DNA 
isolation. Additionally, cells were treated with a combination of APR-246 




efficiently depletes wt-like and pLOF mutants either by apoptosis or by permanent 
cell cycle arrest. Furthermore, p53-independent action of genotoxic compound can 
also contribute to observed effects. 
Our experiments have validated the CSMS as a versatile tool for predicting the 
response of mutant p53-expressing cells to various treatments: MDM2 inhibitors, 
irradiation, and 5-FU. Despite the substantial correlation between datasets, CSMS 
revealed a qualitative difference in response to these treatments. For example, 
prolonged exposure to nutlin strongly depleted synonymous variants indicating 
preferential induction of apoptosis. Conversely, single-dose irradiation or short-term 
(48h) treatment with 5-FU preferentially induced cell cycle arrest, exemplified by 
partial retention of wt-like mutants in the population. Our data argue that the CSMS 
captured an essential mechanistic difference between therapeutic agents and might 
be used to identify p53 mutations that confer drug resistance.  
 CSMS reveals no reactivation of p53 mutants by APR-246 
Mutant p53 reactivation therapy aims at the pharmacological restoration of normal 
tumor-suppressive functions in missense mutants. Several p53 reactivators are 
currently investigated. Some compounds are active against single mutants: e.g., 
PK7088 and ZMC1 reactivate Y220C and R175H, respectively (Blanden et al. 2015; 
Bykov et al. 2018). Other molecules are targeting a broader spectrum of mutant 
proteins. However, most of the p53-reactivating compounds were only tested with a 
small number of exemplary hotspot mutations. Therefore, a comprehensive 
characterization of the response of non-hotspot mutants to p53 reactivators would 
give useful information for selecting patients for clinical trials. To this end, we have 
tested the response of cells expressing the R175 mutant library to APR-246, the 
most advanced compound in the class, which is currently under clinical studies 
(NCT03745716, NCT03931291, NCT03588078, NCT03072043, NCT00900614). 
The optimal concentration of the compound was determined by monitoring the 
growth of two isogenic H1299 cell lines expressing p53 hotspot mutants (R175H and 
R273H) in comparison to parental p53-null H1299 cells. 25 µM APR-246 delayed 
proliferation of both mutant-expressing cell lines but not parental p53-null cells. (Fig. 
26A). We have treated cells expressing the R175 mutant library with two 
concentrations of APR-246 for eight days (12.5 and 25 mM). Since APR-246-
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mediated restoration of p53 activity was shown to synergize with MDM2 inhibition 
(Izetti et al. 2014), we have additionally treated cells with the combination of APR-
246 and nutlin to potentially amplify the effects of p53 reactivation by elevating the 
mutant protein levels.  
We have expected that successful reactivation of mutant p53 with APR-246 would 
deplete some of the missense mutants (for example, R175H) from treated samples. 
Surprisingly, none of the mutants revealed any significant abundancy changes under 
treatment compared to untreated cells (Fig. 26B). Both sequencing datasets 
obtained from the APR-treated cells revealed almost absolute correlation with the 
dataset from untreated cells (Rs=0.989 and 0.993 for 12.5 and 25 µM respectively, 
p>0.0001). No changes in abundance of R175H mutant were observed as well. 
Combined treatment with APR-246 and nutlin revealed no APR-246-specific effects 
(correlations between nutlin-treated samples with or without APR-246: Rs=0.993 
(12.5 µM) and 0.976 (25 µM), ANOVA p=0.88) (Fig. 26B). Again, no depletion of 
R175H variant hinting at p53 reactivation was evident upon combined treatment 
(ES=1.39 versus 1.37 and 1.21 for nutlin and nutlin-APR-246 combinations, 
respectively). 
In summary, we were unable to reveal any p53-reactivating effects of APR-246 in the 
CSMS experiment with the HCT-116Δ/TP53E cell line expressing the R175 mutant 
library.  
3.9 CSMS probes the functional status of hundreds of H1 helix mutants  
We have extensively validated the CSMS for accurate measurement of functional 
consequences of p53 mutations. To explore the applicability of the CSMS for high-
content experiments, we have generated a library of HDR templates carrying 210 
mutations representing all possible amino acid substitutions in the H1 helix of the 
p53 DNA-binding domain (positions C176-S185). H1 helix contains several residues 
essential for p53 function (e.g., C176, H179, E180, R181). Therefore, this small 
region was extensively studied, which makes it especially suitable for performance 
evaluation. 
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To construct the library, 210 double-stranded 34 base pair-long oligonucleotides 
Figure 27. CRISPR-mediated homologous recombination 
reproducibly introduces the library of 210 H1 helix mutants into the 
endogenous TP53 locus of the HCT-116
Δ/TP53E






were cloned into the HR-2-Golden Gate vector and used together with a Cas9-
encoding plasmid in a standard co-transfection procedure. To assess the 
reproducibility of the library production, we have first sequenced three independently 
prepared pools of targeting vectors (plasmid libraries) and found a high correlation 
between samples (Rs=0.87 and 0.84, p<0.0001 for comparison between triplicates) 
(Fig. 27A). Next, to evaluate the TP53 targeting efficacy, we have sampled cells from 
three independently transfected pools before adeno-Cre infection and sequenced the 
H1 helix region. Reassuringly, the variant prevalence in the cellular libraries revealed 
a strong correlation with the targeting vector (Rs=0.8, p<0.0001), indicating that 
library complexity was preserved during mutagenesis (Fig. 27B). Moreover, high 
similarity between replicates of cellular libraries demonstrated reproducibility of the 
protocol (Rs=0.71 and 0.65, p<0.0001 before adeno-Cre infection, Rs=0.64 and 
0.78, p<0.0001 after adeno-Cre infection) (Fig. 27C,D). 
Analysis of libraries prepared from adeno-Cre-infected cells showed that the 
infection did not lead to global changes in variants abundancy since substantial 
correlation with libraries before the infection was evident (Rs=0.89, 0.85 and 0.78, 
p<0.0001) (Fig. 27E). Importantly, no mutations were lost from libraries at any step of 
the procedure, further demonstrating efficient targeting of the TP53E allele with a 
highly complex pool of mutants. 
To assess the stability of the library, we have sampled three adeno-Cre-infected 
replicates after 4, 6, and 8 weeks of passaging. We have revealed significant global 
Figure 27. Continued 
Correlation between a fraction of reads for each variant in the library 
measured in the following samples: 
A. Three independently prepared replicates of the HR-2-Golden-Gate 
plasmid pools carrying saturation mutagenesis library of the H1 helix 
(vector). B. Plasmid pools (library) and the transfected cell pools before 
infection with adeno-Cre (mean of 3 replicates). C. Three replicates of the 
transfected cell pools before adeno-Cre infection. D. Three replicates of 
the transfected cell pools after adeno-Cre infection. E. Three replicates of 
the transfected cell pools before and after adeno-Cre infection. Each 
figure shows one replicate. 
On each figure fraction of reads for each mutant is shown (for individual 
samples or mean of 3 samples) together with corresponding values of 
Spearman correlation coefficients.  
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changes in the abundance of variants after 6 and 8 weeks of library propagation 
(Friedman test, 2 weeks verses 4 and 8 weeks, p=0.0015 and 0.0007 respectively, 
Fig. 28A). Specifically, synonymous mutations were marginally depleted in 8 weeks 
(one-way ANOVA p=0.012), whereas nonsense mutations were slightly enriched 
(one-way ANOVA p=0.76, ns). Missense variants have shown a diverse pattern of 
enrichment and depletion. 
Figure 28. Time course dynamics of H1 helix sequence variants 
during 8 weeks of passaging of library-expressing cells 
A. Cells carrying the H1 helix library were cultured for 2, 4, 6, and 8 
weeks after infection with adeno-Cre. The violin plot illustrates the 
distribution of the fraction of reads for all variant in the library across 
biological replicates. Dashed lines indicate mean. Comparison of 4, 6 and 
8 weeks to 2 weeks is non-significant (Kruskal-Wallis test, p>0,99, 
p=0,31, p=0,126 correspondingly). B. Heatmap illustrates the dynamics of 
individual protein variants along 8-week time course. RFS relative to the 
early timepoint sample (2 weeks) is shown for library triplicates. C. 
Dynamics of 6 variants with mean ES>(mean ESstop codons)x2. R181M 






Of note, repeated measurements at 4, 6, and 8 weeks revealed that some mutations 
were depleted from the population significantly stronger than synonymous variants, 
for example, D184 A, G, I, N, Q, R, T, V, and S (mean ES=0.16±0.08 versus 
0.65±0.2 for synonymous variants at 8 weeks, Mann-Whitney test, p<0.0001) (Fig. 
28B). 
Interestingly, six mutations were enriched stronger than stop codons after 6-8 weeks 
of passaging (mean ES at 8 weeks exceeded more than two times mean ES of stop 
codons) (Fig. 28C). Such behavior likely pointed at GOF effect. However, enrichment 
of most of the variants was very inconsistent between library replicates, reaching 
statistical significance only for R181M (FDR q values 0.000284 and 0.000236 for 6 
and 8 weeks respectively, multiple 2-sided t tests in combination with false discovery 
rates (FDRs). Growth-promoting GOF effects are likely more sensitive to culture 
conditions, cell density and stochastic fluctuations than potent cytotoxic effects of 
wild-type p53. Hence, experiments with a larger number of replicates will be needed 
to rigorously confirm these observations. 
To gain insight into the functional diversity of H1 helix mutants, we have analyzed 
changes in clonal abundance upon treatment with MDM2 inhibitors. The outstanding 
reproducibility of the screening workflow was demonstrated by the uniform depletion 
of all synonymous mutations (mean ES=0.18±0.04), significant enrichment of all 
nonsense mutations (mean ES=1.7±0.5, p=0.002), and high correlation between 
replicates (average for all replicates Rs=0.82, p<0.0001). Similar to the R175 library, 
our analysis did not reveal any significant difference between the effects of five 
distinct MDM2 inhibitors (Rs for all inhibitors >0.95, p<0.0001). 
Further analysis revealed a remarkably distinct sensitivity of H1 helix residues to 
mutagenesis. Residues 182-185 were highly resistant to alterations since most of the 
variants at these positions were depleted as strong as synonymous mutations (Fig. 
29A). On the contrary, mutations at the positions C176-H179 most frequently lead to 
the loss of function, as evident from their strong enrichment. Variants at positions 
H178, E180, and R181 demonstrated the most variable pattern depletion and 
enrichment (Fig. 29B). 
Interestingly, the cluster of amino acids resistant to mutagenesis (C182-S185) 
includes asparagine D184. This residue is conserved among 99 mammalian species, 
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suggesting its critical functional role (Sulak et al. 2016). Therefore, one could expect 
Figure 29. CSMS captures the functional consequences of H1 helix 
mutations 
A. Cells expressing the library of H1 helix variants were treated 2 weeks 
after adeno-Cre infection with 5 mdm2-inhibitors at IC50 concentrations 
and harvested for gDNA extraction after 8 days. RFS values are shown 







that mutations at this position would be damaging and highly prevalent in human 
cancers. In striking contrast, missense mutations of this amino acid are very rare (39 
out of 80400 records in the UMD database). High conservation and low mutation rate 
collectively imply that most of the alterations at this position lead to the enhancement 
of the p53 activity, and therefore, such mutations are non-oncogenic in good 
agreement with CSMS-based classification. 
Moreover, depletion of many D184 variants in our long-term culture experiment to 
the degree exceeding the depletion of wild-type variants also supports this notion 
(average mean ES for D184 A, G, I, N, R, S, Q, T, and V is 0.16±0.08 versus 
0.65±0.23 for wild-type variants) (Fig. 28B). Much like mutations at D184, alteration 
of the serine 183 also did not lead to the loss of protein function and were depleted 
as strong as wild-type variants (mean ES for nutlin 0.16±0.09 versus 0.16±0.04) (Fig. 
29A). Phosphorylation of the S183 by 
 Aurora B kinase promotes p53 degradation (Gully et al. 2012). Hence alterations at 
this site can lead to increased p53 stability rather than to the loss of function. In 
support of this, 140 of 159 annotated variants at this position are nonsense or 
frameshift (UMD database). Therefore, the depletion of most of the S183 variants 
from the screen is in line with the role of this residue in regulation of p53 stability. 
Unlike mutagenesis resistant residues C182-S185, mutations at positions C176-
H179 had a strong damaging effect on p53 functionality (mean ES for all MDM2 
inhibitors 1.28±1.33 respectively) (Fig. 29A). This observation was in good 
agreement with the known role of the H1 helix residues in maintaining the p53 
structure. Cysteine 176 and histidine 179 are critical for coordinating a zinc ion that is 
essential for protein activity (Olivier et al. 2010). Accordingly, CSMS has scored all 
Figure 29. Continued 
C. Enrichment scores for selected mutants ordered according to their 
DNA binding ability in vitro as shown by Schlereth et al., 2010. Inverse 
correlation of ES and DNA binding is evident. Means of replicates for 
each mdm2-inhibitor are shown. Statistical significance was assessed by 
ANOVA with Dunnett’s multiple comparison test. D. CSMS-derived RFS 
are plotted against the relative abundance of each mutant across human 
cancers (UMD database). 
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mutations at these positions as damaging (mean ESC176=1.77±0.43 and 
ESH179=1.73±1.35) (Fig. 29A). Residues P177 and H178 are critical for forming a 
protein-protein interface between two p53 monomers bound to DNA (Brandt et al. 
2009). In line with this, many mutations at these positions also impaired p53 function 
according to CSMS (mean ESP177=1.73±0.67, ESH178=1.08±0.33).  
Residues E180 and R181 demonstrated intermediate sensitivity to mutagenesis (Fig. 
29B). Our group and other investigators have identified these residues as essential 
for the cooperative binding of two p53 subunits to DNA. Oppositely charged arginine 
and glutamic acid of the two p53 monomers form reciprocal salt bridges that stabilize 
the DNA-bound p53 tetramer (Ma et al. 2007; Dehner et al. 2005; Liu et al. 2017; 
Olive et al. 2004). Missense mutations at the codons 180 and 181 alter the 
cooperative DNA binding to a different extent and are referred to as “cooperativity 
mutations.” Cooperativity mutants display distinct DNA binding affinity and, 
consequently, different transactivation capacities. For example, mutants E180L, 
E180R, and R181L have reduced DNA binding and demonstrate impaired apoptosis 
activation but can halt proliferation. 
On the contrary, R181E is unable to transactivate any target genes and is deprived 
of both apoptotic and cell cycle arrest activities (Schlereth et al. 2010a). Notably, our 
screening could uncover functional differences between some cooperativity 
mutations in good agreement with published experimental data. As shown in Fig. 
29C, R181L and E180L were depleted from the pool comparably to wild-type 
variants in line with their partially retained DNA binding and transactivation (mean ES 
for nutlin R181L 0.26±0.13, E180L 0.2±0.05, R181R 0.17±0.03, E180E 0.2±0.04) 
(Fig. 29B). Mutant R181H binds to DNA and transactivates target genes weaker than 
R181L (Schlereth et al. 2010a). Accordingly, this variant demonstrated intermediate 
enrichment in our dataset. Similarly, mutant E180R, which was extensively 
characterized as partial-LOF in vivo (Timofeev et al. 2013), also demonstrated 
significantly lower enrichment compared to nonsense variants (ANOVA with 
Dunnett’s test p<.0001) (Fig. 29C). Mutants with weaker residual DNA binding and 
transactivation (E180K and R181C) showed slightly lower enrichment than nonsense 
mutations, which was nevertheless statistically significant (ANOVA with Dunnett’s 
test p=0.0051 and 0.0007 respectively). Finally, mutants R181E and R181P were 
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described as entirely DNA binding- and transactivation-deficient (Schlereth et al. 
2010a; Timofeev et al. 2019). They showed no significant difference from nonsense 
variants in our screening. Collectively, these observations further justify that CSMS 
can precisely capture even subtle functional differences between p53 variants.On 
the contrary, R181E is unable to transactivate any target genes and is deprived of 
both apoptotic and cell cycle arrest activities (Schlereth et al. 2010a). Notably, our 
screening could uncover functional differences between some cooperativity 
mutations in good agreement with published experimental data. Figure 29C depicts 
enrichment scores of 8 variants of R181 and E180. Mutants were ordered according 
to their in vitro DNA binding capacity measured in electrophoretic mobility shift assay 
with 32P-labelled dsDNA fragment containing p53 concensus response element (data 
from Schlereth, 2010). As shown in Fig. 29C, R181L and E180L were depleted from 
the pool comparably to wild-type variants in line with their partially retained DNA 
binding and transactivation (mean ES for nutlin R181L 0.26±0.13, E180L 0.2±0.05, 
R181R 0.17±0.03, E180E 0.2±0.04) (Fig. 29B). Mutant R181H binds to DNA and 
transactivates target genes weaker than R181L (Schlereth et al. 2010a). 
Accordingly, this variant demonstrated intermediate enrichment in our dataset. 
Similarly, mutant E180R, which was extensively characterized as partial-LOF in vivo 
(Timofeev et al. 2013), also demonstrated significantly lower enrichment compared 
to nonsense variants (ANOVA with Dunnett’s test p<.0001) (Fig. 29C). Mutants with 
weaker residual DNA binding and transactivation (E180K and R181C) showed 
slightly lower enrichment than nonsense mutations, which was nevertheless 
statistically significant (ANOVA with Dunnett’s test p=0.0051 and 0.0007 
respectively). Finally, mutants R181E and R181P were described as entirely DNA 
binding- and transactivation-deficient (Schlereth et al. 2010a; Timofeev et al. 2019). 
They showed no significant difference from nonsense variants in our screening. 
Collectively, these observations further justify that CSMS can precisely capture even 
subtle functional differences between p53 variants. 
Next, we have analyzed how the loss of protein functionality in our screening 
correlates with the prevalence of mutations in cancer patients. Most variants found in 
more than ten cancer specimens had a positive RFS, indicating loss of tumor-
suppressive activity (Fig. 29D). More specifically, mutagenesis-resistant residues 
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182-185 are rarely mutated in tumors (157 out of 58522 missense mutation records 
in the UMD TP53 database, 39 mutations/codon). Thus, mutations at these positions 
do not impair protein functionality and do not give tumor cells a selective advantage.  
By contrast, mutations of residues sensitive to mutagenesis (176-179) are found in 
tumors very frequently (2108 missense mutations in UMD TP53 database, 527 
mutations/codon) (Fig. 29A), and none of these variants are annotated in the UMD 
database as functional in respect of the transactivation, on the contrary to mutations 
in residues 182-185. 
Mutations at residues E180 and R181 have demonstrated a variable pattern of 
functional p53 impairment in CSMS. They have an intermediate frequency in tumors 
(289 UMD TP53 records, 144.5 mutations/codon). 
Summarizing, our analysis identified many pathogenic mutations in the H1 helix in 
good agreement with known structure-function dependencies, previously published 
experimental and clinical data. This demonstrates that the CSMS is suitable for 
accurate functional classification of p53 mutations in a high-content manner. 
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In section 3.7.3 we have explored the effects of mutations in the codon R175 on 
cellular fitness under treatment with 5-FU and APR246. Although 5-FU has a distinct 
mechanism of action than nutlin, our screening revealed a very similar pattern (mean 
Rs=0.93 and 0.87 for 24 and 48h of treatment compared to nutlin (8 days). 
Surprisingly, the treatment of cells with APR-246 failed to identify any mutants that 
could be reactivated by the compound (Fig. 26B). This could be due to the small 
sample size (19 mutants). To confirm our validation experiment results with the 
larger panel of mutants, we have treated cells carrying the H1 helix library with 5-FU 
Figure 30. Impact of mutations in H1 helix on cellular fitness under 
treatment with 5-fluorouracil 
A. Cells harboring the H1 helix library were treated with 5 µM 5-FU for 24 
or 48h, washed with medium, and harvested 8 days after the beginning of 
treatment. Heatmap demonstrates RFS values for 5-FU and nutlin-treated 
cells (n=3). B. Correlation of RFS measured for cell libraries treated with 




and APR-246, as described previously (sections 3.7.2-3). Plotting of RFS computed 
for 5-FU and nutlin-treated libraries revealed a strong correlation (Rs=0.86 or 0.85 
for 24 and 48h, p<0.0001) (Fig. 30A). Similar to the R175-library experiment, 
markedly lower depletion of mutants under 5-FU treatment compared to nutlin was 
noticed (compare X and Y axes on the Fig. 30B). Several variants were not depleted 
after 48 hours of 5-FU treatment, despite strong depletion after eight days of nutlin 
treatment (S183W, C182N), which may indicate preferential induction of cell cycle 
arrest by these mutants under 5-FU treatment. In summary, the experiment has 
Figure 31. Lack of response of H1 helix mutants to the treatment 
with mutant p53 reactivating compound APR-246  
A. Cells harboring the H1 helix library were treated with 12.5 and 25 µM 
of APR-246 alone or in combination with nutlin for 8 days and harvested 
for DNA isolation. RFS values are shown (n=3). B. ES measured after 
treatment of library-expressing cells with 25 µM APR-246 shown for 3 
groups of mutants. p=0.54, unpaired t-test. C. Correlation of RFS 
measured for cell libraries treated with nutlin or with the combination of 




demonstrated that H1 helix p53 mutants reveal similar response patterns under 
treatment with MDM2- inhibitor nutlin and DNA damaging agent 5-fluorouracil. 
Next, we have treated cells expressing the H1 helix library with APR-246. Rescue of 
tumor-suppressive functions of missense mutants would result in APR-246-
dependent elimination of some of the variants enriched under nutlin treatment. 
Therefore, we have expected that such mutants would reveal significantly lower 
enrichment scores than both nonsense and wild-type-like variants (which should 
remain unaffected by APR-mediated p53 refolding). We did not observe any mutants 
demonstrating such behavior: all missense variants that were enriched under nutlin 
treatment (ES>1) showed an APR-246 response similar to nonsense and 
synonymous variants (mean ES=0.95, 1.0 and 1.0; range 0.7, 0.5, and 0.7 for 
synonymous, nonsense and missense variants respectively) (Fig. 31A, B). As noted 
before, APR-246-mediated restoration of p53 activity synergizes with MDM2 
inhibition (Izetti et al. 2014). However, a comparison of RFS measurements from 
cells treated with nutlin or with the combination of two compounds demonstrated a 
high correlation, suggesting a lack of APR-specific effects. Not a single mutant 
conferring resistance to nutlin became depleted by combined treatment with APR-
246 (Fig. 31C, lower right quadrant). In summary, our experiments again failed to 
demonstrate the rescue of mutant p53 functions by APR-246. 
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3.10 CSMS reveals mutations leading to nonsense-mediated mRNA 
decay of TP53 transcript 
Nonsense-mediated mRNA decay is a process used by eukaryotic cells to control 
the quality of mRNA. It detects and degrades mRNAs with nonsense mutations, for 
example, premature termination codons (Meyers et al. 1993; Mateo et al. 2020; Teng 
et al. 2017; Meisler 1975; Jones et al. 2008). In addition, the p53 missense mutation 
K120R leads to the formation of an aberrant splicing site which in turn generates a 
transcript variant with a frame-shifted premature termination codon. mRNA produced 
from this transcript is subjected to nonsense-mediated mRNA decay (Lee et al. 
2019). Expression of p53 variants from the native locus in the CSMS system is 
expected to discover missense mutations leading to aberrant splicing. To explore 
this potential advantage of our protocol, we have isolated genomic DNA and RNA 
from cells expressing R175 and H1 helix libraries. After first-strand cDNA synthesis, 
PCR with a primer pair annealing at the 3’-end of the exon 5 and at the junction 
between exon 6 and exon 7 Nonsense-mediated mRNA decay is a process used by 
eukaryotic cells to control the quality of mRNA. It detects and degrades mRNAs with 
nonsense mutations, for example, premature termination codons (Meyers et al. 
1993; Mateo et al. 2020; Teng et al. 2017; Meisler 1975; Jones et al. 2008). In 
addition, the p53 missense mutation K120R leads to the formation of an aberrant 
splicing site which in turn generates a transcript variant with a frame-shifted 
premature termination codon. mRNA produced from this transcript is subjected to 
nonsense-mediated mRNA decay (Lee et al. 2019). Thanks to the expression of p53 
variants from the native locus the CSMS system is expected to discover missense 
mutations leading to aberrant splicing. To explore this potential advantage of our 
protocol, we have isolated genomic DNA and RNA from cells expressing R175 and 
H1 helix libraries. After first-strand cDNA synthesis, PCR with a primer pair 
annealing at the 3’-end of the exon 5 and at the junction between exon 6 and exon 7 
was performed (primers #11 and #28 correspondingly). Such a design for the 
reverse primer was chosen to amplify exclusively cDNA and exclude amplification of 
genomic DNA. Genomic DNA was amplified as previously described (Fig. 32A). 
Both amplicon libraries were sequenced, and the number of reads assigned to each 
mutation in cDNA and gDNA libraries were compared (Fig. 31A, B). Comparison of 
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read fractions (RF) measured in the R175 library revealed, that missense mutations 
were equally presented in gDNA and cDNA (mean RFgDNA=0.037±0.02, mean 
RFcDNA=0.043±0.025, Mann Whitney test p=0.216). Similar tendency was revealed 
in the H1 helix library: missense mutations were equally presented in genomic DNA 
and cDNA (mean RFgDNA=0.0046±0.0032, mean RFcDNA=0.005±0.003, Mann-
Whitney test p=0.17, Fig. 32 A,B). Notably, nonsense variants and frameshifts  
demonstrated distinct behavior in both libraries. They were significantly less 
abundant in the cDNA as compared to gDNA (shown as red dots, R175 library: 
RFgDNA=0.037±0.008, RFcDNA=0.0021±0,0005, t-test p<0.0001; H1 helix library: 
RFgDNA=0.0072±0.0035, RFcDNA=0.00046±0,0004, Fig. 32A, B). These data imply 
that transcripts containing stop codons and frameshifts are subjected to nonsense-
mediated decay. Importantly, the deletion of the codon 175, which disrupts protein 
functionality but does not influence mRNA stability, was equally abundant in gDNA 
and cDNA libraries (mean read fraction 0.020 versus 0.025, Delta R in Fig. 32A).  
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Interestingly, mutation R175Y was significantly less abundant in cDNA compared to 
all other missense variants (RFmissense=0.043±0,025, RFR175Y=0,015±0,002, 
Mann-Whitney test p=0.0082), suggesting that R175 CGC>TAC mutation might lead 
to mRNA degradation. R175Y was identified as LOF in CSMS and in earlier reports 
(Ryan and Vousden 1998; Kim et al. 2003). Although no data from the literature point 
on its influence on mRNA stability, our findings deserve further investigation. 
Figure 32. CSMS identifies mutations causing nonsense-mediated 
mRNA decay.  
A. Schematic of the cDNA (above) encoded by the TP53E allele (below). 
The junction between exons 6 and 7 in cDNA is indicated with the 
orange line. This junction is absent in the gDNA sequence and the 
fragment with primers #11 and #28 fails the amplification. B,C. Cells 
carrying R175 (B) and H1 helix libraries (C) were cultivated for 2 weeks 
after adeno-Cre infection and harvested for gDNA and mRNA extraction. 
gDNA and cDNA sequencing were performed to quantify the abundance 
of each variant in the population (gDNA) and abundance of variant-
coding transcripts (cDNA). Shown are mean fraction of reads from gDNA 





Collectively, our observations show that CSMS can be used to discover mutations 
causing nonsense-mediated decay of TP53 transcripts. 
3.11 CSMS identifies pathogenic non-coding TP53 mutations 
We devised the CSMS as a system for analyzing TP53 mutations in the context of 
the genomic locus with preserved regulatory elements (such as enhancers, introns, 
and promoters). Mutations at splice sites account for 2% of all detected TP53 
alterations (Fig. 33A) (Bouaoun et al. 2016; Leroy et al. 2014a). The pathogenic 
effects of such mutations cannot be studied using systems based on the expression 
of cDNAs. Consequently, none of the previous studies of the p53 mutome analyzed 
this class of mutations. On the contrary, our system enables capturing the complete 
diversity of alterations at the TP53 locus, including mutations in non-coding regions.  
To evaluate this potential advantage of the CSMS, we have assembled a saturating 
mutagenic library of the splice donor site (SDS) in the 5th intron. Mutations at this site 
were found in cancer patients (Smeby et al. 2019). Specifically, the SDS library 
comprised the following mutations at the junction between exon 5 and intron 5: 
synonymous mutations and stop codons (TAA, TAG, TGA) at positions D184, S185 
and D186, all possible permutations of the last nucleotide (c.559) of exon 5 (forms 
the codon G187 with exon 6), and all possible permutations of the first 12 
nucleotides of the intron 5. 54 double-stranded 26 base pair-long oligonucleotides 
were cloned into HR-2-Golden Gate vector and the resulting library was used in a 
standard co-transfection procedure. Cells carrying the SDS library cells were treated 
for eight days with nutlin and harvested for DNA isolation and sequencing. Strong 
enrichment of nonsense mutations and depletion of synonymous variants 
demonstrated the validity of the analysis (Fig. 33B). Remarkably, mutations at 
positions c. 559, +1, +2, and +5 turned out to impair p53 function, as evident from 
the enrichment of all sequence variants at these positions. These mutations likely 
disrupt splicing of the transcript, in line with stringent sequence requirements for 
positions +1, +2, and +5 in eukaryotic splice sites (G, T, and G respectively) (Burset 
et al. 2001; Shapiro and Senapathy 1987). Notably, mutation c.559+1G>A was 
described as a variant affecting splicing and leading to the production of the 
truncated polypeptide in individuals with the hereditary cancer-predisposing 
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syndrome (ClinVar record NM_001126112.2) (Surget et al. 2013; Lai et al. 1993). 
These results showcase the extended capabilities of the CSMS platform in the 
Figure 33. CSMS reveals non-coding pathogenic mutations of the 
splice donor site in the intron 5  
A. Frequency and distribution of mutations in TP53 splicing sites (red) and 
missense mutations (grey). Frequency of mutations at each codon or 
splice site in the UMD database is shown. Modified from Smeby et al. 2019 
B. Heatmap depicts RFS of mutants in the SDS library measured in 
triplicate cultures of library-expressing cells treated with nutlin. The library 
was composed of 3 synonymous variants and 3 stop codons at positions 
D184, S185, and D186 as positive and negative controls and all possible 
permutations of the last nucleotide of the exon 5 and first 12 nucleotides of 
the intron 5. Wild-type sequence starting from the position c.559 is shown 
below. +1, +2, and +5 are positions in the splice donor site of the intron 5. 
Alignment of the wild-type sequence with the cocensus sequence of the 
donor splice site is shown (modified from Desmet F., Hamroun Dalil, 




characterization of. Mutations at this site were found in cancer patients (Smeby et al. 
2019). 
Donor splice sites are very conserved across eukaryotes (Shapiro and Senapathy 
1987). The concensus sequence of 5’-donor splice sites is AGGTA/GAGT. The 
donor splice site in the 5th intron of TP53 is almost identical to the concensus 
(AGGTGAC). We have included the following mutations at the junction between 
exon 5 and intron 5 into the SDS library: synonymous mutations and stop codons 
(TAA, TAG, TGA) at positions D184, S185 and D186, all possible permutations of 
the last nucleotide (c.559) of exon 5 (forms the codon G187 with exon 6), and all 
possible permutations of the first 12 nucleotides of the intron 5. 54 double-stranded 
26 base pair-long oligonucleotides were cloned into HR-2-Golden Gate vector and 
the resulting library was used in a standard co-transfection procedure. Cells carrying 
the SDS library cells were treated for eight days with nutlin and harvested for DNA 
isolation and sequencing. Strong enrichment of nonsense mutations and depletion of 
synonymous variants demonstrated the validity of the analysis (Fig. 33B). 
Remarkably, mutations at positions c. 559, +1, +2, and +5 turned out to impair p53 
function, as evident from the enrichment of all sequence variants at these positions. 
These mutations likely disrupt splicing of the transcript, in line with stringent 
sequence requirements for positions +1, +2, and +5 in eukaryotic splice sites (G, T, 
and G respectively) (Burset et al. 2001; Shapiro and Senapathy 1987). Notably, 
mutation c.559+1G>A was described as a variant affecting splicing and leading to 
the production of the truncated polypeptide in individuals with the hereditary cancer-
predisposing syndrome (ClinVar record NM_001126112.2) (Surget et al. 2013; Lai et 
al. 1993). These results showcase the extended capabilities of the CSMS platform in 
the characterization of non-coding TP53 alterations.  
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3.12 CSMS-based functional classification of >1200 p53 protein 
variants 
To further evaluate the performance and scalability of the CSMS system, we have 
designed a saturation mutagenesis library encoding 3843 TP53 nucleotide variants. 
Specifically, the library encoded the pool of sequence variants representing all 
possible permutations at each position from Y126 until S186 (encoded by the 5th 
exon). 
To prepare the HDR template library, a pool of 3843 single-stranded oligonucleotides 
(230 bp) was manufactured by Agilent using array-based synthesis. Each 
oligonucleotide was spanning the genomic region Chr. 17: 7.675.045 – 7.675.261 
(assembly GRCh38) and contained a single codon substitution. To make the HR-2 
Golden Gate vector compatible with 230 bp-long oligonucleotides, the BbsI 
recognition sequences were located at the beginning and at the end of exon 5. The 
pool of single-stranded oligonucleotides was converted into double-stranded using 
PCR with primers #26 and #27 containing BbsI recognition sequences at 5’-ends. 
The resulting PCR fragments were cloned into the modified HR-2 Golden Gate 
cloning vector (Fig. 8) using Golden Gate protocol. The plasmid library was purified 
using procedures described in the Materials and methods section. Library quality 
was verified using NGS. 
The pool of library-encoding plasmids was transfected into 100 million HCT-
116Δ/TP53E cells. For adeno-Cre infection and nutlin treatment, the same number of 
transfected cells was used, and the splitting ratio was maintained at 1:2 to retain 
library complexity. Triplicate cultures were treated for eight days with nutlin and 
harvested simultaneously with untreated samples. It is essential to highlight the fact 
that Cre-mediated recombination is not 100% efficient. Therefore, cellular libraries 
always contain non-recombined cells expressing no p53. This results in the 
background from unrecombined (GFP-positive) cells, which does not affect 
sequencing results for the low complex R175 and H1 helix libraries, but becomes an 
important factor in the case of the highly complex exon 5 library. To enrich the 
cellular library for GFP-negative cells which have undergone Cre-mediated 
recombination, we have used FACS sorting. Genomic DNA was isolated from 15 
million cells per replicate. To improve the sequencing coverage, the amount of 
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genomic DNA and the number of PCR reactions was increased as described in 
Materials and methods in section 2.2.10. Next-generation sequencing of the TP53 
locus was conducted as described above. 
The sequencing of the targeting vector revealed that all 3843 nucleotide variants 
were retained in the plasmid preparation. This demonstrated that the large-scale 
oligonucleotide synthesis and cloning procedures were successfully implemented 
(read counts: minimum 45, maximum: 42111, mean: 917). Comparison of 
sequencing data derived from the vector and the cellular library revealed a 
substantial abundance decrease for many mutants: the frequency of the least 
abundant variant in the Cre-infected cell library was 0.0000008 compared to 
0.000013 in the vector (16-fold change, Wilcoxon test p<0.0001 (Fig. 34A) This 
indicates that transfection and subsequent propagation of the library introduced 
substantial bias. Nevertheless, further analysis of the dataset confirmed the validity 
of the experiment. 
Analysis of sequencing data from untreated cells revealed that variant frequencies 
were highly correlated between three library replicates, demonstrating good 
reproducibility of the mutagenesis procedure (Rs=0.9 and 0.86 for library 1 versus 2 
and 3 respectively, p<0.0001) (Fig. 34B). Libraries prepared from adeno-Cre-infected 
and sorted GFP-negative cells yielded 99.79% variant coverage, demonstrating 
preserved library complexity. As shown in Fig. 33C, in two library replicates only 6% 
of nucleotide variants were covered by less than 50 reads, approximately 20% were 
covered by less than 500 reads, and the majority of mutants was covered by more 
than 500 reads (Fig. 34C). The third replicate revealed lower sequencing depth, 
which could be caused by poor DNA quality or some error during library preparation. 
Considering the high coverage of most of the variants in the library and high 
reproducibility of the mutagenesis procedure, we have considered our data to have 
sufficient quality for further analysis, despite some obvious technical issues (Fig. 
34B, C). 
Next, we have assessed the measurement precision by calculating the coefficient of 
variation (CV) for each variant as a ratio of the standard deviation to the mean read 
count across replicates. Comparison of CVs revealed a substantial difference 
between untreated and nutlin-treated libraries. In the untreated dataset, 644 variants 
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had CV >0.25, whereas in the nutlin dataset, only 128 (Fig. 35A). These data imply 
that in the untreated cellular library, variant frequencies are subjected to stronger 
fluctuations than in the nutlin-treated library. To reduce measurement noise, we have 
selected an arbitrary threshold based on CV values. All variants with CVuntreated<0.45 





Figure 34. CSMS protocol enables introduction of a highly complex 
library of 3646 variants in the TP53 locus 
A. Comparison of read fractions for each of 3646 nucleotide variants in the 
plasmid library (vector) and in the transfected cell pool after infection with 
adeno-Cre. B. Correlation of read fractions for all variants across 3 library-
expressing replicates. Rs, Spearman correlation coefficient. C. Heatmap 
depicts variant coverage in the vector and triplicate cultures of library-
expressing cells. Number of reads assigned to each variant is shown 
aligned to the sequence of exon 5 according to the color scale.  
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CVuntreated>0.45 or CVnutlin>0.3 were discarded (Fig. 35B). Application of the threshold 
enabled us to remove the most inconsistently measured mutants without 
compromising the global complexity of the dataset.  
Next, we have summarized filtered read counts for all mutations encoding the same 
amino acid substitution in each replicate and computed normalized read counts for 
protein variants. Application of the threshold resulted in a loss of just 21 protein 
variants from the dataset, 1249 protein variants (98%) were retained in the 
processed dataset. 
The relative abundance of variants upon nutlin treatment revealed expected 
dynamics: all synonymous variants were depleted from the population (mean 
ES=0.6±0.27), whereas missense and nonsense mutations were enriched (mean 
ES=1.26±0.9 and 1.62 ±0.95 respectively) (Fig. 36A).  
To assess the accuracy of the CSMS in a high-content format, we have compared 
results with R175 and H1 helix and libraries as validation datasets since mutations 
present in the two smaller libraries were also contained in the larger exon 5 library. 
Figure 35. Comparison of variance in sequencing data of untreated 
and nutlin-treated cell libraries 
A. Frequency distribution of the coefficient of variation (CV) calculated 
for each variant across triplicates in the untreated and nutlin-treated cell 
libraries. CV was calculated as a ratio of the standard deviation to the 
mean normalized reads. Smaller variance in the nutlin dataset is 
evident. B. CVs for each variant from untreated and nutlin-treated 
libraries were plotted and used to select the threshold: all sequence 
variants outside the lower-left quadrant were excluded from the analysis 
to reduce measurement noise. CV calculation was performed with the 
help of Boris Klimovich. 
B A 
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Reassuringly, both comparisons revealed a significant positive correlation 
(Rs(R175)=0.63, p=0.002, and Rs(H1 helix)=0.72, p<0.0001), demonstrating that high-
content screening mainly reproduces the classification made in the low-throughput 
experiments (Fig.36 B, C). Nevertheless, some variants were classified discordantly 
in two experiments (located in the upper left and lower right quadrants in Fig. 36B 
and 36C). To find the reason for discordant classification, we have compared 
enrichment scores for all variants present in both H1 helix and exon 5 datasets (Fig. 
36D). The comparison revealed a remarkably distinct distribution of RFS values. 
Despite having similar median RFS (-0.15 and 0.07), the H1 helix dataset 
demonstrated significantly larger data spread, exemplified by the higher range and 
interquartile range values (5.42 versus 3.08 and 1.43 versus 0.74 respectively). Data 
presented in Fig. 36 clearly demonstrate that the primary source of higher variance 
in the H1 helix dataset is more substantial depletion of variants compared to the 
exon 5 dataset. Therefore, scaling up the CSMS protocol resulted in decreased 
resolution between LOF and wild-type-like mutants due to reduced depletion of 
mutants from cellular pools. 
To further examine the ability of high-throughput CSMS to capture the functionality of 
p53 variants, we have calculated an evolutionary conservation score (ECS). ECS 
was previously used as an indicator of the vulnerability of p53 residues to functional 
alteration. The most conservative amino acids were identified as highly susceptible 
to mutations, whereas less conservative were resilient to mutations (Kotler et al. 
2018). ECS was computed for each of the 50 residues based on the alignment of 
1498 p53 protein sequences using ConSurf2016 (Ashkenazy et al. 2016). Negative 
scores indicate high evolutionary conservation. Comparison of the ECS with mean 
enrichment score values for each amino acid position revealed significant negative 
correlation (Rs=-0.54, p<0.0001): evolutionary conserved residues with low ECS 
demonstrated higher mean ES in our screening, indicating intolerance to 
mutagenesis (Fig. 37A). Therefore, our experiment performed the classification of 






Figure 36. Comparison of the relative fitness scores measured for 
R175 and H1 helix variants by low- and high-content CSMS 
protocols 
A. ES values measured in the nutlin-treated libraries for 3 groups of 
variants. Synonymous variants are significantly depleted, nonsense 
variants are strongly enriched, enrichment pattern of missense 
mutations is highly variable n=3. **** p<0.0001, unpaired t-test with 
Welch's correction. B. RFS values derived from the exon 5 dataset are 
plotted against corresponding RFS values from the R175 dataset. Rs, 
Spearman correlation coefficient. C. RFS values derived from the exon 5 
dataset are plotted against corresponding RFS values from the H1 helix 
dataset. Rs, Spearman correlation coefficient. D. Comparison of RFS 
values computed for all missense variants from H1 helix and exon 5 




Next, we have analyzed if our functional measurements correlated with the 
transactivating capacity of the mutants. As in Section 3.7, Fig. 18D, we have utilized 
the data capturing transactivation of 8 response elements by p53 mutants derived 
from the yeast reporter assay (Kato S. et al. 2003). We have extracted the reporter 
activity values for 352 variants encoded by the 5th exon and performed principal 
component analysis using ClustVisto to separate mutants with mostly dissimilar 
transactivating patterns (Metsalu and Vilo 2015). Then we have plotted relative 
fitness scores derived from the nutlin treatment experiment versus values of principal 
component 1 (PC1), which explains 79.1% of the variance in the transcriptional 
activity dataset (Fig. 37B). The comparison revealed a significant correlation 
between relative fitness score and transactivating properties of mutants represented 
by PC1 values (Rs=-0.68, p<0.0001). This implies that the high-content CSMS 
captures the global difference in the transactivation capacity of hundreds of mutants. 
We next analyzed whether the functional consequences of mutations in exon 5 
measured by CSMS correlate with mutational prevalence in human tumors. To this 
end, we have selected all exon 5 variants reported in more than 10 patients’ samples 
and plotted their frequency in the UMD database against mean relative fitness 
scores. This comparison revealed a weak but significant correlation between ES and 
mutation prevalence in tumors (Rs=0.33, p<0.0001). The most frequent cancer-
associated hotspot mutant R175H was enriched markedly weaker than many other 
less frequent mutants (Fig. 37C). This fact further highlighted the low resolution of 
the high-content CSMS because, in the experiment with the R175 library, this mutant 
had markedly higher enrichment (1.66 versus 0.83). 
Interestingly, many rare tumor-associated mutations were highly enriched in the 
dataset, supporting earlier observations (Fig. 37C) (Kotler et al. 2018; Ory et al. 
1994). Therefore, the loss of functionality and clinical significance cannot be 
deduced solely from mutation prevalence in patients and highlights the importance of 
functional measurements. 
Plotting individual RFS for each protein variant revealed a diverse pattern of 
sensitivity to alterations (Fig. 38). Anti-proliferative capacity remained almost 
unaffected by mutations at specific positions (for example, 165-170 and 182-186). 
However, p53 functionality was strongly impaired by almost every substitution of 
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Figure 37. Functional effects measured by CSMS correlate with 
evolutionary conservation, transactivation capacity, and 
occurrence in cancer patients 
A. Evolutionary conservation score (ECS) was computed for every 
residue encoded by the 5th exon using ConSurf 2016 and plotted against 
corresponding mean RFS values (calculated for each amino acid 
position across all missense mutations). Rs, Spearman correlation 
coefficient. Analysis performed by Boris Klimovich. B. Data on 
transactivation of p53 response elements in yeast reporter system were 
extracted from the study of Kato (Kato et al., 2002) and subjected to the 
principal component analysis using ClustVis. The resulting PC1 values 
were plotted against RFS. Rs, Spearman correlation coefficient. Analysis 
performed by Boris Klimovich. C. RFS values for exon 5 mutants are 
plotted against their relative abundance in human tumor specimens (from 
the UMD database, Log2-transformed).  
C 
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some residues (e.g., 162-163, 173, 179). Importantly, the cluster of mutagenesis-
tolerant residues (C182-S185), as well as mutagenesis-sensitive Zn-coordinating 
residues C176 and H179, were already revealed in the experiment with the H1 helix 
library. Therefore, our high-content assay displayed a similar phenotypic response to 
mutagenesis compared to low-content validation experiments.  
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Importantly, clusters of mutagenesis-sensitive residues contained the positions most 
frequently mutated in cancers (orange bars, Fig. 38). Taken together, analysis of the 
exon 5 dataset demonstrated that the CSMS platform allows the fast and simple 
generation of large libraries of p53 mutants. We were able to measure the functional 
consequences of more than 1000 protein variants in a single high-content screening 
experiment. We have revealed strong associations between our functional 
classification, evolutionary conservation, transactivating properties, mutation 
prevalence in human tumors, and results of our validation experiments. Despite 
remarkable results achieved in this experiment, further improvements are needed to 




Figure 38. CSMS captures the impact of 3646 mutations on the anti-
proliferative capacity of p53 
Triplicate cultures of adeno-Cre-infected cell libraries were treated with 
nutlin for 8 days. Heatmap depicts RFS for each protein variant. Grey 
bars on top show conservation score (CS) at each position across all 
tumor types (data from ConSurf). Orange bars below show the 
prevalence of mutations at each position across all tumor types (data 
from UMD). Synonymous and nonsense variants are shown separately, 
missing data points are labeled with X.  
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3.13  Comparison of functional classification of exon 5 mutations 
derived from CRISPR- and cDNA-based screening experiments 
 CSMS outperforms the cDNA-based method in the classification of rare 
patient-derived mutations of H1 helix 
To better understand the ability of CSMS to predict the tumorigenic potential of TP53 
mutations, we have compared CSMS-derived classification patterns of p53 
mutations with the recently published dataset from the study of Kotler et al. The 
authors established the cDNA library encoding >10 000 of p53 variants. They 
delivered it into p53-negative H1299 cells using lentiviral infection and cultured cells 
for two weeks. Afterward, the relative abundance of each mutation was quantified 
using deep sequencing. The depletion or enrichment of variants after two weeks of 
cultivation was used as a measure of antiproliferative capacity. On the contrary to 
our experiments, no treatment with MDM2-inhibitors or other compounds was 
performed. We have extracted corresponding enrichment scores for all protein 
variants present in our dataset and plotted them against CSMS-derived RFS values 
(Table S3 from Kotler et al, 2019).  
First, we have compared enrichment scores for all mutations at position 175. 
Noteworthy, both methods yielded a very similar pattern of enrichment and depletion: 
synonymous variants were strongly depleted in both datasets, whereas nonsense 
variants and the most frequent cancer-derived variant R175H were enriched. 
Interestingly, the cDNA-based screen scored several variants as wild-type-like, 
whereas in CSMS these variants were enriched as strong as LOF mutants. Such 
discordant classification raised the question, which estimation is correct. Importantly, 
among these mutations (shown in the lower right quadrant on Fig. 39A), two were 
repeatedly recovered from tumor samples: R175P and R175L (12 and 74 records in 
the UMD database, respectively). R175L was described as a germline mutation 
associated with adrenal cortical carcinoma (West et al. 2006). R175P is a partial-
LOF variant (Crook et al., 1994; Ludwig et al., 1996; Rowan et al., 1996), whose 
mouse analog (R172P) was reported as tumorigenic in a knock-in model (Liu et al. 
2004). Hence, CSMS correctly identified these two variants as pathogenic, whereas 
the cDNA-based system misclassified them as benign.  
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Next, we have expanded our analysis to the H1 helix dataset. We have listed all 
missense mutations from H1 helix found in human tumors and compared the 
classification of these mutations made by CSMS and cDNA-based screening (Fig. 
39B). All variants retrieved from more than 90 tumor samples and therefore being 
undoubtedly cancer-predisposing, were classified as loss of function by CSMS 
Figure 39. CSMS outperforms cDNA-based screening in 
classification of the pathogenic mutations in the H1 helix  
A, B. CSMS-derived RFS values form the R175 (A) and H1 helix (B) 
datasets are plotted against corresponding RFS values extracted from 
the cDNA-based study (Kotler et al., 2019). A. Synonymous and 
nonsense mutations are presented as mean RFS values of all 
corresponding variants (10 synonymous and 10 nonsense). R175P 
(green) and R175L (violet) are two mutations with documented residual 
activities. B. H1 helix mutations are color-coded according to their 
prevalence in cancer patients (from the UMD database). Individual 




(enrichment score >0, red dots). However, the cDNA-based analysis failed to predict 
loss of functionality for two bona fide cancer-driving mutations (C176Y and R181C 
(281 and 101 UMD records respectively, the pathogenicity of the R181C was 
recently confirmed in a mouse model (Kang et al. 2020). Less frequent H1 helix 
mutations found in 10-90 patients still can be considered as likely cancer-
predisposing. In good agreement with this, 71% of them were classified as loss of 
function by CSMS (blue dots). In contrast, just 8 of them (26%) were scored as LOF 
in the study of Kotler. Data from the literature imply that the scoring of the rest 29% 
of intermediate-frequency variants as wild-type-like is also correct. For example, 
mutation R181H is relatively abundant in patients (80 UMD records), lies in the “grey 
zone” in the CSMS dataset, but is scored as wild-type-like in the cDNA screen. This 
is a temperature-sensitive mutant, which exhibits normal properties at 30⁰C and, 
therefore, can exhibit residual activity but is nevertheless tumor-promoting (Soussi et 
al. 2005). Relatively abundant variant D184N (41 UMD TP53 records) is a known 
natural benign SNP (Wang et al. 2013). Two variants: D184H and S183L, were 
shown to retain 60-100% of transactivation of most of the promoters in the study of 
Kato et al. (Kato S. et al. 2003) and are classified by both screenings as more active 
than two synonymous variants annotated in the UMD database (H178H and P177P), 
being most obviously passenger variants or sequencing artifacts. Most variants 
found in less than ten tumor samples, being more likely neutral passenger mutations 
or sequencing errors (grey circles), are consistently classified by both studies as 
wild-type-like, demonstrating that the CSMS system does not over-estimate LOF 
properties of mutants. Finally, we have compared the classification of 532 cancer-
associated variants inferred from our exon 5 CSMS dataset with the cDNA-based 
screening outcome (Fig. 40). As expected, both systems classified most of the very 
rare variants (<10 UMD records, grey dots) as wild-type-like (227 variants), and only 
25 of them were classified by both screenings as LOF, suggesting that most of these 
mutations are either sequencing errors or neutral passenger mutations. 39 variants 
were scored by two systems discordantly: 29 variants were classified as LOF only by 
the CSMS, and 10 only by the cDNA screen. Thus, the high-throughput CSMS could 
overrate LOF properties of mutants compared to the cDNA-based system. Among 
protein variants with the intermediate frequency (11-90 UMD records (potentially 
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tumorigenic) both systems classified 40% as functional and 23% as non-functional 
(72 and 43 variants, respectively). Amid discordantly classified mutations, 43 were 
scored as LOF only by CSMS and 22 only by cDNA-based analysis. 
Out of 32 bona fide cancer-driving mutations (>90 UMD records), 13 were 
consistently classified by both methods as LOF. For other variants, two experiments 
provided contradictory classification. As noted in section 3.9, the most frequent 
hotspot mutant R175H was unexpectedly depleted in the CSMS (RFS=-0.26). Seven 
other variants were scored by the CSMS as functional (depleted), while cDNA-
screen scored them as LOF (Y163C, H179Y, V173M, P151S, C135Y, K132R, 
Y126C). 7 of these mutants had CSMS-derived RFS values markedly higher than 
synonymous variants (-0.22±0.12 versus -0.89±0.2), demonstrating moderate 
depletion. One mutant (Y126C, 98 UMD records) was depleted in CSMS to a degree 
comparable to synonymous variants (mean RFS -0.83 versus -0.88). This mutation 
was characterized in several studies as LOF (Kato et al. 2003; Monti et al. 2011; Shi 
Figure 40. Comparison of CSMS- and cDNA-based classification of 
exon 5 mutants 
CSMS-derived RFS values are plotted against corresponding RFS 
values extracted from Kotler et al., 2019 Mutations are color-coded 
according to their prevalence in cancer patients (from the UMD 
database). Green dot – mean RFS value of all synonymous variants. Rs, 
Spearman correlation coefficient. 
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et al. 2002; Grochova et al. 2008) and therefore is falsely classified as functional by 
the CSMS. 
The opposite classification (LOF in CSMS and wild-type-like in the cDNA screen) 
was derived for six mutants (G154V, C135F, A161T, V143M, P152L, and 
R156P).arge 
Interestingly, both screenings have classified five variants frequently found in tumors 
as partially functional: R158H, C176Y, C141Y, R181C, P151H (315, 281, 230 101, 
and 98 UMD records, respectively). RFS values for these mutants (red dots in the 
lower right quadrant in Fig. 40) were higher than of synonymous variants but below 
zero in both screenings. According to the ClinVar database, all these variants were 
recovered from patients with hereditary cancer predisposition, attesting them as 
cancer-driving. However, several of them were shown to retain residual functions. 
For example, R158H demonstrated transactivating capacity and growth-suppressing 
activity (Campomenosi et al. 2001; Wasserman et al. 2015; Monti et al. 2011). 
R181C has been described as a cancer-predisposing variant in the mouse model; 
however, the phenotype conferred by this mutation was mild compared to the p53-
null allele (30% reduction of median survival, 25% increase in cancer incidence) 
(Kang et al. 2020). Therefore, the classification of these two mutants as partially 
functional seems plausible. Importantly, R181C was undoubtedly scored as LOF in 
our H1 helix dataset (Fig. 29C), as well as the other clearly tumorigenic variant from 
the group: C176Y. 
Taken together, our comparison of the exon 5-CSMS dataset with the study of Kotler 
demonstrates that both systems classify many p53 variants in good agreement with 
their incidence in cancer patients. Both approaches generated discrepant 
classification of many mutants abundant in tumor samples. Notably, several of these 
mutants were classified in the low-content H1 helix dataset as tumorigenic, whereas 
cDNA-based screening scored them as benign. This implies that CSMS is potentially 
more accurate in classifying p53 mutants and calls for further optimization of the 
high-content screening protocol.  
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 CSMS outperforms in silico prediction tools in categorizing of pathogenic p53 
variants 
The introduction of multi-gene panel testing led to the identification of rare TP53 
variants of uncertain clinical significance. Bioinformatic predictors are valuable tools 
for estimating pathogenicity of mutations that were neither reported in families with 
Li-Fraumeni syndrome nor tested experimentally. The IARC TP53 and UMD TP53 
databases contain predictions made by seven tools: SIFT, Polyphen2, REVEL, 
BayesDel, Mutassessor, Provean, and Align-GVGD. SIFT and Mutassessor use 
evolutionary conservation to predict mutations affecting protein functions. Align-
GVGD and Polyphen2 utilize a combination of evolutionary conservation with 
biochemical and structural information. REVEL and BayesDel combine multiple 
algorithms (SIFT, REVEL, Polyphen, and others) for predictions (Leroy et al. 2013; 
Hicks et al. 2011; Adzhubei et al. 2010; Ramensky et al. 2002; Sunyaev et al. 1999; 
Vaser et al. 2016; Sim et al. 2012; Ioannidis et al. 2016; Choi 2012; Choi et al. 2012; 
Reva et al. 2007, 2011). 
Although instrumental, such tools have important limitations: they do not include 
functional test results and do not predict the response of mutation-carrying cancer 
cells to therapy. To our knowledge, no systematical comparison of the performance 
of the in silico predictors with high-content cell-based functional assays has been 
made. 
We, therefore, assessed how the effects of mutations measured in vitro by CSMS 
correlate with in silico-predicted impact. 
First, we have extracted values computed by three in silico predictors (SIFT, 
Provean, and Mutassessor) from the UMD database and plotted them against RFS 
scores from the H1 helix CSMS dataset (we did not use the Polyphen2 scoring 
because it separates variants in just three classes) (Fig. 40A). This comparison  
revealed that most of the H1 helix mutations enriched in the CSMS dataset (RFS>0) 
were accordingly classified as damaging by all three tools tested (lower right 
quadrant on each diagram). However, partial-LOF and wild-type-like variants that 
were depleted in the CSMS screening have demonstrated inconsistent classification 
by algorithms: approximately half of these variants were scored as tolerated and half 
as damaging. Mutassessor predicted 4 neutral mutations, SIFT and Provean 13, 
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whereas CSMS discovered 21 mutations with no apparent impact on protein function 
(RFS below mean score of synonymous mutants (<-2,5).  
Next, we have extended our analysis to the complete exon 5 dataset. As shown in 
Fig. 41B, CSMS and all algorithms tested agreed on the classification of the 
substantial number of mutants as LOF (lower right quadrant). Similar to the H1 helix 
dataset, half of the variants with negative RFS (tolerated) were classified by all 
algorithms as deleterious. Therefore, our comparison revealed a substantial 
discrepancy: all three predictive algorithms significantly overrated the number of 
deleterious variants by contrast to the functional test. 
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Next, we have compared CSMS-derived RFS values with the estimates made by two 
Figure 41. Comparison of the CSMS-based classification of H1 helix 
(A) and exon 5 (B) variants with pathogenicity estimations made by 
3 in silico predictors (Mutassessor, Provean, and SIFT) 
RFS values are plotted against corresponding scores. Dotted lines show 
specific threshold values for each of the methods: Mutassessor: <0.8 – 
neutral mutation, 0.98-1.935 – low probability of pathogenicity, >1.95 – 
the medium probability of pathogenicity. Provean: <-2.5 – deleterious 
mutation, >-2.5 – neutral mutation. SIFT: >0.05 – tolerated mutation, 
<0.05 – damaging mutation- CSMS: <0 – depleted, >0 – enriched. 
Analysis by courtesy of Boris Klimovich. 
B exon 5 A H1 helix 
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pathogenicity predictors: Align GVGD and BayesDel. A combination of these scoring 
algorithms was shown to be the most accurate method for in silico categorization 
(Fortuno et al. 2018). Align GVGD assigns a class value to each mutation (from 0 to 
65, where 0 is the strongest evidence for benign impact, and 65 is the strongest 
evidence for pathogenic impact). Fortuno and colleagues defined optimal cut-off 
parameters: Align GVGD class >15 and BayesDel score >0,16. We have extracted 
both values for each mutant from the IARC database (geneVariationIARC TP53 
dataset), filtered all mutations with BayesDel score >0,16, and plotted 208 variants 
against corresponding RFS values extracted from the CSMS exon 5 dataset. 
Additionally, we have plotted corresponding RFS values from our most rigorously 
validated H1 helix dataset (Fig. 42). The resulting plot depicts all variants from exon 
5 having moderate to strong evidence of pathogenicity (Align GVGD class >15, 
BayesDel >0,16) and their corresponding RFS from the two CSMS experiments. 
Values from the exon 5 dataset were scattered around RFS=0 (red dots), 
demonstrating no consistent pattern. Although CSMS and Align GVGD coherently 
classified many variants as LOF (class >15, RFS>0), a substantial number of 
variants with the highest probability of loss-of-function (class 65) were scored as 
benign by CSMS (RFS<0, 39 of 116 mutants). When we overlaid values from the H1 
helix dataset on the Align GVGD-BayesDel classification (blue dots) we revealed that 
20% of mutants (6 out of 27) belonging to class 65 were scored by the CSMS as 
functional. Among them, the H178Y was depleted below the average level of 
synonymous variants (-4.8 versus -2.5) and is most probably benign (2 UMD 
records), whereas the other five variants had intermediate depletion (from -0.8 to -
2.1). Additionally, among other possibly pathogenic variants (class 25-55) 4 were 
classified in the CSMS-H1 helix dataset as wild-type-like, 2 as intermediate (RFS≈0), 
and only 2 as LOF. Finally, two mutations falling into class 15 (uncertain 
pathogenicity) were classified by the CSMS as LOF and were in 
deed recurrently found in cancer patients (H179Q: RFS 0.7, 91 UMD records, 
H178Q: RFS 0.6, 18 UMD records). 
Therefore, the most advanced predictive approach failed to identify two likely 
pathogenic variants and simultaneously erroneously classified many benign 
mutations as damaging. Summarizing, our observations very clearly demonstrate 
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that the CSMS provides more accurate estimates of pathogenicity of TP53 mutations 
than any of the existing in silico prediction tools. 
  
Figure 42. Comparison of the CSMS-based classification of exon 5 
variants with pathogenicity prediction made by the combined Aligh 
GVGD-BayesDel algorithm (Fortuno et al., 2018) 
The plot depicts all variants from the exon 5 dataset having moderate to 
strong evidence of pathogenicity (red dots) (Align GVGD class >15, 
BayesDel >0,16) (located above the dotted line). X-axis – CSMS-RFS, Y-
axis – Align GVGD classes. The higher is the class – the stronger is the 
evidence for pathogenicity. Additionally, all variants from the H1 helix 
dataset are plotted (blue dots). Analysis by courtesy of Boris Klimovich. 
Note that many H1 helix mutants undoubtedly classified as benign by the 
CSMS, have the highest Align GVGD class.  
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4. Discussion 
Comprehensive functional classification of recurrent cancer-associated TP53 
alterations can improve clinical decision-making (Sabapathy and Lane 2018; Cheok 
and Lane 2017). Compelling evidence suggests that information about individual 
TP53 mutations can be useful for predicting the disease course, chemo- and 
radiotherapy response, and ultimately patient survival (Campling and El-Deiry 2003; 
Schon and Tischkowitz 2018; Richter-Pechańska et al. 2017; Murakami et al. 2000; 
Hamelin et al. 1994; Zhu et al. 2020). The development of numerous p53-targeting 
therapeutics further increases the value of the detailed characterization of TP53 
mutations (Mantovani et al. 2017; Di Agostino et al. 2019). For example, TP53 status 
is the main eligibility criteria for clinical trials of MDM2 inhibitors (Jiang and Zawacka-
Pankau 2020). The inclusion of mutant p53 in the list of actionable targets requires 
precise characterization of the full spectrum of p53 variants beyond the most 
frequent hotspot mutations.  
Two recent studies have performed a thorough investigation of the p53 mutome and 
substantially updated the catalog of p53 variants (Kotler et al. 2018; Giacomelli et al. 
2018). One severe limitation of these studies is the employment of lentiviral cDNA 
libraries to express p53 protein variants. Expression of the transgene from 
heterologous promoters may result in non-physiological protein levels and, 
consequently, in biased classification. Moreover, such an experimental setting 
excludes many other variables from the analysis, such as mutations in non-coding 
regions and splicing sites, p53 isoforms and miRNA-dependent regulation of the 
transcript stability (Feng et al. 2011). 
We aimed to create an improved phenotypic screening system that probes the 
effects of multiple TP53 mutations in the native genomic context. As a result, we 
have developed the CRISPR-based saturated mutagenesis screening, a high-
throughput protocol that enables precise functional characterization of thousands of 
p53 variants.  
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4.1 CSMS: a novel system for high-content functional 
classification of TP53 mutations 
We have envisioned a screening system where p53 mutations are targeted into the 
TP53 locus using CRISPR-Cas9-induced homology-directed repair. Although 
numerous attempts to improve HDR-driven genome editing were undertaken, its 
inherently low frequency remains a major obstacle for high-content applications (Lin 
et al. 2014). To overcome this limitation, we have engineered the original cell line 
(HCT-116Δ/TP53E) to achieve the highest possible gene editing efficiency. The 
resulting cell line became a cornerstone of the CSMS platform and had several 
important features. It enables editing of the single TP53 locus in each cell by using 
an allele-specific CRISPR-nuclease. During the editing process, the allele is inactive, 
which ensures the editing in the absence of the efficiency-limiting p53-induced DNA 
damage response (Bowden et al. 2020; Haapaniemi et al. 2018; Ihry et al. 2018). 
Multiple approaches were attempted to enhance HDR-mediated gene editing 
efficiency, for example, chemical or genetic modulation of mediators of DNA repair, 
usage of mutant Cas9 variants, and conjugation of Cas9 nuclease with 
oligonucleotides (Liu et al. 2018; Nambiar et al. 2019). Most of these improvements 
lead to several-fold increased HDR frequency (up to roughly 30%, reviewed in (Ling 
et al. 2020; Liu et al. 2018). Our protocol achieved a very high editing rate (80%, Fig. 
10A). The simplicity of the protocol and the underlying mechanism (p53 inactivation 
and selection of recombined cells with puromycin) suggests that this approach can 
be easily adapted for other cell lines. 
We have demonstrated the efficient generation of cell lines carrying multiple 
individual p53 variants (Fig. 11), implying that our protocol can be used to generate 
large panels of isogenic cell lines rapidly. CRISPR-Cas9 technology was previously 
used to perform saturation mutagenesis of tumor suppressor genes (BRCA1) 
(Findlay et al. 2018; Kweon et al. 2020) and oncogenes (BCR-ABL) (Ma et al. 2017) 
and to introduce single point mutations into the TP53 locus (Boettcher et al. 2019). 
To our knowledge, the present work is the first successful attempt of CRISPR-
mediated saturation mutagenesis of the endogenous TP53 locus. 
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Editing of the single TP53 allele in the HCT-116Δ/TP53E cell line ensured unambiguous 
genotype-phenotype correlation. The drawback of this approach is a reduced level of 
p53 expression evident in Fig. 7. P53 is the haploinsufficient tumor suppressor: lack 
of one gene copy reduces transcript levels up to 4-fold, decreases protein levels, and 
impairs DNA damage response  (Lynch and Milner 2006; Teoh et al. 2014). 
Reduction of gene dosage was shown to accelerate carcinogen-induced tumor 
formation (Venkatachalam et al. 2001). Consequently, decreased basal expression 
levels in the HCT-116Δ/TP53E cells compared to the parental line could reduce 
functionality, blunted transactivation, and apoptosis resistance. This, in turn, could 
lead to the misclassification of wild type-like variants as LOF or pLOF. However, our 
analysis has clearly demonstrated that wild-type variants were markedly depleted 
from cellular libraries even without additional stabilization with nutlin (Fig. 17A, 27B), 
suggesting adequate expression levels. Data shown in Fig. 39 demonstrate that 
most of the rare tumor-associated variants (found in less than 10 samples) are 
classified by CSMS as wild-type (28 out of 35) in good agreement with the cDNA-
based screening (Kotler, 2019). This further substantiates that the p53 expression 
level in the cell line is sufficient to drive a full-blown p53-mediated response and that 
the CSMS does not overestimate the pathogenicity of neutral variants.  
We have performed a comprehensive evaluation of the performance of the CSMS 
protocol by conducting saturation mutagenesis of codon R175 and, subsequently, of 
the H1-helix. Encouragingly, we have confirmed the reproducible introduction of both 
libraries into the TP53 locus (Fig. 14, 27). Analysis of variant dynamics in the cell 
population after treatment with a panel of MDM2 inhibitors revealed the excellent 
performance of the screening system. All variants with an expected loss of function 
(nonsense, R175 codon deletion, as well as the most frequent cancer-associated 
variant R175H) were strongly enriched after treatment, whereas synonymous 
mutations were eliminated, supporting the robustness of measurements (Fig. 12). 
The comparison of the CSMS results with the prevalence of mutations in human 
tumors further confirmed the outstanding ability of the workflow to identify pathogenic 
mutants: most of the cancer-associated H1-helix variants were scored as LOF (Fig. 
29D). 
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4.2 CSMS grasps the complexity of the TP53 mutome: 
classification of rare pLOF and wt-like variants 
Correct estimation of LOF phenotype by the CSMS would not be sufficient for 
reliable categorization of the plethora of p53 variants. To produce clinically-relevant 
predictions, the system should capture the complex of natural phenotypic diversity of 
the p53 mutome and provide sufficient resolution to separate mutants with partially-
retained functionality form truly LOF and fully functional variants. Reassuringly, in all 
our experiments, synonymous (fully functional) variants were reproducibly depleted 
form the library to a much higher degree than missense mutants concordant with 
their fully preserved anti-proliferative functions (Fig. 17C, 29A, 36A). This underlines 
the reliable identification of neutral mutations, which is critical for distinguishing 
between non-damaging passenger variants and genuine driver mutations. 
Discriminating driver and passenger mutations is a considerable challenge for 
cancer genomics. Driver mutations affect critical positions in tumor suppressor genes 
or oncogenes, support transformation, and confer growth advantage, whereas 
passenger mutations are randomly scattered across the genome and confer no 
malignant traits. A good demonstration of the power of the CSMS in identifying 
passenger mutations is the R175C variant. Despite being a clear cancer-associated 
mutant (71 UMD records), it was classified as wt-like by the CSMS (Fig. 17C). 
Further analysis of published data confirmed the intact functionality of the variant 
(Fig. 18) (Ryan and Vousden 1998; Flaman et al. 1998; Blagosklonny 1997; Ory et 
al. 1994; Blagosklonny 2002). Several other lines of evidence further support that the 
R175C is a neutral passenger variant. First, 30% of tumors with this mutation have 
other TP53 alterations. Second, this variant has never been described as a germline 
mutation (Leroy et al. 2014a). Third, mutation R175C originates from C>T transition 
at the methylated CpG site, which is the most frequent mutation signature of TP53 
(Giacomelli et al. 2018). The other transition type, G>A, happens at a similar rate. 
Therefore, mutations generated by these two transition types are expected to arise 
with equal probability. This holds true for hotspot codons 248 and 273. Variant pairs 
R248Q-R248W and R273H-R273C have similar frequencies and share LOF 
phenotype (2562, 2003, 2361, and 2214 UMD records, respectively). However, 
R175H mutation originating from G>A transition is 50 times more frequent than the 
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R175C. Therefore, R175C mutation is not selected during neoplastic transformation 
and is a neutral passenger variant. Notably, the benign phenotype of R175C could 
not be deduced from the variant occurrence in cancer patients or from in silico 
predictors (Fig. 18A). Conversely, direct functional measurement inferred from the 
CSMS unambiguously identified the mutant as benign, again underscoring the utility 
of the system.  
Detailed analysis of the H1-helix dataset further showcased the excellent ability of 
the CSMS to explore the complex mutational landscape of TP53. 
CSMS revealed a mutagenesis-resistant region in H1-helix (C182-S185): almost all 
substitutions at these positions were classified as non-damaging (Fig. 29A). Among 
these residues, two are highly conserved: S183 is found in all mammals, whereas 
D184 is almost invariant among 99 animal species (Sulak et al). Highly conservative 
residues in p53 are frequently mutated in tumors in line with their functional 
importance (Baugh et al. 2018). The p53 protein contains 64 amino acid residues 
that are conserved in all vertebrates. Most of these residues are frequently mutated 
in cancers (between 25 and >2,000 UMD records) (Soussi 2014). However, 
missense mutations F19 and W23 have never been reported in cancer. These 
residues are essential for the binding of MDM2 to p53; therefore, any substitutions at 
these positions would be lethal for the cell due to uncontrolled p53 stabilization 
(Kussie et al. 1996). Likewise, missense mutations at conserved positions D184 and 
S183 are strikingly rare. The UMD database contains only 73 mutations at D184 and 
19 at S183 (the mean frequency of missense mutations in DBD is 287 per residue). 
Collectively this indicates that alterations at position 184 do not give a fitness 
advantage and do not lead to enhanced tumorigenesis. Similar to D184, missense 
mutations of the conserved residue S183 were eliminated from the cell library in the 
screening, as well as mutations at S185. Phosphorylation of the S183 by Aurora B 
kinase was shown to stimulate p53 degradation (Gully et al. 2012). The recent report 
from our group further supported the data on the inhibitory role of phosphorylation of 
S183/S185. Timofeev and colleagues reported on the mouse knock-in model of the 
phosphorylation-deficient mutant p53 S180A (unlike a human, mice have one serine 
residue in H1 helix). Cells expressing S180A demonstrated enforced DNA binding 
and increased transactivation of target genes. Elevated p53 activity translated into a 
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reduced incidence of spontaneous and oncogene-induced cancer. Interestingly, 
despite lower susceptibility to cancer, S180A mice demonstrated shortened lifespan 
due to accelerated aging (Timofeev et al. 2020). These results were also confirmed 
in human HCT-116 cells. Isogenic cell lines expressing the double phospho-deficient 
mutant (S183A, S185A) were generated by the author using the procedure 
described in section 3.5. HCT-116Δ/TP53S183A, S185A cells demonstrated enhanced 
target gene expression and apoptosis in response to DNA damage. Taken together, 
these results strongly suggest that phosphorylation of S183 and S185 have inhibitory 
effects on p53 function; therefore, alterations at these positions are expected to be 
benign in good agreement with CSMS predictions, which explains their low 
frequency in human tumors. 
Finally, alterations at C182 were previously shown to have a minor effect on p53 
functionality, in good agreement with our data (Stoner et al. 2009; Eldar et al. 2013; 
Kaar et al. 2010). In summary, the discovery of the mutagenesis-resistant region 
(C182-S185) in the H1-helix made by CSMS is supported by several lines of 
evidence, including the cDNA-based screening (Kotler et al.), functional data from 
animal models, and clinical observations. This further demonstrates that the CSMS 
protocol correctly classifies neutral TP53 variants. Reliable identification of benign 
mutations has an important medical implication. Although rarely, such mutations are 
found in human tumors. For example, the UMD database contains 157 cases with 
missense mutations at mutagenesis-resistant positions C182-S185. 
Moreover, the UMD database contains 187 cases with mutations in H1-helix 
classified by the CSMS as neutral. Such mutations must be considered wild-type, 
and patients carrying them can profit from therapy with MDM2 inhibitors and should 
be included in clinical trials. Furthermore, detection of such benign p53 variant in the 
germline of a cancer patient would indicate a lack of inherited cancer predisposition 
(if no other predisposing mutations (e.g., in BRCA1/2) are also not found). Therefore, 
family members of such individuals do not have an elevated risk of developing 
cancer, do not need to be screened for this variant, and can evade unnecessary 
screening procedures and preventive measures (e.g., prophylactic mastectomy). 
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Closer examination of the mutational effects within positions E180 and R181 
underlined the exquisite ability of the CSMS to detect partially-functional p53 
variants. Residues E180 and R181 form a salt bridge between two adjacent 
monomers in the DNA-bound tetramer (Ma and Levine 2007; Dehner et al. 2005). 
Alterations at these positions modulate DNA binding cooperativity and were 
extensively studied by our group and others (Madhumalar et al. 2009; Schlereth et 
al. 2010a; Timofeev et al. 2013). Therefore, these positions are especially suited for 
the characterization of partially-active mutants because comprehensive data on DNA 
binding for multiple variants are available. The fitness advantage conferred by eight 
distinct mutations revealed a striking correlation with DNA binding strength inferred 
from biochemical studies (Fig. 29C) (Schlereth et al. 2010a). Among 8 mutants, the 
R181L showed antiproliferative capacity mostly similar to the wild-type. This is a 
well-characterized tumor-associated apoptosis-deficient partial-LOF mutant with 
preserved transactivation of certain target genes (CDKN1A, MDM2) and the ability to 
activate cell cycle arrest (Ludwig et al. 1996; Schlereth et al. 2010a). The other well-
characterized pLOF mutant in H1-helix is E180R. It also demonstrated a selective 
apoptotic defect and retained the cell cycle arrest (Timofeev et al. 2013; Klimovich et 
al. 2019). Importantly, its DNA binding was weaker than of R181L (Schlereth et al. 
2010a; Schlereth et al. 2010b). In good agreement with weaker DNA binding, E180R 
was depleted from the library significantly weaker than the R181L. 
In the work of Schlereth and coauthors, tumor-suppressive properties of other H1 
helix mutants inferred from DNA binding strength, transactivation of p53 response 
elements, and proapoptotic activity declined in the order WT > R181L > R181H > 
R181C > E180K > R181P. Strikingly, the CSMS-derived measurement of the activity 
of protein variants reproduced precisely the same pattern, justifying the single CSMS 
screening ability to replace a multitude of functional assays to decipher the complex 
landscape of p53 mutants. 
4.3 High-content CSMS protocol: advantages and limitations 
Successful validation of the CSMS performance using the R175 and H1-helix 
datasets prompted us to establish the high-throughput CSMS workflow to perform a 
comprehensive analysis of thousands of p53 variants. The CSMS design enabled a 
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relatively simple scale-up of the procedure. We have engineered a novel targeting 
vector to accommodate large 230-bp long oligonucleotides spanning the whole 5th 
exon and increased the number of cultured cells and input DNA used for the 
sequencing library construction to compensate for the increase in library complexity. 
Importantly, the same system can be easily employed for extended analysis to the 
complete DNA binding domain encoded by a relatively short region (exons 5-8 span 
1,5 kb). For this purpose, one would need to design a set of targeting vectors with 
extended homology arms spanning the region between intron 4 and intron 9. 
Because the maximum size of synthetic oligonucleotides slightly exceeds 200 
nucleotides, each exon will be targeted by a separate vector. Therefore, each of the 
3 vectors needs two recognition sites for type IIs restriction enzymes flanking 
corresponding exons for cloning oligonucleotides using the Golden Gate protocol. 
Since the probability of homologous recombination significantly decreases with the 
distance from the double-strand break, additional modification of HCT-116Δ/TP53E cell 
line might be needed to ensure efficient editing. Specifically, the generation of a 
novel recognition site for the allele-specific CRISPR-nuclease could be required to 
shift the location of the double-strand break closer to the region of interest. This can 
be achieved by transfecting HCT-116Δ/TP53E cells with a CRISPR-nuclease specific to 
intron 7 or 8. Random nucleotide polymorphisms in the TP53E allele generated by 
non-homologous end joining can be used as a target for the allele-specific nuclease, 
as it is shown in Fig. 7 for exon 5. Finally, minor modifications of PCR protocols and 
bioinformatics pipeline will make the CSMS platform suitable for analysis of >90% of 
the complexity of the p53 mutome. 
Analysis of the exon 5 dataset revealed that despite strongly increased library 
complexity, 99.79% of mutants were successfully integrated into the TP53 locus, 
supporting the applicability of our methodology for high-content mutagenesis. 
However, a comparison of the scorings retrieved from the exon 5 dataset with the 
measurements made in the validation experiments (R175 and H1 helix libraries) 
showed substantial inconsistency between low- and high-throughput protocols (Fig. 
36 B,D). We have observed markedly lower depletion of variants as a major source 
of these discrepancies and concluded that applying the high-content protocol 
resulted in decreased resolution between LOF and wild-type-like mutants (Fig. 36 C). 
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Most probably, this issue was a result of the suboptimal passaging schedule used 
during nutlin treatment. During two weeks of nutlin treatment, library-expressing cells 
were passaged with a low split ratio (1:2) to avoid accidental loss of rare mutations 
and maintain the complexity of the library. Passaging at high density can result in a 
decreased effective concentration of nutlin, ineffective killing of nutlin-sensitive cells, 
and consequently reduced depletion of wild-type-like variants. At the same time, the 
exponential outgrowth of resistant cells can be limited by high culture density. Both 
factors will reduce the dynamic range of the system. 
Despite this technical issue, the relative fitness landscape derived from the high-
throughput CSMS experiment was highly correlated with the study of Kotler and with 
the distribution of mutants in human tumor specimens (Fig. 39 and 40). This implies 
that we have successfully captured a large portion of phenotypic diversity in our 
cellular library. 
We are convinced that simple measures can further improve the performance of the 
high-throughput protocol. Reducing cell density and prolonging the expansion of the 
population would enhance the separation of wild-type and LOF variants. Increasing 
the cell number and adding more replicates would reduce the drop out of mutations 
from the pool. Therefore, despite the need for minor protocol improvements, the 
CSMS has fully demonstrated its utility as a high-throughput phenotypic screening 
platform. 
4.4 CSMS dissects distinct p53-dependent tumor-suppressive 
programs  
Previously reported screening systems employed the antiproliferative activity as a 
single measure of p53 functionality (Giacomelli et al. 2018; Kotler et al. 2018). To 
demonstrate the value of CSMS for in-depth characterization of the p53 mutome, we 
have employed our system to dissect two p53-mediated programs, apoptosis and 
cell cycle arrest, in the context of the R175-variant library. To this end, we have 
performed two experiments described in section 3.8.1. In the first experiment, we 
have compared populations of cells treated with nutlin for a short or prolonged time 
and identified mutants, which were able to arrest proliferation temporarily but could 
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not kill cells by apoptosis (Fig. 20). In the second experiment, we have compared 
mutations prevalent among annexin V positive and negative library fractions after 
nutlin treatment to directly reveal apoptosis proficient and deficient mutants (Fig. 13 
A,B). These experiments gave several interesting insights into the functional impact 
of R175 mutations. For example, the non-damaging tumor-associated variant R175C 
has demonstrated preserved proapoptotic activity in good agreement with published 
data, further confirming its benign properties (Xu-Monette et al. 2012; Ory et al. 
1994). Interestingly, mutants R175C and R175S exhibited very similar transcriptional 
profiles in the study of Kato et al. (Fig. 18C,D) (Kato S. et al. 2003). However, they 
demonstrated distinct features in the annexin-V experiment. Apoptosis-proficient 
R175C was depleted to the level of wild-type, whereas R175S was apoptosis-
deficient (Fig. 21B). This example clearly shows the advantage of phenotypical 
functional measurements. 
Several apoptosis-deficient mutants recovered from the annexin-negative fraction 
(Fig. 21B, R175I/K/N/P/S) demonstrated remarkable behavior in the other 
experiment: they were moderately enriched after short nutlin treatment but 
progressively depleted upon more prolonged exposure, suggesting their ability to 
induce cell cycle arrest (Fig. 20B). Strikingly, all these mutants were previously 
shown to provoke cell cycle arrest when separately expressed in p53-negative Saos 
cells (Ryan and Vousden 1998). Moreover, the murine analog of R175P, R172P 
revealed similar properties in a mouse model (Liu 2004). These findings have further 
strengthened our confidence that CSMS is a powerful tool for the elaborate 
functional characterization of p53 variants. Two simple experiments allowed us to 
dissect between mutants proficient in the induction of cell cycle arrest or apoptosis in 
exceptional agreement with previous experimental observations.  
Sorting of library-expressing cells according to the expression of a particular marker 
(as we did with annexin) is a simple and elegant approach to decipher complex 
genotype-phenotype correlations. The array of markers can be easily extended to 
quantify proliferation (EdU), DNA repair (γH2AX), the activity of certain promoters 
(using reporter genes), or even phosphorylation states (using phospho-specific 
antibodies) or metabolic conditions. 
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4.5 CSMS quantifies the impact of p53 mutations on cellular 
response to therapeutic agents  
p53 plays a central role in apoptosis induction in response to DNA damage. 
Therefore, mutations in TP53 confer resistance to chemo- and radiotherapy, which 
rely on DNA damage induction(Stiewe and Haran 2018; Hientz et al. 2017; Zhou et 
al. 2019). Besides reduced sensitivity to apoptosis, various GOF mechanisms have 
been implicated in protecting cancer cells from chemotherapy-induced death (He et 
al. 2017; Blandino et al. 1999; Keshelava et al. 2000; Zhang et al. 2020). However, 
little is known about the impact of non-hotspot mutations on therapy resistance. 
Considering the complexity of the p53 mutome and the multitude of mutant p53 
protein interactions with binding partners and the genome, a systematic 
characterization of the drug resistance phenotype conferred by multiple p53 
mutations has an important clinical implication.  
p53-reactivating compounds can potentially tackle mutant p53-induced drug 
resistance. Some p53 reactivators are directed against specific mutants (for 
example, PK083 and NSC319726 target Y220C and R175H, respectively), whereas 
other molecules affect a broader spectrum of variants (for example, APR-246) 
(Bykov and Wiman 2014). All emerging mutant p53-targeting therapeutics have been 
tested on several exemplary hotspot mutants, and none of them was systematically 
assayed with multiple protein variants in an isogenic context.  
Previous functional studies of the p53 mutome did not address the issue of drug 
resistance. In the work of Kotler and colleagues, the proliferation of untreated cells 
was used as a readout. In the Giacomelli study, cells were treated with nutlin or 
etoposide; however, etoposide treatment was used solely to identify wild-type-like 
variants. Therefore, we have utilized the CSMS to investigate the influence of p53 
mutations on the response to therapeutic agents. Besides treating the library with the 
non-genotoxic p53 activator nutlin, we have subjected cells to irradiation and 
treatments with the chemotherapeutic 5-fluorouracil and the p53 reactivator APR-
246. Our analysis revealed significant similarity in response of mutant-expressing 
cells to treatment with nutlin, irradiation, and 5-FU (Fig. 23B and 25B). However, one 
mutant group demonstrated a substantial difference in enrichment pattern: wild-type-
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like mutants were depleted significantly stronger under nutlin treatment than under 
treatment with DNA-damaging agents, demonstrating preferential induction of cell 
cycle arrest by wild-type like mutants under tested conditions as compared to nutlin. 
Although all three stimuli activate apoptosis in HCT-116 cells, distinct dynamics of 
the p53 activation play a significant role in controlling p53 response outcome. 
Irradiation induces rapid activation of p53 followed by pulsing p53 protein levels of 
decreasing amplitude (Hafner et al. 2017; Lev Bar-Or et al. 2000), leading to 
preferential activation of arrest-inducing genes and recovery from DNA damage. 
Conversely, continuous treatment with MDM2 inhibitors results in sustained p53 
activation expression of proapoptotic target genes and cell death (Paek et al. 2016; 
Purvis et al. 2012). Distinct behavior of the group of synonymous and wild-type-like 
mutants under distinct stimuli likely reflects the influence of p53 signaling dynamics 
on cell fate.  
We did not reveal any other mutants which dynamics were significantly distinct under 
non-genotoxic p53 activation with nutlin and after exposure to genotoxic agents. This 
suggests that resistance to apoptosis is the most important determinant of therapy 
resistance in our system. 
Besides genotoxic agents, we have treated library-expressing HCT-116 cells with the 
p53-reactivating compound APR-246. It is the most advanced p53 reactivator and 
currently undergoes clinical testing (12 studies listed at clinicaltrials.gov). A 
successful rescue of functions of mutant p53 would result in depletion of selected 
missense LOF mutants from the library compared to nonsense and synonymous 
mutations. Surprisingly, our analysis did not reveal any mutant-specific effects (Fig. 
26 and 31). Neither the R175H mutants shown previously to be refolded with APR-
246 nor other missense mutants showed any depletion below the basal level (Zhang 
et al. 2018; Ceder et al. 2020; Bykov et al. 2016; Bykov et al. 2002).    
Mutant p53 is constitutively stabilized in cancer cells. Refolding of the mutant protein 
with a reactivating compound leads to rapid accumulation of active p53 and 
cytotoxicity. However, mutant p53 stabilization is not an immediate consequence of 
p53 mutation but rather an acquired hallmark of the cancer cell (Schulz-Heddergott 
and Moll 2018; Yamamoto and Iwakuma 2018). HCT-116 cells express wild-type p53 
and therefore likely lack alterations essential for p53 stabilization. Consequently, the 
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introduction of the mutant allele into HCT-116Δ/TP53E cells did not result in the 
accumulation of the mutant protein: expression levels of missense mutants were 
comparable to the wild-type (Fig. 11C). Treatment of mutant-expressing cells with 
nutlin increased p53 levels (Fig. 11C). The synergy between nutlin and APR-246 has 
been shown before (Izetti et al. 2014). However, our experiments did not reveal any 
APR-246-specific cytotoxicity under combined treatment with nutlin and APR-246 
(Fig. 31). Nutlin induced a moderate increase of p53 levels in mutant-expressing 
HCT-116Δ/TP53E cells (Fig. 11C). By contrast, mutant p53-expressing cell lines usually 
demonstrate massive protein accumulation (Zandi et al. 2011). Therefore, the most 
likely explanation for the failure to observe any effects of APR-246 in our system is 
insufficient expression levels of mutant proteins. Presumably, using a mutant p53-
expressing cell line with a high basal level of mutant protein would enable us to 
explore the p53 mutome in the context of continuous p53 stabilization. However, 
gene editing in p53-mutated cell lines presents a substantial challenge due to 
genomic instability and frequent copy number alterations of the TP53 locus 
(Donehower et al. 2019).  
In conclusion, our work is the first study that has attempted to assess the impact of 
p53 mutants on the response to therapeutic regimens. The simplicity of our system 
enables rapid and cost-effective testing of multiple compounds to gain insight into 
mutant p53-mediated drug resistance and expand the knowledge about the 
selectivity of mutant p53 targeting compounds.  
4.6 GOF of mutant p53 in CSMS 
Numerous p53 mutations confer neomorphic GOF activities to the protein. These 
activities foster cancer cell proliferation, enhance invasion and metastasis and 
promote chemoresistance (Walerych et al. 2012; Walerych et al. 2015; Mantovani et 
al. 2019). GOF effects are mutant- and context-specific. Therefore, high-content 
profiling of GOF properties of multiple p53 mutant variants would significantly impact 
personalized cancer treatment. 
We have identified several mutants that displayed higher enrichment than nonsense 
variants upon prolonged cultivation of the untreated H1-helix library, suggesting that 
these mutants stimulate proliferation (Fig. 28 C). However, the detected proliferative 
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advantage was statistically significant only for a single mutant (R181M, not found in 
tumors). Interestingly, variant H179Y, which demonstrated strong enrichment in one 
of three library replicates but failed to reach a statistically significant difference with 
nonsense mutants, was reported to promote the proliferation of embryonic lung 
fibroblasts (Di Yang et al. 2007). Enrichment of mutants with suggested GOF activity 
showed substantial variance between replicate libraries (Fig. 28C). Therefore, to 
discriminate between true neomorphic activities and stochastic fluctuations of variant 
frequency in the complex library, experiments with an increased number of replicates 
might be needed.  
Besides fueling proliferation, GOF mutants can promote radio- and chemoresistance 
(Valenti et al. 2011; Lisek et al. 2018; He et al. 2017; Yue et al. 2017). Therefore, we 
have analyzed data from nutlin-, 5-FU and X-ray treatment experiments to identify 
mutants with GOF properties. However, we did not detect any variants with 
enrichment significantly exceeding nonsense mutations. For example, in the library 
treated with MDM2 inhibitors, ES of 98% of missense mutants lies within 3 standard 
deviations of the mean ES of nonsense variants. The only mutant with enrichment 
exceeding this level in all 5 libraries is P177D, but its high enrichment is due to the 
extremely low amount of reads in one of the untreated library replicates (8 reads, 
obvious outlier) (Supplementary Fig. 1). Similarly, we found no evidence of more 
extensive enrichment for any of the missense mutants under 5-FU treatment or after 
irradiation. Therefore, our analysis suggests that most p53 mutants exhibit no GOF 
phenotype in the CSMS system. 
The stabilization of mutant p53 is a prerequisite for its tumor-promoting GOF 
(Alexandrova et al. 2017a; Hingorani et al. 2005; Terzian et al. 2008; Schulz-
Heddergott and Moll 2018). Tumor dependence on sustained elevated levels of 
mutant p53 has been demonstrated in elegant animal models: ablation of mutant 
p53 expression results in tumor regression, decreased metastasis, and improved 
survival (Muller and Vousden 2014; Weissmueller et al. 2014; Vogiatzi et al. 2016). 
Therefore, mechanisms driving mutant p53 stabilization are attractive therapeutic 
targets (Alexandrova et al. 2015; Schulz-Heddergott and Moll 2018; Yue et al. 2017; 
Yue et al. 2015). As already noted, none of the missense mutants showed 
expression levels exceeding the wild-type protein when expressed in HCT-116Δ/TP53 
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(Fig. 11), despite some of these mutants showing prominent stabilization in tumor 
samples (e.g., R175H and mouse equivalent of E180R) (Timofeev et al. 2013; 
Hwang et al. 2018). The lack of clearly detectable GOF properties in our screening is 
in line with previous observations. Both comprehensive high-throughput mutagenesis 
screens failed to identify any GOF properties in in vitro experiments (Kotler et al. 
2018; Boettcher et al. 2019). However, clear predominant expansion of cells carrying 
hotspot mutants with proven GOF properties was demonstrated in tumor xenografts 
grown in nude mice in the study of Kotler. This exceptionally interesting observation 
highlights the difference between selective forces operating in vitro and in vivo. 
Although HCT-116 cells used in the CSMS do not show stabilization of mutp53 in 
vitro and reveal no addiction to the mutant protein, adaptation of the cellular library to 
the growth in a complex in vivo setting could result in a selection of subclones with 
stabilized mutp53 with neomorphic activities conferring the selective advantage. 
Therefore, optimization of the CSMS procedure for in vivo experiments could enable 
the identification of mutants with GOF and further improve the clinical value of our 
work. 
Two recent studies attested DNE as a universal feature of p53 mutants (Boettcher et 
al. 2019; Giacomelli et al. 2018). Unfortunately, the CSMS is unable to capture the 
DNE because it utilizes a cell line with a single TP53 allele. However, minor 
modifications would enable us to do this. Specifically, one needs to establish a cell 
line with an editable TP53 allele and preserved second wild-type allele. The 
generation of such cell lines is currently underway in our group. 
4.7 CSMS identifies pathogenic mutations in non-coding regions 
CSMS has demonstrated its outstanding performance in measuring the functional 
impact of missense p53 mutations. However, all these experiments could also be 
performed in cDNA-based screening systems with comparable results. The 
unquestionable advantage of the CSMS approach is its ability to assess the 
consequences of mutations in non-coding regions of the endogenous locus. Our 
experiments showcased this advantage of the CSMS by identifying the known 
pathogenic variant of the splice site in the 5th intron (c.559+1 G>A ) (ClinVar record 
NM_001126112.2) (Surget et al. 2013; Lai et al. 1993; Smeby et al. 2019) (Fig. 33). 
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Mutations in non-coding regions are rarely found in cancer patients (156 splice site 
mutations are listed in the UMD TP53 database). However, their actual frequency in 
cancers may be underestimated since mutational analysis is mainly restricted to 
protein-coding regions. They are frequently mutually exclusive with exonic variants, 
highlighting their pathogenicity (Li et al. 2018). Identification of intronic pathogenic 
variants in TP53 outside splice sites suggests that non-coding tumor-predisposing 
TP53 variants are more frequent than previously considered (Peller et al. 1995; 
Avigad et al. 1997; Sailaja et al. 2012; Barel et al. 1998).  
Interestingly, several synonymous SNVs (sSNV) in the coding TP53 sequence were 
identified as pathogenic. For example, two sSNV at codon 125 (c.375G>A or 
c.375C>T) at the end of exon 4 are adjacent to the donor site in intron 4 and impair 
TP53 splicing) (54 UMD records) (Varley et al. 1998). Similarly, sSNV c.672G>A 
(encodes E224) is likely to disturb splicing (Leroy et al. 2014a). cDNA-based 
methods would undoubtedly characterize these rare mutations as benign but likely 
scored correctly as pathogenic by the CSMS. 
Summarizing, we believe that the CSMS is a powerful novel platform for discovering 
novel pathogenic variants in non-coding regions of p53. Identification of intronic 
pathogenic variants in TP53 outside splice sites suggests that non-coding tumor-
predisposing TP53 variants are more frequent than previously considered (Peller et 
al. 1995; Avigad et al. 1997; Sailaja et al. 2012; Barel et al. 1998). This further 
emphasizes the advantage of the CSMS over cDNA-based screening protocols for 
the comprehensive classification of rare TP53 variants.    
4.8 CSMS outperforms cDNA-based methods in the classification 
of pathogenic variants 
Comparing the CSMS-derived measurements with the cDNA-based screening 
results revealed a clear correlation between the two datasets (Fig. 39 and 40) (Kotler 
et al. 2018). However, the classification was discrepant for some variants. Notably, 
several of these variants are experimentally confirmed LOF (R175P, R175L, R181C) 
(Kang et al. 2020). Moreover, another mutant (C176Y) is also definitely pathogenic 
(it was frequently found in ovarian and other cancers, 281 UMD records) (Kang et al. 
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2013; Mullany et al. 2015). These four mutants were erroneously classified in the 
cDNA-based screen as functional but correctly scored by the CSMS as non-
functional. 
Furthermore, CSMS scored several potentially tumorigenic H1 helix mutants with 
intermediate occurrence in tumor samples (10-90 records) as LOF. Again, the cDNA-
based screen failed to assign these variants to the pathogenic category (Fig. 39). At 
the same time, our screening did not overestimate the pathogenicity of mutation 
since most of the mutations found in less than 10 patient samples were classified as 
benign. Therefore, CSMS demonstrated a more accurate classification of H1-helix 
variants compared to the cDNA study. Unfortunately, the low dynamic range of the 
exon 5 dataset resulted in imprecise classification (as illustrated by low RFS values 
of the R175H mutant). However, we expect that minor modifications of screening 
conditions would be sufficient to confirm the superior performance of the CSMS over 
cDNA-based methods.  
We did not include the other similar study in the analysis because it quantified wild-
type and LOF effects in two separate experiments, making the direct juxtaposition of 
data cumbersome (Giacomelli et al. 2018). Direct comparison between studies of 
Kotler and Giacomelly was performed recently and found their excellent agreement 
(Carbonnier et al. 2020). Therefore, we can anticipate that our conclusions would be 
valid for the second study as well. Finally, most of the very rare variants (<10 UMD 
records, being likely sequencing artifacts or neutral bystander mutations) are 
unequivocally classified by both systems as functionally normal, suggesting that our 
protocol does not overestimate the amount of LOF mutations. Summarizing, a 
detailed comparison of our data with the dataset of Kotler et al. provides compelling 
evidence that the procedure established in our study is significantly more accurate in 
the categorization of pathogenic TP53 mutations, especially mutations with residual 
functions. 
4.9 Method limitations 
CSMS demonstrated impressive performance in our hands. However, we ought to 
address some limitations of our approach. Our aim, among others, was to improve 
the catalog of p53 mutations used for testing patients with increased cancer 
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susceptibility. From this perspective, the important limitation is the employed 
readout. We assessed the tumor-suppressive properties of mutants by quantifying 
the antiproliferative capacity of p53 mutants under treatment with mdm2 inhibitors. 
However, the ability of a p53 variant to kill cancer cells upon mdm2 inhibition is not a 
direct measure of “tumor suppression,” the ability of a protein to prevent initiation and 
progression of cancer in vivo. Two observations can exemplify this notion. 
On the one hand, therapeutic response to nutlin in murine Eµ-Myc lymphoma solely 
relies on Puma-mediated apoptosis (Valente et al. 2016b). At the same time, neither 
loss of Puma alone nor in combination with the other critical proapoptotic factor Noxa 
does not accelerate tumorigenesis to the same extent as p53 loss (Valente et al. 
2016a). Even more strikingly, p53 efficiently suppresses spontaneous tumorigenesis 
in mice deficient for p21, puma, and noxa in the absence of its three main programs: 
apoptosis, cell cycle arrest, and senescence (Valente et al. 2013). These 
observations clearly demonstrate that classical p53 functions assessed by 
mutagenesis screens, including CSMS, are dispensable for tumor suppression. 
Other activities, such as maintaining genomic stability, can be more crucial but are 
difficult to assess in vitro in a high-content manner (Eischen 2016; Hanel and Moll 
2012; Liu et al. 2004). Therefore, caution is needed when applying data on sensitivity 
to mdm2 inhibitors to identify cancer-predisposing mutants. 
The other limitation of our method stems from the usage of the isogenic setting: all 
mutants are expressed in the same cell line. Despite obvious advantages, this 
approach dramatically simplifies the cellular context and limits the findings to the 
single colorectal cell line. However, p53-mediated effects and their importance for 
tumor suppression are considerably distinct between tissue types. For example, p53-
null mice predominantly develop T-cell lymphomas and soft tissue sarcomas, 
whereas other cancer types are much rarer, pointing at the paramount importance of 
p53 for tumor suppression in the hematopoietic compartment in mice. In humans, the 
most frequent tumor type among carriers of germline TP53 mutations is breast 
cancer (Donehower et al. 1992; Bouaoun et al. 2016). TP53 mutational spectrum 
varies significantly between cancer types (Kastenhuber and Lowe 2017). To a large 
extent, this variation can be explained by specific mutagenic processes operating in 
different tissues (Alexandrov et al. 2016; Giacomelli et al. 2018). However, tissue-
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specific oncogenic GOF might also shape the mutational landscape (Barta and 
McMahon 2019). Collectively this suggests that the prognostic value of a mutant 
determined in colorectal cancer cell line can be distinct in the other tumor types. This 
can be especially relevant for low penetrant cancer-predisposing mutants acting in a 
tissue-specific manner, such as R337H. This inherited p53 variant is found in the 
Brazilian population and predisposes to developing adrenal cortical tumors and lung 
adenocarcinomas (Ribeiro et al. 2001; Vieira et al. 2021). Importantly, R337H is a 
pLOF mutant with preserved proapoptotic capacity. Therefore, its tissue-specific 
tumorigenic effects would presumably be difficult to capture in experimental systems 
based on cancer cells of distinct tissue origin.   
Tissue specificity of p53-driven response has an important implication for therapeutic 
response: the outcome of p53 activation can be very heterogeneous in different 
tissues. For example, in normal tissues, irradiation-induced p53 activation damages 
hematopoietic tissues and hair follicles due to apoptosis induction but exerts 
protective effects due to activation of cell cycle arrest and DNA repair in small 
intestine (Gudkov and Komarova 2010). Diverse p53-mediated responses are 
dictated by tissue-specific activation of p53 targets and distinct dynamics of p53 
levels (Fei et al. 2002; Tanikawa et al. 2017; Stewart-Ornstein et al. 2021). A 
paradoxical example of tissue-specific action of p53 in the context of cancer therapy 
is the tumor-protective action of wild-type p53 in breast cancer. Contrary to a 
textbook view, wild-type p53 was shown to mediate poor chemotherapy response in 
murine MMTV-Wnt1 mammary tumors compared to the mutant. Mechanistically, p53 
activated cell cycle arrest and senescence, which protected cancer cells from 
doxorubicin-induced DNA damage. 
Conversely, mutant p53 was unable to halt proliferation which leads to cell death via 
mitotic catastrophe (Jackson et al. 2012; Tonnessen-Murray et al. 2018). A similar 
protective action of p53 was revealed in melanoma (Webster et al. 2020). These 
observations underscore the importance of tissue context when assessing the 
response of cancer cells to chemotherapy and translation of results of high-content 
screenings.  
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The application of isogenic background in our screening has another important 
implication. TP53 mutations never act as the sole driver of malignant growth. 
Conversely, in many tumors, p53 loss is a late genetic event, which cooperates with 
multiple preexisting oncogenic alterations to fuel aggressive cancer growth (Fearon 
and Vogelstein 1990). Every tumor carries a unique combination of genetic 
alterations, which collectively determines its properties, including the behavior of 
wild-type or mutant p53. Cooperating oncogene may dramatically change the effect 
of p53 mutations on tumor development and therapy response. For example, murine 
leukemia arising from progenitors expressing AML1/ETO fusion protein 
demonstrates strongly increased aggressiveness and therapy resistance upon loss 
of p53. 
Conversely, leukemias initiated by the MLL/ENL fusion protein are highly aggressive 
and resistant to chemotherapy independently of p53 status (Zuber et al. 2009). This 
example underscores that functional screens based on a single cell line are confined 
to a unique combination of mutations. The importance of genetic background is 
further exemplified by the fact that even p53-wild-type cell lines demonstrate a fairly 
distinct response to mdm2 inhibitors, determined by additional genetic alterations 
(e.g., MDM2 amplification) (Ishizawa et al. 2018; Saiki et al. 2015). Accordingly, 
phenotypic effects of p53 mutations are partially determined by the cooperating 
mutations. Colorectal cancer cell line HCT-116 harbors activating mutations in b-
catenin and KRas (G13D) (Sekine et al. 2002; Steckel et al. 2012). Additionally, it 
contains a mutation of the CDKN2A locus encoding p14ARF protein. p14ARF acts 
as an mdm2 inhibitor and activates p53 in response to oncogenic signaling. 
Therefore, the CDKN2A mutation enables cells to maintain high levels of Ras-driven 
MAPK signaling and evade activation of the wild-type p53. Importantly, the 
introduction of p53 mutants into HCT-116 cells creates a genetic configuration that 
rarely exists in tumors: TP53 and CDNKN2a mutations are mutually exclusive 
(Donehower et al. 2019). Assaying the effects of mutant p53 in such context have 
important consequences. In a typical mutant p53-expressing cell with wild-type 
CDKN2A, constitutively active KRas drives p14ARF-dependent stabilization and 
accumulation of mutant p53. P53 stabilization is a prerequisite for oncogenic GOF 
(Suh et al. 2011). Lack of ARF in HCT-116 cells prevents stabilization of mutant 
169 
variants. This might explain the lack of detectable GOF effects in our system and 
emphasize the necessity to perform screenings in multiple cell lines. Another 
important consequence of the usage of ARF-mutant cell line concerns the testing 
p53 reactivating compounds. Cells harboring p53 mutations are not responding to 
the restoration of wild-type p53 equally well. Conversely, p53 reactivation 
successfully eliminates only those tumors where upregulated oncogenic signaling is 
translated into ARF-dependent stabilization of mutant p53 (Junttila et al. 2010; 
Feldser et al. 2010). Accordingly, screening in ARF-deficient HCT-116 cells will likely 
keep effects of p53-reactivating compounds such as APR-246 obscured. 
In summary, the aforementioned limitations need to be considered when interpreting 
and generalizing data of our study. We are convinced that CSMS-based 
classification of most LOF and wild type-like variants could be applied to a broad 
spectrum of cancer entities. In support of this, the CSMS dataset obtained from 
colorectal cancer cells revealed a reassuringly high correlation with the study of 
Kotler and colleagues performed in the H1299 cell line (expresses oncogenic NRas 
and wild-type p14ARF). Furthermore, a recent report revealed an excellent 
correlation between the study of Kotler and another cDNA-based screening 
performed in A549 cells (Carbonnier et al. 2020). However, our estimates regarding 
pLOF mutants could be affected by cell line-specific traits (e.g., tissue-specific p53-
dependent transcriptome, cooperating mutations) and can therefore be confined to a 
particular cancer subtype. Likewise, CSMS-based predictions regarding GOF and 
the impact of mutations on response to chemotherapy or p53-reactivating 
compounds can be predetermined by choice of the host cell line and need to be 
interpreted with caution.  
4.10  Conclusion 
TP53 is mutated in up to 80% of human cancers (Donehower et al. 2019; Leroy et al. 
2014a), and the proper systematization of p53 mutants is in high demand. Our study 
provides the foundation of the first catalog of functional consequences of p53 
variants encoded by the native TP53 locus in an isogenic genetic background.  
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At present development of the system in our group progresses further. For instance, 
the editing of the TP53 locus in the HCT-116Δ/TP53 cell line was implemented in exons 
6, 7, and 8, and reassuring preliminary data were obtained. Furthermore, the CSMS 
toolkit was expanded with a lung cancer cell line. TP53 mutations are very abundant 
in lung cancer patients; therefore, the addition of non-small cell lung cancer cell line 
to the screening will provide valuable information and broaden the clinical relevance 
of generated data. 
Over the decades, studies of p53 mutations were mainly focused on bona fide 
cancer-driving hotspot variants. Pathogenicity of rare non-hotspot alterations 
remained ambiguous due to the small number of reported patients and lack of 
experimental evidence (e.g., cell lines or mouse models). Clinical interpretation of 
rare variants was greatly empowered by bioinformatic tools such as SIFT, PolyPhen, 
REVEL, and others (Ng and Henikoff 2003; Adzhubei et al. 2013; Ioannidis et al. 
2016). Nowadays rapid development of gene editing technologies and next-
generation sequencing offered the exciting possibility to directly test phenotypic 
effects of hundreds of mutants in parallel in a time- and cost-effective manner. We 
have demonstrated that the CSMS-based classification is significantly more precise 
than existing bioinformatic predictors (Fig. 41). Moreover, CSMS has showcased its 
outstanding ability to predict the impact of mutations on therapy response, whereas 
none of the currently available algorithms are able to do this.  
Although several earlier studies have already reported high content characterization 
of the p53 mutome, the CSMS approach has several unique advantages and is likely 
more accurate. Therefore, we are convinced that the findings of the present work will 
serve as a substantial contribution to the further development of public p53-focused 
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of triplicates are shown. Dotted line: 2x mean ES of nonsense variants. 
Note that only single missense variants are enriched above this 
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